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VOORWOORD 
In de gezondheidszorg vindt modelbouw meer en meer ingang als hulpmiddel bij 
het nemen van beslissingen. Waarschijnlijk het best bekend zijn de besliskundige 
modellen die worden toegepast bij beslissingen rond diagnostiek en behandeling 
van individuele patienten. Deze worden echter relatief weinig gebruikt bij het 
nemen van praktische beslssingen. Ook op populatie-niveau worden, ter 
onderbouwing van strategische beleidsbeslissingen, modellen gebruikt voor het 
voorspellen van ontwikkelingen in morbiditeit, mortaliteit en gebruik van 
gezondheidszorg, en voor het analyseren van speciale programma's voor 
bestrijding van ziekten, zoals vaccinatie en bevolkingsonderzoek. 
In dit proefschrift wordt de toepassing van modellen voor analyse van 
bevolkingsonderzoek dat zich richt op vroege opsporing van borstkanker en van 
baarmoederhalskanker. 
De engelstalige hoofdtekst en samenvatting geeft een wetenschappelijke 
verantwoording van mijn onderzoekswerk op dit terrein. In de Nederlandse 
samenvatting heb ik getracht om in voor iedereen te begrijpen bewoordingen de 
inhoud en het belang van het onderzoek onder woorden te brengen. 

PREFACE 
Models are gradually becoming an accepted tool in decision making in health 
care. Probably best known are the decision-tree like models Umt aim at assisting 
a physician in selecting appropriate diagnostic and treatment procedures for 
individual patients. At population level, epidemiometric models are being used to 
predict future trends in morbidity, mortality and demand for health care facilities, 
and to evaluate disease control progranunes. 
The beginning of my involvement in epidemiometric modelling at the 
Department of Public Health and Social Medicine was in 1977, when the 
SCRMOD computer simulation program developed in the U.K. by E.G. Knox 
was used to predict Ule effects of cervical cancer screening in the NeU1erlands. 
The results were presented at ule symposium organized at the event of the 
retirement of professor Burema. Based on Ulls experience, it was decided to start 
developing our own computer simulation progranune, wlllch was given the 
acronym MISCAN (Mlcrosimulation SCreening ANalysis). This was the start of 
the research project "Decision making about mass screening for cancer ll • 
MISCAN-based models for breast and cervical cancer screening have been 
used for analyzing some of the major screening projects in the world and in The 
Netherlands: the HIP randonlized controlled trial of breast cancer screening, the 
cervical cancer screening programme in British Columbia, the Dutch pilot study 
for cervical cancer screening, Ule breast cancer screening projects in Nijmegen 
and Utrecht, and the Swedish randonlized trials for breast cancer screening. 
These analyses yielded models that subsequently have been used in 
comprehensive cost-effectiveness evaluation studies of cervical cancer screening 
and breast cancer screening, ftrst for The Netherlands but more recently also for 
other countries. 
The practical relevance of our modelling work for cancer screening has 
become evident after we reported Ule results of the cost-effectiveness studies. The 
outcomes for breast cancer screening were in support for the screening strategy 
as proposed in The Netherlands. Both our favourable conclusions about the ratio 
of costs and effects, and ule finding Umt Ule adverse effects of a well-organized 
and conducted programme would be relatively minor in comparison with the 
anticipated mortality reduction, have contributed to the decision to start 
nationwide screening. The results of Ule evaluation of cervical cancer screening 
challenged Ule current practice of screening in The Netherlands, and have clearly 
influenced the decision for a change in screening policy. 
Publication of our cost-effectiveness results has also resulted in a demand 
for this type of analyses in other countries. Collaborative efforts have resulted in 
ill 
cost-effectiveness analyses of breast cancer screening in Australia and Gennany, 
and at present similar analyses are carried out in cooperation with groups in Italy 
and Spain. 
The experience gathered in modelling screening for cancer has been used in a 
number of modelling efforts in which I have been involved: models for tropical 
disease control and for public health problems in developed countries. 
A direct descendant of MISCAN is the HUMP AR model for evaluation of 
control programmes for the tropical infectious disease onchocerciasis (river 
blindness). The model has been used in analyzing and predicting the decreasing 
trend in infection load as a result of large scale vector control carried out in the 
Onchocerciasis Control Programme (OCP) in Western Africa. The relatively 
simple HUMP AR model has now been superseded by the comprehensive 
ONCHOSIM model, which describes the full transmission cycle of river 
blindness, the development of blindness, and dIe impact of different intervention 
strategies based on vector control or chemodlerapy (ivennectin). The 
ONCHOSIM model is not only highly complex, it has also been quite influential, 
since it has been used extensively in preparing policy decisions about control 
activities widlin the OCP. Similar models are under development for other 
tropical infectious diseases: lymphatic filariasis, schistosomiasis, and leprosy. 
Examples of Public Health models oriented to dIe problems in the 
Netherlands include die PREVENT and TAM models, and a model for predicting 
trends in accident mortality. The PREVENT describes the interaction between 
risk factors and diseases in a population, and can be used to predict dIe heaWI 
effects of preventive measures. The TAM model can be viewed as a ambitious 
extension of PREVENT, and aims at giving a general description of the public 
health and the demand for health care in The Netherlands. 
This thesis describes the first, essential step in model-based evaluation of 
screening for cancer: the construction, estimation and validation of 
epidemiometric models for breast cancer screening and cervical cancer screening. 
A series of articles on evaluation of screening is preceded by a general overview 
of modelling and its application to breast cancer screening and cervical cancer 
screening (Chapter 1). Chapters II-VI provide examples of analyzing results of 
breast cancer and cervical cancer screening projects. In dIe concluding Chapter 
(VII), the results of the model-based analysis and directions for further 
investigation are discussed. 
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I. INTRODUCTION 
Evaluation of screening for cancer 
The main goal in evaluation of screening for cancer is to assist in decision 
making about a screening program: Should it be initiated at all? What screening 
policies can be recommended: what age groups, what frequency of screening. 
Should special attention be paid to high risk groups? If a screening program is 
already running, should screening be continued in view of the results? Should the 
present policy be changed? 
In this chapter, I will describe the complexities involved in answering these 
questions. These difficulties lead to the conclusion that models are indispensable 
in the interpretation of observed results of screening and in the prediction of 
effects and costs of different screening policies. 
Screening for cancer 
From a public health perspective, the most attractive method of cancer control 
is primary prevention by reducing the exposure of the population to risk factors. 
Primary prevention will reduce both mortality and morbidity. Secondary 
prevention by means of early detection and treatment is a method of cancer 
control which aims at a substantial reduction in mortality from a specific type of 
cancer. A secondary aim, which will be more difficult to achieve, is to reduce 
morbidity. Mass screening implies examination of a population of apparently 
healthy individuals, using a suitable screening test to identify those who are likely 
to have an early stage of cancer. Mass screening programmes for cervical cancer 
and breast cancer exist in many countries, especially in Northern and Western 
Europe. 
Evaluation 
A inherent problem of mass screening is that adverse effects will occur such as 
false positive test results or treatment of screen-detected cancers which would 
never have been diagnosed in the absence of screening. These will strike persons 
that will not have any of the benefits of screening, such as less intensive 
treatment, prevention of invasive cancer andlor of death from the cancer. The 
existence of a group of persons that will suffer from being screened, dictates that 
screening programmes should be evaluated carefully to assess whether the 
anticipated favourable effects outweigh these adverse effects. Another reason for 
careful evaluation is important in an era of cost containment: mass screening 
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programmes are expensive, and although considerable financial savings in 
treatment costs are possible, they will in general be much smaller than the extra 
costs of screening. Furthermore, whereas most of the costs (and the adverse 
effects) are made when performing screening tests and in follow-up of screen-
positives, the possible savings will only be acquired years later. 
Assessment of the effects of screening is far from straightforward (Morrison, 
1992; Habbema ef al., 1982ab). The main effects, such as prevented deaths on 
the one hand, and unnecessary treated screen-detected cases on the other hand, 
cannot be established directly on basis of data recorded in screening registries 
(positive screening results, screen-detected cancers) and cancer registries 
(clinically detected cancers, survival). Only a careful comparison of a screened 
population and an unscreened population, by means of a randomized controlled 
community trial may give a decisive answer on the question of mortality 
reduction. 
The difficulties involved in decision making about mass screening become 
evident when comparing the (recommended) screening policies for cervical cancer 
and for breast cancer in different countries, see Tables I.I and I.2. The 
discussion regarding breast cancer screening policies (Table I.I) is focusing on 
the issue whether women younger than 50 should be screened. The variation 
between policies is largely due to different interpretation of the outcomes of 
randomized trials and some non-randomized pilot studies. 
Table 1.1 Recommended and actual screening policies for breast cancer. 
Country Age·range Interval Source 
(years) 
The Netherlands 50-68 2 Van der Maas et al.(1989) 
USA 40+ <50:1 or 2, NCIIACS (1987) 
> 50:1 
United Kingdom 50-64 3 Vessey (1991) 
Finland 50-59(-69) 2 Hakama (1988). Pamilo et 
al. (1993) 
The large differences in recommenced cervical cancer screening policies (Table 
1.2) cannot be explained easily. One reason of variation might be differences in 
the objectives of screening. Focusing on the (intermediate) objective of 
maximizing the number of screen-detected preinvasive stages would lead to 
emphasis on screening at young ages, and with relatively short intervals. 
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Minimizing the incidence of invasive cervical cancer and subsequent mortality 
would result in a shift to higher ages and longer intervals. 
A further complication in many countries is that the actual screening pattern 
differs substantially from the recommended schedule, with a considerable 
proportion of smears being made in very young women and/or at very short 
intervals. However, it seems that at least in Europe, a consensus is growing about 
the age range (from ±2S to ±6S) and the screening interval (at least 3 years), 
see Europe Against Cancer (1993). 
Table 1.2 Differences in screening policies for cervical cancer 
Country Age·range Interval (years) Source 
The Netherlands, old 35-53 3 Evaluation 
Committee (1990) 
The Netherlands, new 30-60 5 
USA 18+ NCI (1987) 
United Kingdom 20-65 5 Holland and 
Stewart (1990) 
Sweden 30-49 4 
Finland 30·55 5 UiMi et al. (1987) 
Iceland 25-69 2-3 
Canada 18-60 <35:1, >35:5 Canadian Task 
Force (1982) 
European Union 25-65 3-5 Europe Against 
Cancer (1993) 
Retrospective and prospective evaluation 
In evaluation of mass screening for cancer, a distinction can be made between 
retrospective evaluation of existing screeni ng projects, and prospective evaluation 
of proposed screening policies. The goal of retrospective evaluation is to analyze 
data from screening projects in order to explain the observed screening results, 
and (if possible) to draw conclusions about the effects of screening. The findings 
can subsequently be used in prospective evaluation, which aims at making 
predictions about the effects of screening policies. This may lead to 
recommendations about starting or continuation of a screening programme and 
about efficient screening policies. Evaluation should continue when the mass 
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screening is an established component of health care ("monitoring"), in order to 
check whether the expected benefits have indeed been accomplished. 
Analysis of screening results 
A prerequisite for a detailed retrospective evaluation (or analysis) is that 
empirical data from well-designed experimental studies are available. Ideally, 
randomized controlled trials (RCT's) should have been conducted. In the absence 
of a RCT, or in addition to it, longitudinal data from screening programmes, 
including cancer incidence and mortality are useful. An indication for the effect 
of screening can also be obtained from case-control studies. 
Retrospective evaluation first of all requires a careful statistical analysis of the 
available data. In addition, model-based analyses may be carried out to make 
inferences about the parameters governing the results and effects of screening. 
The most important parameters describe the so-called underlying processes (Bross 
and Blumenson, 1968; Eddy and Shwartz, 1982): the preclinical course of the 
disease, the quality of the screening test, the impact of early detection and 
treatment on a patients' prognosis, and the association between disease risk and 
participation in screening. These processes cannot be observed directly. Statistical 
comparison of data from screened and unscreened population may already give 
an indication of regression (Boyes el al., 1982), the duration of preclinical stages 
(Hakama et al., 1986a; Day, 1985a) and the sensitivity of the screening test 
(Day, 1985b). 
Characteristics of 
screening project 
Model 
Assumptions 
MODEL 
PREDICTED 
screening 
results 
OBSERVED 
screening results 
Statistical 
testing 
Result: 
Good-fitting 
Model Assumptions 
Figure la Model-based analysis of mass screening results. 
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Modelling can improve these direct methods in two ways. First, instead of 
estimating the parameters of these underlying processes separately, joint estimates 
(including their correlation) are derived, for example regarding the duration of 
the screen-detectable stages and the sensitivity of the screening test. Second, 
more data can be included in the analysis, e.g. detection rates at successive 
screenings, interval cancer rates, clinical incidence in unscreened persons. 
A general procedure for model-based analysis is outlined in Figure Ia. 
Different model assumptions are investigated by means of a statistical comparison 
of the screening results predicted by the model and the observed results of 
screening projects. The choice of the model structure and the selection of 
observed screening results are of critical importance for the quality of the model. 
It is hoped that the result of this modelling stage will be a set of model-
specifications that are in good agreement with available empirical screening data. 
Subsequently, these good-fitting model assumptions can be utilized in prospective 
evaluation of screening policies, see Figure lb. 
Prospective evaillation 
In view of the many parameters that determine the direct results and long-term 
effects of screening for cancer, modelling is the method of choice for evaluating 
the impact of proposed screening policies. In prospective evaluation, policies will 
be compared on basis of the expected favourable and unfavourable effects, and 
their costs, in a specific population, see Figure lb. The model predictions can be 
used to produce a complete overview of the expected benefits and potential risks, 
which may serve as a guidance for the individual person who is invited for 
screening. In addition, predictions may be made regarding the impact of 
screening on existing health care services. 
In this thesis I will focus on the first stage of modelling as depicted in Figure Ia: 
development and testing of models. I will describe two different approaches for 
model development and parameter estimation: a statistical-numerical approach, 
and a simulation approach which uses the MISCAN programme. These two 
methods represent different trade-offs between methodological correctness on the 
one hand and medical/epidemiological plausibility ("face-validity") of the model 
assumptions on the other. Ideally, these two approaches are combined, starting 
with a statistical-numerical analysis which is then followed by a more 
comprehensive simulation modelling effort (Chapter IV of this thesis; Van 
Ballegooijen et al., 1993). 
Application of these models to the second stage (Figure lb) of cost-
effectiveness evaluation requires extensions in which the cost of the screening 
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(good-fitting) 
Model 
Assumptions 
Screening 
Policies 
MODEL 
Chapter I 
Evaluation 
Criteria 
Predicted COMPARISON 
costs and effects --;. of effects 
of screening and costs 
Result: 
Efficient 
Screening Policies 
Figure Ib Prospective evaluation of screening policies. 
organisation, the medical procedures, and the quality of life in different phases 
are added to the model. Modelling of these extensions is not a subject of this 
thesis, the assumptions made and the resulting predictions have been described 
elsewhere (Van der Maas et al., 1989; Van Ballegooijen el al., 1990, I 992a; De 
Koning el al., 1990a,1991; Koopmanschap el al., 1990a). 
An important aspect in the development of a model is the implementation in 
computer programme(s). Although much effort has been devoted to the 
development of the MISCAN computer programme (Van Oortmarssen el al., 
1982; Habbema el al., 1984,1987), only a brief overview of the program and the 
simulation procedure will be presented in this thesis. 
Analysis of screening projects 
In analyzing data from screening activities for deriving estimates of the effect of 
screening, a distinction has to be made between experimental studies, i.e. 
randomized controlled trials, and non-experimental studies, for example cohort 
studies, case-control studies and geographical correlation. Each study design 
requires special methods of analysis. Designs will also differ with respect to the 
degree in which systematic bias in estimates can be avoided (Morrison, 1992). 
Biases in effect estimates are best illustrated for a method of evaluating the 
effect of screening which used to be quite common in the early days of screening: 
comparison of survival. Screen-detected and clinically diagnosed cases are 
compared on basis of data recorded in survival registries. Survival outcomes, for 
example the proportion of persons that survives after 5 years, or the full 
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distribution of time between diagnosis and death, are inadequate for analysis of 
the effect of screening because of the disturbing influence of several sources of 
bias: lead time bias, length bias, patient self selection bias, and overdiagnosis 
bias. Even if screening would have no effect at all, the survival would be more 
favourable for screen-detected cases than for clinically diagnosed cancers. The 
survival time, i.e. the time interval between diagnosis and death, will be longer 
in screen-detected cases, because of the addition of the lead-time period between 
detection by screening and the moment at which the cancer would have been 
diagnosed clinically in the absence of screening. In addition, screening will tend 
to pick up relatively slow developing cancers, and miss fast growing ones: length 
biased sampling. And it could well be that slowly growing cancers have a better 
than average survival, which leads to further bias in the survival time 
comparison. 
Patiellf self selection occurs when health-conscious persons who are more 
likely to participate in screening, also have lower mortality risks in the absence 
of screening. This is not as unlikely as it may seem. People who are alert to 
slight symptoms may be more inclined to participate in a screening programme 
than persons who postpone medical examination in spite of alarming symptoms. 
This will again lead to a seemingly longer survival time for screen-detected cases. 
Overdiagnosis bias of survival time will occur when cases are detected by 
screening which would never have been diagnosed in these absence of screening 
because the condition ("pseudodisease") will only be detected by a screening test, 
but never lead to severe symptoms. If these cancers have a good prognosis, the 
lethality and cancer mortality of screen-detected cancers will be lower than in an 
unscreened population, even if screening has no effect at all. Another type of 
overdiagnosis of screen-detected cancers, which is especially important at older 
ages, occurs in case of death from other causes during the lead time period. But 
this does not necessarily lead to biased survival outcomes, since it will not affect 
relative survival figures. The negative health effects of "unnecessary" diagnosis 
and treatment of these cancers are of course important in evaluation of screening 
at older ages (Boer et al., 1994b). 
The impact of these four sources of biases of the survival can be large 
(Habbema et al., 1983; Walter and Stitt, 1987; Shwartz, 1980; Morrison, 1992; 
Pelikan and Moskowitz, 1993). Thus, it is impossible to use survival time 
comparisons for estimating the true effect of screening because of biases that are 
specific for screening. Other, more laborious methods should be used that are 
less vulnerable for bias, although some amount of bias will always will be 
present, either the screening-related biases or general problems in measuring the 
effect of interventions in health care, like for example placebo effects. 
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Randomized cOllfro/led trials 
A randomized controlled design is the method of choice for obtaining objective 
estimates of the effect of screening in reducing mortality. Still, bias cannot be 
excluded because of practical constraints in designing a RCT. Ideally, one would 
like to use total mortality as an endpoint to avoid bias because of possible side-
effects of screening, see for example the higher mortality from suicide in the 
Kaiser Health Plan trial (Friedman et al., 1986), and also because of differences 
in classification of mortality. But using total mortality requires a much larger 
study population than the already giant population needed for demonstrating a 
significant reduction in mortality from the cancer under consideration. Other 
practical problems concern the level of randomization (individual, general 
practitioner, county), "contamination" with screening in the control group, and 
the cessation of the trial (stop screening in the screening group or introduce 
screening in the control group) with the associated problem of avoiding extra 
cases in the study group, a special kind of overdiagnosis bias. 
A delayed entry RCT uses a slightly different approach in that screening will 
be offered to the total study population, but the screening starts later in the 
control group than in the study group. The delayed entry design is also useful in 
a non-experimental screening programme. Introducing a (nationwide) mass 
screening requires a build-up period, and the resulting differences in time-at-entry 
into the programme can be used in analyzing the results and effects on incidence 
and mortality. This approach is currently tested in the Finnish breast cancer 
screening programme. First all women born in even years have been invited, and 
the women in the adjacent odd-years serve as control population during the first 
part of the build-up period (Hakama, 1988; Hakama et al., 1991). 
Cohon studies: comprehensive analysis of screening data 
Comprehensive analysis of screening data from non-randomized screening 
programmes may provide a direct estimate of the effect on mortality, but may 
also be used for estimating other key factors in the evaluation of screening. In 
comparison with RCT's, the resulting estimates may be severely biased, 
especially because of the self-selection bias: participants in screening may have 
a lower risk of having the disease than non-participants, and since participating 
women tend to be relative health-conscious, they might also have a better 
prognosis in the absence of screening. The best examples of this approach 
address the evaluation of cervical cancer screening, which is no surprise given 
the absence of RCT's for this type of cancer screening. 
Introduction 9 
The British Columbia Cohort Study (Boyes et al., 1982) was aimed at deriving 
estimates for the incidence of preclinical stages of cervical cancer, and assessing 
the proportion of these lesions that regress spontaneously. Two birth cohorts were 
selected, and for women in these cohorts screening records and cervical cancer 
records were linked for a 20-year period (1950-1969). This enabled estimation 
of the age-specific incidence of preinvasive cancer. By comparing this incidence 
with the pre-screening, cross-sectional incidence of invasive cancer, the 
proportion of regressive cases could be estimated. A model-based analysis of the 
same data is reported in Chapter IV. 
The pilot projects for breast cancer screening and cervical cancer screening in 
the Netherlands have also been analyzed extensively (Peeters et al., 1989; Peer 
et al., 1994; De Waard, 1984; Collette et al., 1992ab; Evaluation Committee, 
1989; Van der Graaf, 1987). In Chapter III a model for breast cancer screening 
is presented which is based on the data from the projects in Utrecht (DOM 
project) and Nijmegen. 
Correlatioll studies 
Correlation studies for the effect of screening compare regions or countries, 
attempting to correlate screening activities with observed changes in clinical 
incidence and mortality. Convincing evidence for the effectiveness of screening 
for cervical cancer has been obtained in this way by comparing data from the 
Nordic countries (Uiiirii et al., 1987), and by comparing provinces of Canada 
(Miller et al., 1976). 
Case-control studies 
In case-control studies, the exposure to screening of all cancer cases in a well 
defined population and period is compared with the exposure of non-cancer 
controls. Usually, the controls are matched against the cases on bases of known 
or suspected risk determinants (e.g. age, neighbourhood). The screening 
experience of cases and controls is compared, and the odds ratio is interpreted 
as an indicator for the effectiveness of screening in reducing the number of cases. 
This offers a relative quick method for evaluation of screening projects that do 
not use a randomized design. 
A specific problem is the definition of cases. The definition should reflect the 
condition which is to be prevented, and Ilot detected, by screening, i.e., death 
from cancer or an advanced stage of cancer that will be diagnosed anyhow. 
However, this may in practice lead to difficulties in collecting the data regarding 
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the screening history. Use of alternative case definitions, e.g. all diagnosed 
cancers, will give rise to biased estimates. 
Case-control estimates for the effectiveness of screening are also likely to be 
biased because of self-selection bias. Another potentially important source of bias 
which especially applies to case-control studies of screening is the heafthy 
screellee bias. Again consider the situation that early detection does not affect 
risk of death from the cancer. Then, cases will on average have a smaller number 
of screenings before the moment of death than comparable (matched) controls, 
because of the period of disease which precedes death, and in which persons are 
not eligible for screening. Comparison of crude exposnre to screening would 
suggest a beneficial effect. More appropriate measures of exposure have been 
proposed and used. The adaptations needed depend on the characteristics of 
screening patterns in a population, and the kind of relation considered, e.g. ever 
versus never screened, or a dose-response relation. 
See (Morrison, 1982,1992; Brookmeyer et af.; 1986; Sasco et at., 1986; 
Friedman and Dubin, 1991; Weiss, 1994) for a discussion of these and other 
problems involved in applying the case-control design to cancer screening. 
Many case-control studies have been reported, both for breast cancer screen-
ing, in which mortality usually is the end-point (e.g., Collette et af., 1984,1992; 
Verbeek et af., 1984; Pam et al., 1986), and for cervical cancer screening, in 
which invasive cancer is usually taken as end-point (e.g., Clarke and Anderson, 
1979; Macgregor et af., 1985; Lynge and Poll, 1986; Van der Graaf, 1987). In 
Chapters V and VI it will be shown that the use of invasive cervical cancer as 
case definition will lead to biased estimates of the long-term impact of cervical 
cancer screening on mortality. 
Meta allalysis 
Given the absence of a randomized controlled trial of cervical cancer screening, 
a IARC/WHO study group concluded that a combined analysis of major non-
randomized screening studies would give convincing estimates of the reduction 
in risk of invasive cervical cancer after one or more negative Pap smears 
(Hakama et af., 1986a). The advantage of this approach can be seen by 
inspecting the estimates for the separate projects, which are less convincing 
because of the relative small numbers of cancers in each of the projects. We have 
used the model constructed on basis of the British Columbia cohort study to 
analyze the outcomes of the IARC study, and demonstrated that a single 
quantification of the underlying processes gives a good explanation of both data 
sets. 
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For breast cancer screening, a number of combined analyses of the outcomes 
of the randomized trials have been reported (Rutqvist et al., 1990; Glasziou, 
1992; Vessey, 1991; Fletcher et al., 1993; Screening brief, 1994). However, a 
weak point of these analyses is that the obvious differences in the characteristics 
of the trials are not (or insufficiently) taken into account. This limitation can only 
be overcome by using explicit models. 
Surrogate outcome measures 
The enormous size and long duration of randomized controlled trials of cancer 
size prohibits testing of a range of policy options, and also means that major 
changes occurred with respect to the screening test, diagnostic tests, or treatment 
possibilities at the time when the results become available. This has given rise to 
search for alternative methods for empirically testing policy options. One relative 
recent method which is to consider surrogate (or illlerll/ediate) outcome measures 
instead of the real outcome measure (mortality) (Day, 1991; Morrison, 1992). 
First, the relation between the surrogate outcome as determinant of the real 
outcome has to be established. Policy options are then compared in studies which 
take the surrogate outcome as endpoint, and the relation with the real endpoint 
is used to translate the intermediate outcome into the final effect. 
Model based analysis 
In the studies mentioned in the preceding section, model-based reasoning is used 
in evaluation of screening projects, for example in searching for appropriate 
measures and formulas for analyzing screening data. But the results are calculated 
without explicit use of models. The outcomes of the studies are mostly in terms 
of risk reduction and therefore have a direct interpretation both for individuals 
who contemplate screening and in assessing the public health impact of screening. 
However, the outcomes are specific for the characteristics of the projects under 
study and cannot be generalized easily to other circumstances regarding screening 
policy, epidemiological situation (e.g., clinical stage distribution), etc. 
The goal of model-based analysis of screening results is to test hypotheses and 
to make inferences about the underlying dynamic processes which cannot be 
observed directly, but may be assumed to apply to other circumstances as well. 
Two underlying processes that together relate the screening policy to the effect 
of screening should be distinguished: 
(I) DETECTION, the process of detecting a cancer in an early stage; 
(2) PROGNOSIS, the improvement in prognosis resulting from early detection. 
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These two processes are the building blocks of the basic cancer screening 
model structure which comprises 9 states, see Figure Ic and Table I.3. Persons 
start in state No CANCER, and the large majority will not have a cancer history 
and experience only one transition to state DEATH FROM OTHER CAUSES. The 
two preclinical screen-detectable states at the left-hand side will normally remain 
unnoticed in the absence of screening, and the cancer will be diagnosed after 
presenting symptoms (state CLINICAL INVASIVE). Treatment may result in CURE 
or can be unsuccessful and the person dies from the cancer (DEATH FROM 
CANCER). Screening may result in early detection of stages SCREEN-DETECTABLE 
NONINVASIVE and SCREEN-DETECTABLE INVASIVE. In the figure, it is assumed 
that treatment of SCREEN-DETECTED NON-INVASIVE cancers will always result in 
cure. Persons with treated SCREEN-DETECTED INVASIVE cancers will have a lower 
risk of dying from the cancer than treated CLINICAL INVASIVE cancer cases. 
The basic events that would be recorded in a cancer registry are indicated by 
ErEs. The ages and results of the screening tests (Gloo.Gk) would be available 
from a screening registry. The corresponding detection rates at successive 
screening examinations, the incidence of interval cancers, and the clinical 
incidence in unscreened persons can be used to estimate the "deep" parameters 
of the underlying processes. The parameters of the DETECTION part 
characterize transition rates in the preclinical disease process (PI-P4) and the 
sensitivity of the screening test (Ps, pc;l. The remaining parameter (P7) of the 
PROGNOSIS part describes the relation between earliness of detection and 
mortality risk, which can be estimated from observed mortality difference 
between screened and unscreened populations, ideally from the mortality rates in 
the study- and control group of a randomized controlled trial. 
The surface parameters DrD4 can usually be based directly on local data from 
the area under consideration. Indeed, these parameters may differ considerably 
between areas: the false positive rate D2 in breast cancer screening in The 
Netherlands and Sweden is much lower than in countries like the USA, and also 
survival rates D3 show significant variation between countries. Some of the deep 
parameters are likely to have a local component as well. For example the level 
and age-distribution of the onset depends on risk factors in the population, and 
the test sensitivity may be influenced by local factors, e.g. training, quality 
control, and follow-up protocols. Both in transferring a model to other areas and 
in making predictions one shonld take possible changes in parameter 
quantifications into consideration. 
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Figure Ie Basic structure of a model for cancer screening. 
Table 1.3 Parameters and events in the basic model of cancer screening. 
Deep parameters Surface parameters Events 
P, Onset 0, Participation E, Clinical 
Incidence 
P2 Regression of pre-invasive O2 False Positives E2 Mortality from 
stages cancer 
P3 Progression of pre-invasive 03 Clinical Survival E3 Detection Rate 
stages Pre-Invasive 
P4 Duration of preclinical 0 4 Death from other E4 Detection Rate 
invasive stage causes Invasive 
p. Test Sensitivity, pre-invasive E6 Death from 
stage other causes 
Po Test Sensitivity, invasive 
stage SCREENING HISTORY 
P7 Improvement in prognosis G, ... Gk Ages and results of 
k screening tests 
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For specific applications, this basic model will should be refined to reflect the 
characteristics of both the cancer under study and the screening projects that are 
analyzed. For cervical cancer screening the primary aim is detection of the non-
invasive stages of the disease, therefore the non-invasive state of the model can 
be subdivided in dysplasia and CIS (or, CIN IIII/III). For breast cancer, the 
screen-detectable invasive state is the most important. By subdividing this state 
according to tumour diameter and/or lymph node status, the shift in stage 
distribution resulting from screening according to the model can be compared 
with observed stage distributions in screen-detected and interval cancers. And the 
assumptions about improvement in prognosis can be checked against stage-
specific survival data, both for screen-detected cancer and clinical cancers. 
Modelling approaches 
A large number of cancer screening models have been published and reviewed 
(Eddy and Shwartz, 1982; Prorok, 1986,1988; Alexander, 1989; Baker el al., 
1991). 
The models differ in objective, in comprehensiveness, and in (numerical) 
methods used in implementation. Objectives are: (a) formal (mathematical) 
description of the processes involved; (b) parameter estimation and hypothesis 
testing; (c) prediction of the results of screening policies; (d) cost-effectiveness 
analysis; (e) optimization of policies. In objectives (a-c), the goal may be to study 
one or more specific aspects, which leads to a partial model, for example models 
that only address the DETECTION part of figure I.c. Still, these partial models may 
be very detailed. Comprehensive models are required for cost-effectiveness 
analyses and for optimization of screening strategies. 
The objectives (a) .. (e) might be considered as a sequence in which models 
development starts from a largely theoretical basis, followed by estimation and 
validation, and can then be applied as a decision support tool in public health 
decision making. In practice this trajectory has never been fully completed, 
although the modelling efforts of Eddy (1980,1981,1987,1988,1990), Shwartz 
(1978ab,1980,1981,1992), Gustafsson and Adami (1989,1990,1992) and our 
MISCAN work address most of the objectives. 
Mathematical descriptions of screening for cancer resulted in highly theoretical 
work (Blumenson, 1977; Louis el al., 1978; Prorok, 1976ab), but also served as 
a starting point for analysis of screening data (Day and Walter, 1983; Gustafsson, 
1986) and prediction of screening policies (Eddy, 1980; Shwartz, I 978b) and thus 
influenced applications of great practical relevance (Walter and Day, 1983; 
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Eddy, 1980,1981,1988,1990; Gustafsson and Adami, 1989,1990,1992; Shwartz, 
1978a, 1980, 1992). 
Two classes of models only aim at certain objectives: descriptive statistical 
models and macrosimulation models. 
A considerable number of descriptive statistical models has been developed for 
addressing specific questions regarding components of the general structure in 
Figure Ie. Examples are the ROC models describing the change in false-positive 
and false-negative rates when different criteria are used in classifying results of 
screening tests, and the Age-Period-Cohort model for describing temporal 
changes in incidence and mortality. 
Macro-simulation (or discrete-time Markov) models are a type of dynamic 
stochastic models that are mainly used for predictions of the results of screening 
policies. "Stochastic" implies that transitions between disease states are described 
by probability distributions. The term "dynamic" is used to stress the importance 
of time-related events and their associations, e.g. aging of persons, development 
of disease including dwelling time of preclinical screen-detectable stages, survival 
time, and timing of screening examinations. The best example is the model of 
Knox (1973,1975) which has also been used by our group (Habbema et al., 1978) 
and in other countries (Yu et al., 1982; Stevenson et al., 1991; Carter et al., 
1993). In macro-simulation the complete distribution over all possible 
combinations of states (including disease states, dwelling time in state, screening 
history, birth cohort, and age) is calculated at each time-step (usually I year). 
The number of combinations will rapidly become very high (for example 80 ages 
x 25 dwelling times x 25 disease states x 16 types of screening histories = 
800,000 combinations), and require much computer memory and computer time 
when these calculations have to be made for e.g. 80 yearly birth cohorts. Also, 
the 1 year time-step may be too crude for some output, e.g. of interval cancers. 
For these reasons, macrosimulation is not very well suited for analysis of 
screening data. 
Two types of numerical modelling approaches are more useful for 
comprehensive analysis of screening data: statistical-numerical models and 
microsimulation models. Essentially, they differ only in the numerical technique 
which is applied to the dynamic stochastic cancer screening model shown in fig 
Ic. The most elementary dynamic model, involving I disease state and I 
screening test, was described mathematically by Zelen and Feinleib (1969), and 
demonstrates the existence of length biased sampling, the way it influences the 
lead time, and the relation with the distribution of the preclinical screen-
detectable state. 
More refined dynamic models will rapidly become too complex for analytical 
solution. Then, statistical-Ill/merical techniques can be applied for obtaining 
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estimated values for the parameters of the model. The numerical approach used 
is comparable to macrosimulation models, with two major differences: the time-
perspective and the time-step. Macro-simulation proceeds in a forward direction. 
Starting from an initial distribution over all states, this complete distribution is 
updated at successive time steps. This time step is fixed (usually I year), which 
might lead to inaccuracies with respect to the possibility of multiple events 
occurring during a single step. In the statistical-numerical approach a backward 
direction is adopted. For each outcome variable of the model that has to be 
calculated, equations are derived that integrate over all possible earlier states. 
Numerical integration routines are used which can achieve high accuracy. This 
approach is more efficient in case of limited number of (aggregated) observed 
data points that have to be fitted by the model, and for relatively simple models. 
Most statistical-numerical models are confined to the DETECTION box in 
Figure Ie. The best known example is the one-stage/multi screening model of 
Day and Walter (Day and Walter, 1984; Day el al., 1988; Walter and Day, 
1983) which especially applies to breast cancer screening (or in general, to 
screening for a disease with a relatively short, progressive preclinical stage). The 
parameters (mean duration P4 and sensitivity PtV are estimated from detection 
rates (E4) and interval cancers (EI) in subsequent screening rounds. Application 
to data from different screening projects showed that the duration of the 
preclinical stage of breast cancer can be adequately described by an exponential 
distribution, implying considerable variability, i.e., both high proportions of fast 
growing and of very slowly progressing cancers. 
This model has been generalized in different ways: two preclinical states 
(Brookmeyer and Day, 1987), time-dependent sensitivity (Verbeek and 
Straatman, 1988), multi-state/two screening methods (Alexander, 1989a). Our 
statistical/numerical cervical cancer model (described in Chapters IV-VI) may 
also be regarded as an extension of the model of Day and Walter. It consists of 
the complete DETECTION box in Figure Ie with its 6 parameters PI"P6, and has 
4 additional parameters: age-dependent pre-clinical incidence, age-dependent 
regression, variability of the preinvasive stage, and risk difference regarding 
onset of pre-invasive stages between participants and non-participant in screening. 
A similar cervical cancer screening model has been used to analyze Swedish 
screening, incidence, and mortality data (Gustafsson and Adami, 
1989,1990,1992). This model includes the PROGNOSIS box of Figure Ie. Another 
model which includes both the DETECTION and the PROGNOSIS boxes has been 
developed for lung cancer screening (Flehinger and Kimmel, 1987,1993). Partial 
breast cancer screening models addressing the PROGNOSIS part have been 
proposed by Habbema et al. (1983), Walter & Stitt (1987) and Connor el 
al.(1989). 
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Parameters are estimated in an iterative procedure involving calculation of 
the model outcomes and of the likelihood, and subsequent adaptation of 
parameter values. 
In the statistical-numerical approach, the elements of the general analysis 
scheme (Figure Ib) are combined in an iterative procedure which is shown in 
Figure Id. The MODEL step requires writing down the equations which express 
the expected rates for the screening data as a function of the parameter values 
(see for example Chapter IV, appendix B). In general, these equations will be too 
complex to be solved analytically, and numerical approximation methods are used 
to calculate expected rates from the model for given parameter values. Parameter 
estimation is based on maximization of the likelihood, assuming that the observed 
numbers of cases are realisations of a Poisson distribution with mean value = 
predicted rate x observed number of persons "at risk". Starting with a set of 
initial parameter values, the iterative optimization routine will result in maximum 
likelihood (ML) estimates of the parameters. Hypotheses can be tested by means 
of the likelihood-ratio test. The goodness of fit is checked by looking at the 
deviance and the Pearson Chi-square. 
The statistical-numerical method is relatively fast in terms of computer time. 
However, it requires substantial effort for deriving the formulas involved, which 
will rapidly become complicated when a model is extended. This imposes 
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restrictions to the complexity of the model, and also hampers testing of the 
robustness of the model assumptions. The main advantage of the approach is that 
standard maximum-likelihood methods can be used for testing hypotheses and 
deriving confidence regions. 
A completely different approach is used in microsil1llllatioll, a technique based on 
generating large numbers of random trajectories, governed by the probability 
distributions which describe the processes in the model. Applied to cancer 
screening, this means that individual life-histories of (fictitious) persons are 
generated, including a possible disease history and the results and effects of 
screening examinations. A simulated life-history is characterized by the events 
which are related to cancer screening (see G1" and E1" in fig Ie). A file of these 
life-histories can be considered as simulated population-, cancer-, and screening 
registry, and model output is calculated correspondingly by counting the number 
of cases and the number of person(year)s at risk. 
The output of a microsimulation run will be subject to random variation and 
will only represent an estimate of the true outcomes of the model. Repeating the 
simulation with the same input specifications will give different output results. 
The variability in the output depends on the number of histories that are 
simulated, and can be influenced favourably by using variance reduction 
techniques (Law and Kelton, 1982; Ripley, 1987; Kleijnen and Van Groenendaal, 
1992). 
Compared to the statistical-numerical approach, a single simulation run will 
take (much) more computer time, and the variability in the output implies that the 
likelihood methodology and standard optimization routines cannot be used. 
Testing the goodness of fit can be done by Chi-Square testing in which the 
variance of the simulated output is taken into account. Special stochastic 
optimization routines that allow for stochastic output are being applied for 
microsimulation disease models (Plaisier et al., 1994; Seaholm, 1988), see 
Chapter VII for further discussion. 
Despite these drawbacks, microsimulation has a number of advantages that 
make it worth consideration for analysis of cancer screening data. A model can 
be implemented in a computer programme within a relative short time, and 
modifications and extensions are in most cases also implemented easily. Apart 
from the computer time, there are no real restrictions with respect to the type of 
functional relations used in the model. For example, using a Weibull instead of 
an Exponential distribution requires only a minor modification. A distinct 
advantage is that the approach and the model that are used in data analysis can 
directly be used in predicting the effects and costs of screening policies. With the 
steadily increasing computing power the disadvantages of microsimulation will 
Introduction 19 
become of lesser importance since sufficiently large numbers of histories may be 
simulated within a reasonable time limits. 
In the next section, I will give a brief description of our microsimulation 
programme MISCAN, which was developed on basis of our experiences with the 
SCRMOD macrosimulation model (Habben,. el al., 1978). Apart from 
MISCAN, one other microsimulation cancer screening model has been published 
(Parkin, 1985,1986). 
MISCAN 
The MISCAN simulation package has been developed both for analysis of data 
from screening projects, and for making predictions about effects (and costs) of 
alternative screening policies. The package consists of a coherent set of computer 
programs. The main program is the microsimulation program which can be used 
to simulate dynamic-stochastic models of screening for disease. See (Van 
Oortmarssen el at., 1982) for details on the micro-simulation approach, and 
(Rabbema el al., 1984) for an overview of the possibilities of the programme. 
The main simulation program offers a general framework for specifying the 
processes which describe the disease, the characteristics of the screening test(s), 
the impact of early detection on prognosis, and the various aspects of the 
screening programme. It can be used for simulating models of different levels of 
complexity, from very simple to quite complex. Because of the great variation 
in design and data-collection between screening projects, adaptations of the 
simulation program may be needed when a specific screening project is analyzed. 
These adaptations mainly concern the invitation system and the way in which data 
are reported. The program will then produce simulated output which conforms 
to the format of the results of the screening project. 
The core of the MISCAN program; the natural history of the disease and early 
detection by screening has remained largely unchanged since the 1984 
publication. One extension is used in Chapter III: the dwelling-times in a state 
can now be made age-dependent. For predictions about costs and effects of 
screening, the time of birth has been added to the life histories, which enables 
MISCAN to simulate a complete population and not only a single birth-cohort of 
persons. Some of the model-parameters, for example the cumulative incidence 
of the disease, can be made dependent on the birth cohort. Other parameters, 
especially those describing the screening programme, can change over calender 
time. 
Further calculations, for example goodness of fit testing, or calculation of 
predicted costs, are made in application-specific post-processing routines which 
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are presently often implemented in spreadsheet programs. In prospective 
evaluation the simulated screening results are combined with data on medical 
procedures (assessment, therapy), with data on costs, and when possible with 
utility values expressing the quality of life in a specific disease stage. The cost-
effectiveness approach was first outlined in (Habbema el al., 1987), and later 
applied to breast cancer screening (Van der Maas el al., 1989; De Koning el al., 
1991; see section 1.6) and cervical cancer screening (Koopmanschap el al., 
1990a; Van Ballegooijen el al., 1990,1992,1993; see section 1.7). 
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Figure Ie Analysis of screening data with the MISCAN model. 
Parameter estimation 
The estimation procedure for parameters of a MISCAN model follows the same 
steps that are used in statisticalfnumerical modelling (Figure Id). But adaptations 
are necessary to account for the stochasticity of the simulation (already discussed 
in section 1.4), see Figure Ie. 
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For a given set of parameter values, MISCAN simulates screening results. The 
goodness of fit between these simulated results and the observed data is 
determined by Chi-Square tests that takes the variability in simulated results into 
account. Special optimization routines which allow for stochasticity of model 
outcomes may then be used to locate the combination of parameter values which 
minimizes the Chi-Square test. The dashed box "change in parameter values" 
indicates that we did not use fully automated iterative optimization routines in 
MISCAN applications thus far. In the analysis of the HIP study (Chapter II) a 
quadratic function is fitted to Chi-Square results of simulated parameter 
combinations, and new parameter values are chosen manually on basis of 
inspection of the fit results. This procedure can be regarded as a semi-automatic 
version of the Response Surface optimization method (Ripley, 1987). 
Auxiliary programmes 
In addition to MISCAN, we have developed and utilized a number of auxiliary 
models for analysis of data related to cancer screening. These models can be used 
to analyze a component of the model in detail, or can be regarded as 
simplification of a large part of the comprehensive MISCAN model. 
Age-Period-Cohort (APC) models have been used for detailed analysis of time-
trends in mortality and incidence of a cancer. APC models are especially useful 
in case of cervical cancer, where there is substantial evidence for a cohort trend 
in incidence and mortality, probably related to changes in sexual behaviour and 
corresponding incidence of infections with certain strains of the Human Papilloma 
Virus (HPV) that have to be shown to be strongly associated with cervical 
cancer. Although APC models cannot be used to prove such a trend, they can 
serve to decompose the observed data into the three APC components on basis 
of presuppositions (Osmond and Gardner, 1982; Van Putten et al. , 1981; Moens 
and Van Oortmarssen et al., 1987; Holford et al., 1994). In case of cervical 
cancer, we used this model to derive cohort-specific relative risks on basis of 
mortality data (Habbema et al., 1988; Van Ballegooijen et al., 1993). 
Other examples of detailed sub-models are the incidence-duration model which 
has been used for back-calculation of incidence rates for screen-detectable stages 
on the basis of (known) clinical incidence rates and (assumptions about) the 
duration of screen-detectable stages (Van Ballegooijen et al., 1993), and a sub-
model that has been used to test the consistency of age-specific data on clinical 
incidence, survival, and mortality. 
The duration/sensitivity model developed by Walter and Day (1983) has been 
used to select starting values of parameters in the analysis of the HIP study data 
(see Chapter II). 
22 Chapter I 
Model-based analysis of breast cancer screening 
MISCAN based-analyses have been carried out on data from the HIP study, 
from the two breast cancer screening projects in the Netherlands, and from the 
WE and Malmo trials in Sweden. The main objective of these analyses was to 
build and quantify a model which would allow us to translate the findings 
concerning reduction in breast cancer mortality of the randomized trials (HIP and 
Swedish projects) to other circumstances and to other screening policies, and in 
particular to the nationwide screening programme in The Netherlands. The breast 
cancer model conforms to the general structure presented in figure Ie, although 
the preclinical invasive stages are much more important than the non-invasive 
stages (e.g., ductal Carcinoma in Situ). 
Before doing the model-based analysis, we analyzed the data from the HIP 
randomized trial study in detail. A copy of the statistical tape of the study was 
made available to us, containing datasets regarding participation and screening 
test results of the full study population and follow-up of all breast cancers 
diagnosed in the study group in which women were invited for screening and the 
control group of women who were not invited. We analyzed survival data from 
the screen-detected cases and the clinically diagnosed cases, investigating the 
potential impact of lead time bias and length bias (Habbema el af., 1983). 
Effectiveness of screening under age 50. 
The issue whether the HIP study indicated that breast cancer screening is 
effective in reducing breast cancer mortality in women under age 50 is discussed 
in (Habbema et af., 1986). Evaluation of the HIP data has given rise to much 
debate, especially about the effectiveness below age 50. This paper, and a paper 
from Prorok el al. (1981), were the first to challenge the prevailing opinion that 
the HIP data indicated that screening women under age 50 was hardly effective 
(Shapiro, 1977; Shapiro el al., 1982). The main findings are given in 
Table I.3, Table I.3, showing a significant overall reduction in breast cancer 
mortality. Age-specific comparison suggests a beneficial effect of screening in all 
age-groups. However, the reduction is not significant in any of these groups. 
The beneficial effect, expressed in life-years gained by screening, is based on the 
assumption that the difference in number of breast cancer deaths stabilizes after 
the 14 years offollow-up represented in the data available at that time. Note that 
the highest gain is found in the youngest age group. 
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Table 1.4 HIP study: effectiveness of breast cancer screening 
Number of breast cancer deaths within 14 years after entry, in study· and 
control group, among cases diagnosed in first 7 years after entry; percent 
reduction in mortality with 95% confidence limits, and esti";ated number of 
life·years gained per 1000 women in the study group. 
Age group Breast cancer Mortality reduction 
(at entry) deaths (numbers) 
Study Control % range 
group group 
40·44 27 39 31 [·12, +59) 
45·49 37 43 14 [·35,+46J 
50·54 42 54 22 [·17,+50J 
55·59 35 43 19 [·28, +49J 
60·64 24 33 27 [·24, + 59J 
TOTAL 165 212 22 [+ 4,+37J 
Estimated 
Life·years 
gained per 
1.000 women 
51 
20 
44 
29 
35 
36 
In a later article (Chu et 01., 1988), our finding of a homogeneous decrease in 
mortality across age·groups was reinforced. By using different and rather 
optimistic assumptions in statistical testing, Chu et al. demonstrated a significant 
(p<0.05) mortality difference for women who were below age 50 at entry. 
MISCAN analysis of HlP study 
The MISCAN analysis of the HIP study (see Chapter II) included both the 
DETECTION and the PROGNOSIS parts of figure Ie. A search was made for 
good· fitting values of the key parameters for both parts of the model. The HIP 
analysis resulted in estimates for the sensitivity of the two screening tests 
(mammography and physical examination), and also for the duration of the pre-
clinical stages. An adequate fit of the HIP results was obtained, with two 
exceptions: the age-specific detection rates (see Figure If) and the incidence of 
interval cancers by time since negative last screening, see Figure Ig. In the latter 
figure, only one very strong discrepancy occurs: the model prediction of the 
incidence within the first 6 months since a negative examination is much too 
high. The discrepancy is at least partly due to the assumption of a constant 
sensitivity within a disease state. In reality, the sensitivity of clinical examination 
will probably be quite high in the months before a cancer is diagnosed on basis 
of clinical symptoms. 
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MISCAN analysis of Dutch projects 
The past decades showed tremendous improvements in mammographic techniques 
and a considerable shift in clinical stage distribution (see for example Coebergh, 
1990). When we started the analysis of the costs and effects of nationwide breast 
cancer screening in The Netherlands, the HIP model had to be adapted in view 
of these trends. We analyzed the data from the screening projects in Utrecht 
(DOM project) and in Nijmegen, using the HIP model as a starting point, see 
Chapter III. In the HIP model, the clinical stage distribution was already 
explicitly included, and the quality of the mammography is represented by the 
sensitivity parameter. The possibility of finding tumours below 1 em. in diameter 
was included by subdividing the stage" <20 mm." into two stages" < 10 mm." 
and "10-19 mm.". Also, the stage intraductal carcinoma in situ was added, 
because of the increasing proportion of screen-detected cancers in this stage. The 
transition probabilities between preclinical stages were made age-dependent, 
which allows for age-dependent duration of the duration of the preclinical stage. 
Furthermore, the improvement in prognosis following early detection as specified 
in the HIP model had to be reconsidered because of these redefinitions of disease 
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Figure If MISCAN analysis of HIP study: incidence of interval cancers by 
time since last negative screening test (per 1,000 women· 
years). 
stages in the model. 
We found a strong age-dependency of the duration of preclinical screen-
detectable stages, the mean duration ranging from approximately 2 years at age 
40 to 5 years at age 70, see Chapter III. Comparison of this model and the HIP 
model shows: 
(I) If the same age-dependent duration of preclinical stages had been used in 
the HIP model, then the discrepancies between this model and observations 
from the HIP study would have been removed, see Figure If. 
(2) The mean durations in comparable stages are indeed quite similar, 
reinforcing the validity of the model. 
(3) The sensitivity of mammography shows a distinct improvement, see Table 
1.5. 
Note that in the DOM project, which uses clinical examination in addition to 
mammography just like the HIP study, the incidence of interval cancers in the 
first half year is also lower than predicted by the model (see Figure lIIe in 
Chapter III). 
Our findings about (age-dependent) duration have been used in explaining the 
accelerated rise in breast cancer incidence in the USA (Feuer and Wun, 1992). 
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Tabla 1.5 
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Comparison of sensitivity of mammography in HIP model and 
in Dutch model. 
HIP model Dutch model 
diameter (mm.) sensitivity diameter (mm.) sensitivity 
< 20 28% { 
2020 56% 
< 10 
10-19 
2020 
70% 
95% 
95% 
Tumour doubling times based on repeated mammography in the Nijmegen 
project shows a age-dependency which is similar to our model assumptions: the 
median volume doubling times are 80 days for women younger than 50 years, 
and 188 days for women older than 70 years (peer el al., 1993). This paper 
reports a median volume doubling time of 157 days in the age group 50-70, 
which would indicate a median duration of 1.3 years for stage 10-19 mm. This 
is slightly longer than assumed in our model, which has an exponential 
distribution with lIIeall duration of 1.3 years in this age-group, corresponding 
with a median duration of I. I years for the 85 % of the cancers in this stage that 
have a transition to stage ~20mm. 
The analysis reported in Chapter III was confined to only part of the data from 
the Dutch projects. From the DOM project, only the first cohort invited in the 
city of Utrecht was included in the analysis, and from the Nijmegen project we 
only analyzed the first four screening rounds. In the mean time we arrived at a 
model that explains both the data from the first 6 screening rounds in Nijmegen 
and the additional data from the Utrecht region (De Koning el al., 1990b,1991). 
We did not use the findings concerning mortality reduction from the two Dutch 
projects, since these findings are based on case-control studies and are therefore 
possibly biased. Instead, we used the DETECTION model based on the Dutch 
projects to simulate the randomized trials in Sweden in order to analyze 
PROGNOSIS part of the model, i.e. the improvement in prognosis following early 
detection. Preliminary results, restricted to the Kopparberg/Ostergotiand trial, are 
mentioned in Chapter III. 
If the differences between the Swedish projects in Kopparberg/Ostergotiand 
and Malmo regarding age-range, screening interval, and participation rate are 
taken into account, the model predicts almost equal mortality reduction 
percentages for the two projects. The difference in observed reduction is 
therefore interpreted as being random, and we derived an average effect by 
combining the results of these projects, weighting for the difference in size of the 
study populations (Chapter 7 in De Koning el al., 1990b; De Koning et al., 
1991). 
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Prospective evaluation 
In 1986, we were commissioned by the Dutch Health Insurance Council to 
perform an analysis of the effects and costs of nationwide breast cancer 
screening. The results were to be used in decision making about the 
implementation of the program, and in deciding about policy alternatives. 
The model quantifications which resulted from the analysis of the screening 
projects have been used in predicting the results and effects of different policy 
alternatives and scenarios for the screening programme. Screening policies are 
simulated during a 27-year period, and compared with the situation of no breast 
cancer screening. Important output measures are the number of life-years gained, 
the increase in number of quality-adjusted life-years which summarizes the 
balance between favourable and adverse effects of screening, and the incremental 
costs per (quality-adjusted) life-year gained. In principle, these measures would 
enable comparisons to be made with similar figures for other investments in 
health care, provided that similar basic assumptions are being used. 
The cost-effectiveness calcu[ation have focused on the policy that is currently 
being implemented in the Netherlands, and in which women between ages 50 and 
68 are invited for 10 screenings, i.e., a screening interval of 2 years. A 
comparison has been made with alternative policies in which women in the same 
age group will be invited with other intervals, or in which screening is extended 
to older andlor younger age-groups. 
The reduction in total breast cancer mortality resulting from the main policy 
is predicted to be about 16% in the long term, or about 650 breast cancer deaths 
per year. The costs per life-year gained are 7,650 guilders (5% discount rate). 
Adjustment for changes in the quality of life does not lead to major changes. 
Compared to the negative effects, the positive effects other than gain in life-years 
are of the same magnitude. More details can be found in (Van der Maas el al., 
1989; De Koning el al., 199[; De Haes el al., [991). In addition, calculations 
have been made regarding the impact of screening on demand for diagnostic and 
treatment facilities on national and on regional level (De Koning el al., 1990a). 
Sensitivity analyses have been carried out for major uncertainties. The main 
uncertainty concerns the impact of early detection on mortality. On basis of the 
confidence interval derived from the Swedish trials, we predicted that the cost-
effectiveness may vary between 4,500 and 22,000 guilders per life-year gained 
(De Koning et al., 199 [). 
Similar MISCAN-based analyses have been carried out for other countries such 
as Australia (Carter el al., [993), Italy (Paci el al., [994), and Germany 
(Beemsterboer el al., [994). 
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Model-based analysis of cervical cancer screening 
From a public health point of view, cervical cancer is less important than breast 
cancer in The Netherlands. Both the incidence and the mortality from breast 
cancer are approximately 10 times higher than from invasive celvical cancer. 
Evaluation of cervical cancer screening is more difficult, however, for a number 
of reasons: 
(I) The natural history of cervical cancer is more complicated. Many of the 
pre-invasive lesions that are detected by the screening test (Pap-smear) will 
probably regress spontaneously, see Chapter IV. The long average duration 
of pre-invasive lesions means that although some lesions may develop 
rapidly, most of the progressive lesions that emerge in young women will 
only become invasive much later, see Chapter V. Thus, age is a key 
variable in analyzing cervical cancer screening data, whereas in breast 
cancer it is possible to analyze age-groups separately. A relatively minor 
complication is that women may have a hysterectomy for other reasons than 
cervical cancer, which protects them from developing invasive cancer. 
Modelling improvement in prognosis is relatively easy, since it can be 
assumed that treatment of screen-detected non-invasive cases will practically 
always result in cure. 
(2) Significant incidence trends can be observed, related to both birth cohort en 
(calendar-) time. 
(3) The effectiveness of cervical cancer screening has never been tested in a 
RCT. Still, there is quite convincing evidence for a strong effect on 
mortality. Comparison of Scandinavian countries with and without long-
running nation-wide screening programmes shows a clear effect of screening 
(Liiiirii el al., 1987, Day, 1984). Further evidence is supplied by case-
control studies that were conducted to estimate the risk reduction 
accomplished by screening (Hakama et ai, 1986; Van der Graaf, 1987). 
(4) In many countries, including The Netherlands, organized and opportunistic 
screening co-exisl. Usually, no complete registry exists of all smears and 
all detected cases, which seriously impedes data analysis and estimation of 
model parameters. And it is very difficult to make realistic predictions about 
alternative strategies for organized screening, as it is largely unknown how 
opportunistic screening patterns will adapt to different strategies. 
Moreover, in recent years a strong association was found between presence of 
certain strains of the Human Papilloma Virus (HPV) and (pre-invasive and 
invasive) cervical cancer, suggesting a causal link between HPV infection and 
development of cervical cancer. HPV-based screening tests are available, and 
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evaluation of cervical cancer screening now has to consider different alternatives 
for using cytologic and HPV-based tests, alone or in combination. 
The effectiveness of cervical cancer screening can be analyzed by combining 
data regarding the "exposure" to screening with incidence and mortality figures. 
This may be done for a complete population, but it is more efficient to use a 
case-control design in which all cases (usually invasive cancers) are compared 
with a (stratified) sample from other women. The use of invasive cancers is not 
without problems however, since invasive cancers can be detected by screening. 
In the IARC/UlCC study on the evaluation of cervical cancer screening 
programmes (Hakama el al., 1986; IARC, 1987), in which we participated, a 
combined analysis was performed on data from screening programmes in 8 
countries, see also section I.2. The goal of the study was to estimate the risk of 
cervical cancer associated with different screening intervals. The study compares 
the incidence of invasive cervical after one ore more negative Pap-smears with 
the incidence in unscreened women of the same age. 
Table 1.6 Relative protection against cervical cancer as a result of 
screening 
The relative protection (RP) is given by time elapsed since last negative 
smear. Figures in parenthesis are No of women with cervical cancer. 
Estimates for British Columbia, and geometric mean for centrally organized 
screening programmes. Adapted from Tables II and III in (tARC, 19861. 
Months since One previous Two or more previous negative 
last negative negative smear smears 
smear British Columbia British Columbia All programs 
RP (N) RP (N) RP (N) 
0-11 2.5 (10) 8.8 (7) 15.3 (25) 
12-23 2.1 (10) 4.6 (7) 11.9 (23) 
24-35 7.5 (2) 14.1 (1 ) 8.0 (25) 
36-47 5.8 (2) 3.9 (2) 5.3 (30) 
48-59 1.6 (3) 2.8 (30) 
60-71 3.6 (16) 
72-119 1.9 (12) 1.6 (5) 1.6 (6) 
> 119 0.8 (7) 
Never 1.00 1.00 1.00 
screened 
Our contribution to this study was to make risk calculations for the British 
Columbia screening programme, see Van Oortmarssen and Habbema, 1986. The 
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reduction in risk is expressed in terms of relative protection, i.e. the ratio of the 
incidence in unscreened women to the incidence in screened women. The findings 
for British Columbia and the average for all centrally organized programmes 
included in the study are presented in Table 1.5. The data for British Columbia 
alone, although indicating a considerable reduction in risk for screened women, 
do not show a clear trend. This is caused by the low number of cases observed, 
even where the total number of women in the program is over 120,000. In 
contrast, the pooled results for the 5 centrally organized programs (including 
British Columbia) show a striking regular trend. 
We used MISCAN for analyzing the data from the British Columbia cohort study 
(Habbema et af., 1982c). In this analysis, many presuppositions were made, 
especially about the age-dependencies included in the model. We found that 
assuming a high proportion of regressive lesions would result in a good fit of the 
data, and we could not find a good fit without regression. However, because of 
the intricacy of this MISCAN cervical cancer screening model and the numerous 
pre-suppositions, it proved to be difficult to perform a formal test of hypotheses 
or to test the goodness of fit. We concluded that a better approach would be to 
start from a very simple model which could then be extended in successive steps. 
Although this could have been done with MISCAN, a statistical-numerical 
approach offers a number of advantages as discussed in section 1.4. Therefore, 
I made another attempt to analyze the same screening data, with a model which 
can be regarded as a simplified version of the MISCAN model. The model, 
which is described in Chapters IV-VI, only covers the DEfECTION box from the 
basic structure in Figure Ie. This implies that the mortality from cervical cancer 
and the impact of early detection on mortality are not included in the model. In 
Chapter VI a simple link between incidence and mortality is added to the model. 
The model has IO parameters (see Table IV.I, Chapter IV), which describe 
the incidence, the duration, and the progression of pre-invasive lesions, the 
relative risk of participants and non-participants, and the test-sensitivity of the 
Pap-smear. Mathematical formulas have been devised that express the clinical 
incidence and the detection rates at subsequent screening tests in terms of these 
parameters, see Chapter IV, appendix IVB. Numerical approximations of the 
formulas are used to calculate expected incidence and detection rates on basis of 
a given set of parameter values. 
The model is fitted to the data from British Columbia using the procedure 
outlined in figure Id. Hypotheses are tested about regression of pre-invasive 
lesions and its possible age-dependency. It appears that a model with a high 
proportion of regressive lesions in women under age 34, and a high proportion 
of progressive lesions in older women, gives the best fit of the cohort study data. 
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Figure Ih Comparison between observed results from British Columbia 
and model results concerning clinical incidence in unscreened 
women and detection rate at the first, second and third or later 
smears. 
Figure Ih shows the striking agreement between model and data. 
Estimates are derived for the duration of pre-invasive lesions, for the 
proportion regression among these lesions, and for the test-sensitivity of the Pap-
smear. The combined confidence regions for these parameters as shown in fig 
VII.2 can be interpreted as follows: a higher proportion of progressive lesion will 
give a too high clinical incidence and the detection rates will become too high. 
The impact on clinical incidence is compensated in Ca) and Cb) by a lower total 
onset of pre-invasive lesions and a higher mean duration of pre-invasive lesions 
is higher, respectively. The impact on detection rates is compensated in Cc) by 
assuming a lower sensitivity. 
32 Chapter I 
Table 1.7 Summary of parameter estimates for cervical cancer screening models 
Screening project British British Dutch pilot The 
Columbia Columbia regions Netherlands 
type of model simplified MISCAN MISCAN MISCAN 
Van Oortmarssen Hahbema Hahbema (1988) Van Ballegooijen 
(1991) (l982c) (1994) 
mean duration of pre- 10-15 12-17 15-19 10-15 
invasive stages (years) 
progression (%) 25-45 30-50 32-38 N.A. 
sensitivity (%) 76·85 60-80 67-73 76-85 
The estimated mean total duration of pre-clinical stages is 16 years. In the 
MISCAN analysis both the estimates for the mean duration and for the percentage 
of progressive lesions were slightly higher, see Table 1.7. A larger difference 
occurs for the estimates of the sensitivity of the Pap-smear and also for the onset 
rate of pre-invasive lesions (1.7 per 1000 women-years under age 35). 
A serious drawback of this simplified model is that the assumptions are in general 
very crude. For example, the age-dependency of the incidence of pre-invasive 
stages is modelled by distinguishing only two levels, for young women and for 
middle-aged women. At age 34, the incidence changes from 2. I I x 10-3 to 
1.06xlO·3, and the proportion of progressive lesions jumps from 16% to 60%. 
These sudden changes are not plausible, and one might wish to add additional 
assumptions to the model to make it more realistic. An alternative would be to 
assume other functional relations, e.g. a two-parameter Weibull distribution for 
describing the total onset as a hazard rate which decreases with increasing age, 
and a sigmoid type of function which describes the proportion of progressive 
cases as a function of age. But the fit of the present model is already very good, 
which means that additional data are required for discriminating between the 
present model and extensions. Another problem is that the complexity of the 
model equations will readily become too high, indicating that at some stage in the 
analysis, a switch from the statistical/numerical approach to a microsimulation 
model will become inevitable. 
The statistical model has been validated against the outcomes of the IARC 
study concerning the relative protection following negative smears, see Chapter 
V. A mean duration of 16 years for the preclinical stage may seem incompatible 
with the more rapid decrease in relative protection following negative smears 
calculated in the IARC study (Table 1.5). It appears that this apparent 
contradiction can be explained by acknowledging that women who had had a 
series of (negative) smears are likely to have more smears at which an invasive 
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cancer can be detected. When available information about screening frequency 
is used in the model, then its predictions are in close agreement with the 
outcomes of the IARC study. 
The consequences of these findings for the interpretation of the relative 
protection results published by the IARC study are discussed in Chapter VI. A 
considerable proportion of the screen-detected invasive cancers will be micro-
invasive, and will on average have a much better prognosis than clinically 
diagnosed invasive cancers. Thus, the relative protection against incidence will 
be an underestimation of the reduction in risk of dying from cervical cancer 
following negative smears. In my opinion, the IARC recommendations of 
screening intervals of at most 3 years will lead to too frequent screening, since 
intervals of 5 years will still give 90% reduction in the risk of mortality from 
cervical cancer. 
Further MISCAN-based analyses of cervical cancer screening have been 
carried out on the data from the screening program in three pilot regions in the 
Netherlands. A first analysis, reported in (Habbema et al., 1985,1988) was 
performed in preparing the prospective evaluation of costs and effects of cervical 
cancer screening. The data from the pilot regions and the trends in the national 
cervical cancer mortality could be reproduced well. However, we encountered 
serious difficulties in fitting the data regarding cancers diagnosed outside the cen-
trally organized screening program, presumably in part because of inconsistencies 
within these data. The main parameter estimates are quite similar to the values 
found in the analysis of British Columbia data, see Table I. 7. A recent analysis, 
which concentrated on progressive lesions and the impact of screening, resulted 
in a good fit of the age-specific trends in the incidence of invasive cervical cancer 
and in cervical cancer mortality (Van Ballegooijen et al., 1993) 
Prospective evaluation 
Although the same general (MISCAN-based) approach was used for prospective 
evaluation of screening for cervical cancer and for breast cancer (see section I. 7), 
evaluation of cervical cancer screening proves to be more laborious (and 
challenging) because of the complications mentioned earlier in this section. The 
range of potentially (cost-)effective policies is very broad, and considerable 
differences in effectiveness exist between different screening ages or screening 
intervals. Many screening policies (differing in age-range, interval between 
screening, etc.) have been simulated to predict the beneficial and adverse effects, 
and the costs and savings of screening in the Netherlands during a 27 year 
period. For each policy, a comparison is made with the (highly hypothetical) 
situation in which no preventive Pap-smears are being made. The policies have 
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been compared on basis of the effectiveness and the cost-effectiveness ratio. 
Systematic comparison of costs and effects of policies resulted in identification 
of a series of e./ficiem policies, i.e., the policies that give maximum favourable 
effects at a given amount of incremental costs. The simulation results have been 
used to make recommendations about the ideal screening interval and age-range 
(Koopmanschap et at., 1990a). 
These efficient policies have been compared with the screening policy which 
had been used since 1976 in the Netherlands (7 invitations at 3 year intervals 
between age 35 and 53), with opportunistic screening, and with the combination 
of these two modes which is actually the situation which can be expected to 
occur. All three of them appear to be by far inferior to the efficient (organized) 
policies. Opportunistic screening is especially inefficient, and should in our 
opinion be discouraged. The cost-effectiveness of the existing organized policy 
with 7 invitations could be improved by approximately 50% by choosing a longer 
screening interval. A high attendance rate will have a favourable impact on the 
cost-effectiveness of screening (Koopmanschap et al., 1990b). The first cost-
effectiveness analysis pointed out that screening should not start at very young 
ages and suggested that screening should be extended to older age groups (55 
years and over) (Van Ballegooijen el at., 1990). This model had been fitted on 
available data in The Netherlands, with emphasis on the screening results in age-
groups 35-54. The latter two conclusions, however, pertain to younger and older 
women, respectively. 
It was decided to take a closer look at the data regarding younger and older 
women. After some adaptations, e.g. in the age-distribution of the onset of 
progressive pre-invasive lesions and in the age-dependency of survival of 
clinically invasive cancer, the Dutch incidence and mortality data of younger 
women could be fitted adequately. A special study has been carried out in which 
the incidence of invasive cancers in women between ages 55 and 68 has been 
related to the screening history of these women (Van der Graaf et at., 1991). 
Model analysis of the outcomes of this study support our hypothesis of persisting 
onset of progressive pre-invasive lesions in these age-groups. Subsequent 
evaluation of the cost-effectiveness of screening policies reinforced our 
recommendations to extend screening to older ages, and to start between ages 25 
and 30 and end around age 65 (Van Ballegooijen el at., 1993). 
These findings have influenced the recent policy modification in The 
Netherlands. Instead of 7 invitations between ages 35 and 53, invitations now 
start at age 30 and continue with 5-year intervals up to age 60. Another policy 
revision in the near future cannot be excluded, given the potential possibilities of 
the HPV -based screening test. 
II. A MODEL-BASED ANALYSIS OF THE IDP PROJECT 
FOR BREAST CANCER SCREENING 
Introdnction 
The HIP randomized trial was the first study to provide conclusive evidence of 
the effectiveness of annual mass screening for breast cancer (Shapiro el al. 
1982; Habbema el al. 1986; Chu el al., 1988). The HIP findings are sup-
ported by the results of recent non-randomized studies (Collette el al., 1984; 
Verbeek el al., 1984; UK Trial, 1988). Randomized trials are in progress in 
Sweden, the UK and Canada. For women in the age group 50-70, results from 
the Swedish 2-county trial confirm the HIP findings by showing a significant 
mortality reduction of 39% (Tabar el a/., 1985, 1989). The trials in Malmo 
and Edinburgh reported a smaller and non-significant reduction in mortality of 
about 20% in this age-group (Andersson el a/., 1988; Roberts el al., 1990). 
None of these modern trials showed a clear mortality reduction for women 
below the age of 50. 
In spite of the results of these trials, the choice of age-groups to be 
screened and intervals between screening examinations will still be difficult, 
since each trial only gives direct evidence concerning the screening policy 
used in the trial. Ideally, recommendations about breast cancer screening 
should be based on a cost-effectiveness analysis, in which the effects and costs 
of screening are estimated for different policies. These estimates should 
preferably be made with the aid of mathematical or simulation models. 
Important factors in these models are the duralion of pre-clinical breast 
cancer, the sensitivily of the screening test(s), and the impact of early 
diagnosis and treatment on mortality (efficacy). 
Models have indeed proven to be a valuable tool in the evaluation of 
screening for breast cancer (Eddy and Shwartz, 1982). Many of these models 
are primarily designed for the problem of finding effective screening policies 
(Knox, 1975), and not for a detailed analysis of results of ongoing screening 
projects. On the other hand, models can be found that are useful for analysis 
of (part of) the results of screening projects (Walter and Day, 1983). Like a 
few other models (Shwartz, 1978; Eddy, 1980), the MISCAN simulation 
program (Habbema el al., 1984) can be used both for a detailed analysis of 
available data, and for subsequent prospective evaluation of screening policies. 
We now report the results of the MISCAN al/alysis of the data from the HIP 
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study. In comparison with earlier model-based analyses of HIP data, this 
analysis is more detailed: the sensitivities of mammography and of physical 
examination are considered separately, a subdivision is made for tumour 
diameter, and the parameters describing duration, sensitivity and efficacy are 
analyzed simultaneously. 
The central question addressed is: 
which numerical assumptions for the duratioll of pre-clinical stages and 
sellsitivity of the screening tests result in good agreement between model-based 
simulated results and observed results of the HIP study? 
Material 
The HIP study for the early detection of breast cancer started in 1964. About 
60,000 women aged 40-65 were randomly assigned to the study group or to 
the control group (Shapiro and Venet, 1966). Women in the study group were 
invited for an initial screening. Participants in the first round were offered 3 
additional yearly screening examinations (in practice, the average interval 
between screenings was about 13 months). Two screening tests were applied at 
each examination: mammography and physical examination. All new breast 
cancer cases in study and control groups have been recorded during a period 
of 10 years since entry in the study, and are followed-up for mortality. Results 
for 14 - 18 years of follow-up have been published (Shapiro et at., 1982, 
1988; HIP Study, 1981 ; Chu et al., 1988). 
The present analysis uses data from breast cancer cases detected within 7 
years after entry into the study, with a follow-up of 14 years. Thus, all breast 
cancer cases diagnosed within about 31h years after the final screening round 
in the study group are included. This "catch-up" period is needed to ensure 
that the control group counterparts of the screen-detected cases in the study 
group will (nearly) all be diagnosed. Without such a catch-up period, the 
effect of screening on mortality would be underestimated (Habbema et al., 
1986). 
Model assumptions are tested by comparing observed results from the HIP 
study with results obtained by simulation using specific assumptions about the 
model-parameters. An overview of the HIP data used is given in Table 11.1, 
detailed information is given in Appendices IIA and lIB. 
The 443 cases of breast cancer diagnosed in the control group within the 7 
year study period have been classified by age at diagnosis. The 425 study 
group cases have been grouped according to the mode of detection: diagnosis 
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as a result of screening (132 cases), interval cancers diagnosed after a negative 
screening result (173 cases), or cancers diagnosed in women who did not 
participate in the first screening round (120 cases). The screen-detected 
cancers and the interval cancers are classified by screening round, age at diag-
nosis, and tumour diameter (under or over 2 cm). Screen-detected cases are 
also classified by the mode of detection (mammography alone, physical 
examination alone, or both tests positive). Interval cancers are also classified 
by the time since the last negative test result. 
Table 11.1 Overview of observed data from the HIP study that have 
been used in testing of model-assumptions. 
All data were derived from the Statistical Tape of the HIP study. 
Results of the testing procedure are indicated for the standard 
model: No mark: p> .05, *: 0.01 <p< .05, **: p< .01 
A. HIP Control group results. 
1. Incidence by age 
2. Case-mortality by age 
B. HIP Study group: screen·detected breast cancers. 
1. Detection rate by age at diagnosis, first round. 
2. Detection rate by age at diagnosis, rounds 2,3,4. 
3. Detection rate by screening round (2,3,4) 
4. Distribution according to modality, by screening round (1, > 1) 
5. Distribution according to tumour size, by screening round (1, > 1) 
C. HIP Study group: Interval cancers. 
*1. Incidence by age at diagnosis . 
... 2. Incidence by time since last screening 
3. Incidence by round of last screening 
4. Distribution according to tumour size. 
D. HIP: Difference in breast cancer mortality between study group 
and control group. 
1. Mortality difference in absolute numbers, by time since entry. 
2. Difference in case-mortality, by time since entry. 
The breast cancer mortality in study and control groups in the HIP study is 
analyzed by age at entry and by years since entry. Both absolute numbers of 
deaths and case-morlality rates are considered. Standard actuarial techniques 
have been used in calculating the case-mortality, thus correcting for death 
from other causes and for cases that are lost to follow-up. 
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Survival figures, based on 7 to 14 years of follow-up, are used directly to 
model the survival of control group cases. Breast cancer incidence rates for 
the US (Third National Cancer Survey, 1975) are used to extend the model to 
age-groups that were not included in the HIP study. Within the age-range of 
the HIP study, the incidence in the HIP control group appears to be some 13 % 
higher than the TNCS incidence (US totals). Breast cancer mortality rates in 
the HIP control group are also a little higher than rates reported from New 
York (NCHS, 1980). 
Method 
The MISCAN computer program (Rabbema et al., 1984) uses micro-
simulation, i. e., simulation of individual life-histories of (fictitious) persons. 
The same persons are considered twice. First, in the absence of screening, 
they add up to an unscreened population, e.g., the HIP control group. Next, 
screening is simulated. Some of the life-histories will change as a result of 
screening. The life-histories then add up to a screened population, which for 
example may be compared with the study group of the HIP study. 
The life-histories are simulated according to the specifications of a breast 
cancer epidemiology aod screening model. Some of the model parameters, like 
the age-distribution of the screened population, and the survival of clinical 
stages of breast cancer, can be assessed directly from available data. 
Simulations are carried out to test assumptions for parameters for which direct 
estimation is not possible (Figure IIa). These simulations will produce 
simulated results of the HIP study. Goodness-of-fit statistics (Chi-square, 
Student t) are used for comparing the simulated results with the observed HIP 
data. 
The model 
Pop Illation and screening policy 
The age distribution of the simulated population at first screening is obtained 
from the HIP cohort. The life table used in the model (death from causes 
other than breast cancer) is based on the New York State life table 1969-1971 
(NCHS, 1980). 
Attendance at first screening is taken to be 66.8 % for all age-groups. This 
corresponds to the level in the HIP study, in which no clear age-trend was 
observed. The participants in this first round were invited for 3 more 
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screenings. In modelling their attendance pattern, the observed strong 
association between participation rates in subsequent rounds has been taken 
into account. The interval between screenings is assumed to be I.OS years for 
all women and all rounds. The resulting simulated participation rates in rounds 
2-4 differ less than I % from the observed rates. 
The observed breast cancer incidence rates in the control group and in non-
participants have been employed in estimating the relative risks of participants 
(RR= 1.1) and non-participants (RR=O.S). 
Characteristics of 
the HIP study 
Parameter 
values 
MISCAN 
- duration 
- sensitivity 
- efficacy 
SIMULATED 
screening 
results 
HIP: OBSERVED 
screening results 
Chi-Square 
test 
"------ i --;h~~g: ~~ - '",: :--:-:-( ~ ~ Minimum? 
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Figure II. 
ESTIMATED 
PARAMETER 
VALUES 
Use of the MISCAN simulation program in finding model 
assumptions which result in a good fit of the results of the HIP 
study, by testing simulated results against observed results. 
Disease model 
The natural history of the disease is modelled as a progression through a 
number of states, starting from state NO BREAST CANCER (Figure lIb). The 
upper part of Figure lIb describes the course of the disease in the absence of 
screening. The boundary between NO BREAST CANCER and pre-clinical disease 
is defined in terms of detectability at a screening examination: the screen-
detectable stage is entered when the tumour becomes detectable by the 
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screening modalities used. For the HIP study, the critical tumour diameter is 
about 1 cm. 
The pre-clinical screen-detectable phase is subdivided in 2 states, according 
to tumour diameter. Variability in the growth rate between tumours is 
represented by an exponential probability distribution of the dwelling times in 
the pre-clinical states. A high correlation between the durations in the 2 states 
is used to reproduce approximately constant growth rates of individual 
tumours. Thus, the duration of pre-clinical breast cancer is fully described by 
the 2 mean dwelling times in the pre-clinical states. 
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Figure lib Structure of the disease model for breast cancer. 
From the HIP control group, it is estimated that in the absence of screen-
ing, about 30% of breast cancers are diagnosed before the tumour is 2 cm in 
diameter. This corresponds with transition to the state CLiNtCALLY DIAGNOSED 
BREAST CANCER ,,; 2 CM. The other 70% first proceed to state PRE-CLINICAL 
BREAST CANCER > 2 CM, and then to CLINICALLY DIAGNOSED BREAST 
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CANCER > 2 CM. After diagnosis and treatment, women are at risk of dying 
from breast cancer and also run the same age-dependent risk of dying from 
other causes as women in NO BREAST CANCER and in pre-clinical states. 
In the case of early detection women will enter one of the two "SCREEN-
DETECTED" states in Figure lIb. 
Efficacy 
The efficacy of early detection is expressed as a change in the age of death 
from breast cancer in screen-detected cases. There are 3 possibilities: no 
difference in time of death, delay, and cure. A 4th possibility, earlier death as 
a result of early detection and treatment, is assumed to be negligible. The 
probabilities of cure and delay, and the distribution of the delay time, are 
estimated from the Relative Case Fatality Rates (RCFR's). The case fatality is 
the complement of case survival, and has been calculated by standard actuarial 
methods, again correcting for patients who are lost to follow-up and patients 
who die from other causes. The observed RCFR is calculated from the 132 
screen-detected cases in the HIP study group. The expected RCFR of these 
cases in a situation without screening is computed from the survival data of 
control group cases, with a correction of 2 years for the lead-time bias 
(Habbema et al., 1983) 
The ratio of observed to expected RCFR is used as a measure of the ef-
ficacy of early detection and treatment, see Figure lIc. A quadratic curve was 
fitted to the ratios in years 3-14, and extrapolated to a full 20 year follow-up 
period. Just after diagnosis, the ratio is about 30%, representing the breast 
cancer cases that do not benefit at all from screening. In the long run, 
the ratio approaches 70%. The other 30% represents the proportion of cure, 
i. e., women who do not die from breast cancer after early detection by 
screening, but who would have died from breast cancer in the absence of 
screening. The remaining 40% represents women in whom breast cancer death 
is delayed as a result of screening. 
These efficacy estimates apply directly to a model with a single pre-clinical 
state. For the 2-state model, the probability of cure will be highest for state 
,;;2 Col. With cure rates of 40% and 10% for earlier and the later states, 
respectively, the overall cure rate of 30% is maintained. It is assumed that 
both pre-clinical states have the same probability of delay (40%). 
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Figure lie. Observed relative case fatality rate (RCFR) for the 132 screen-
detected breast cancers in the HIP study, and expected RCFR in 
the absence of screening, obtained from control group cases by 
correcting for lead time. A quadratic curve has been fitted to the 
ratio: Observed RCFR I Expected RCFR . 
Basic parameters 
There are statistical and practical limitations to the number of parameters that 
can be varied in the analysis of the HIP data. Therefore, the analysis was 
confined to 4 basic parameters: the mean duration of the 2 pre-clinical states, 
and the sensitivity of the screening tests in these states. These 4 parameters 
have been assumed not to depend on age. 
Results 
Duration al/d sensitivity 
Combinations of assumptions about the mean duration and the sensitivity of 
the screening tests in the 2 states have been tested. Values for the 4 basic 
HIP breast cancer screening model 43 
parameters can be arranged in a 4-dimensional grid. A search procedure was 
used to identify the area of HIP-compatible assumptions in this grid, i.e., 
assumptions for which the simulated results show a good fit with the observed 
results of the HIP study. 
The best-fitting values are presented in Table n.2. Within the 2 states, quite 
large variations in assumptions are allowed: the mean durations in each state 
may vary between 1.0 and 1.5 years. The best-fitting value for the sensitivity 
in state ~ 2 Col is 55 %. Although this is lower than the value of 85 % found 
in state > 2 em, much variation around these values is possible and the areas 
of good-fitting values show a considerable overlap. The allowed variation in 
the total mean duration and the average sensitivity is smaller. Figure lId shows 
the area of HIP-compatible assumptions. The average sensitivity can vary 
between 50% and 80%, and the total mean duration between 1.6 years for 
high sensitivity values and 2.7 years for low sensitivity. 
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Figure lid. MISCAN Analysis of HIP Study. Area of combinations of 
assumptions about average sensitivity and mean total duration in 
the pre-clinical states that are in agreement with results of the 
HIP study. 
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Table 11.2 Values of basic parameters of the standard model. 
PARAMETER value 
Mean duration 
pre-clinical tumour, diameter :s 2 em 
pre'clinical tumour, diameter > 2 em 
mean total pre-clinical duration 
Sensitivity of combined screening tests 
pre-clinical tumour, diameter,;; 2 em 
pre·clinical tumour, diameter> 2 em 
mean sensitivity 
1.25 years 
1.4 years 
2.23 years' 
55% (MGM 28%, PE 38%) 
85% (MGM 56%, PE 66%) 
68%" 
• only 70% of tumours will pass through both states .•• average based 
on stage distribution in first round. MGM - mammography, PE - physical 
examination 
The best fitting combinations of assumptions are found in a narrow range 
around what we will call the "standard model", which has an average sensiti-
vity of 68 % and a total mean duration of 2.2 years (Table lI.2). 
Comparison of simulated alld observed resllits 
The fit of the standard model is good for all data (p > 0.05), except for 
interval cancers by age (0.01 <p<0.05) and interval cancers by time since 
last negative screening (p < .01) (Table II.I). 
The simulated age-specific breast cancer rates for the control group are 
based directly on the observed rates. Therefore, finding a perfect fit is hardly 
surprising. Figures lIe and lIf show the results for the screendetected cases in 
the first round and for the interval cancers. The simulated rates in the 2 
figures are similar, and reflect the incidence in the control group. This is a 
direct consequence of the assumption that neither the duration of pre-clinical 
breast cancer nor the test-sensitivity depend on age. 
The fit for the trend in detection rates per round is good. A statistically 
significant discrepancy between simulated and observed results for interval 
cancers by time since last negative screening occurs in cases diagnosed within 
112 year: the simulated rate is too high. This discrepancy may be due to the 
assumption that the sensitivity is constant within each state. In reality, the 
sensitivity can be expected to be higher shortly before symptomatic diagnosis 
of brea~t cancer, and lower just after entering the screen-detectable state. 
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Figure lie. MISCAN Analysis of HIP Study: Comparison of observed and 
simulated results of the standard model. Screendetected breast cancers per 
1000 women examined in the first round, by age at diagnosis. Dots and 
vertical lines represent observed results with 95% confidence intervals; the 
continuous line connects the simulated rates. 
The tumour size distribution is most favourable for the cancers detected in 
the repeat rounds. The observed proportion of tumours smaller than 2 em is 
just over 40% for the interval cancers, while for the cancers detected in the 
first round, the simulated proportion is more favourable (53%) for screen-
detected (first round) cases (Table 11.3). Both the simulated and the observed 
proportion of interval cancers below 2 em are higher than the observed 
proportion (30%) in the control group. 
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Table 11.3 MISCAN Analysis of HIP Study: Comparison of observed 
and simulated results of the standard model. Percentage of 
tumours with diameter s 2 cm, by mode of detection. 
Screen·detected, round 1 
Screen·detected, round 2-4 
Interval Cancers 
Control Group 
2.5 Incidence rate xlOOO 
53% 
69% 
38% 
30% 
2.0 ............................ ""."."".".""."".""" 
1.5 ............................................... . 
1.0 .......................................................... . 
0.5 ........................................................... . 
0.0 L-__ L-_---' __ --'-__ --'-__ -'-__ -' 
40 45 50 55 60 65 70 
Age at diagnosis 
41% 
67% 
43% 
30% 
f HIP Observed 
Simulated 
Figure lit. MISCAN Analysis of HIP Study: Comparison of observed and 
simulated results of the standard model. Breast cancers detected after a 
negative screening test, per 1000 woman-years since last examination, by 
age at diagnosis. Dots and vertical lines represent observed results with 
95 % confidence intervals; the continuous line connects the simulated rates. 
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Figure IIg. MISCAN Analysis of HIP Study: Comparison of observed and 
simulated results of the standard model. Case-mortality in study and control 
group, by time since entry into the study. lines connect simulated rates, 
points represent observed rates. 
Case-mortality is the ratio between number of deaths and number of 
diagnosed breast cancers in which the time of entry into the study is the 
starting point (Breslow et al., 1981). In Figure Iig, the simulated difference in 
case-mortality between the two groups is compared with the observed 
difference. In the first years. the simulated differeuce is smaller than 
observed. This discrepancy cannot be removed within the present framework 
of the model. The fit for 8 to 14 years of follow-up is adequate, but not 
perfect. It could have been improved by calibration of model parameters 
concerning efficacy of early detection. At 14 years since entry, both the 
simulated and observed differences in case-mortality rate or equal to 0.09. The 
same difference of 0.09 was predicted for 18 and 20 years of follow-up. Pub-
lished results for 18 years of follow-up (Shapiro et al., 1988) show a slightly 
higher difference of 0.107 in case mortality rate. 
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Discussion 
The model gives an adequate fit of the HlP results for a mean pre-clinical 
duration of between 1.6 years and 2.7 years, and a sensitivity for the screen-
ing test of between 50% and 80%. 
Simplified model 
In the exploratory stages of the analysis, simplified models have been used, 
for example a model with a single pre-clinical state in which the screening 
examination is not separated into 2 modes of detection (mammography and 
physical examination): the I-state/J-mode model. This model differs from the 
2-state/2-mode model discussed in the previous sections in 2 (related) respects: 
it has fewer parameters and, most importantly, less HIP results can be used in 
testing the parameters. Different types of probability distributions for the 
duration of the pre-clinical screen-detectable state were tested. Good results 
have been obtained with the exponential distribution. These could not be 
improved upon by using more complex distributions. The same conclusion has 
been drawn using a similar but simplified model (Day and Walter, 1984). 
Therefore, the exponential distribution has been used subsequently in the 
2-state/2-mode model. 
The area of HlP-compatible assumptions for duration and sensitivity is 
much larger for the I-statell-mode model than for the 2-state/2-mode model. 
In the I-statell-mode model, values of the sensitivity between 80% and 100% 
are not rejected, see also Walter and Day (1983) and Day and Walter (1984), 
but these values clearly appear to be incompatible with HIP results in the more 
detailed 2-state/2-mode model. 
Sensitivity 
In the present analysis, it is assumed that false negative test results are 
completely random, i. e., that there is no association between results of 
mammography and physical examination, and no association between test 
results at different examinations. This is probably unrealistic, since some 
tumours may be more difficult to detect than others. Introduction of (some 
degree of) systematic false test results would result in somewhat lower values 
for the combined sensitivity than we have found. 
Goldberg and Wittes (1978) assume, like us, that the results of 
mammography and physical examination are independent. They consider the 
modality distribution of screen detected cancers in the HlP study, and estimate 
a range of 0.44-0.76 for the sensitivity of the combination of the 2 tests, 
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which is comparable to our range of 0.50-0.80. Sensitivity values below 0.50 
would give rise to too high rates of interval cancers, these are not considered 
by Goldberg and Wittes. 
Duratioll of pre-clillical slages 
Previous duration estimates are based on a sensitivity of 100% (Shapiro el al., 
1974; Zelen and Feinleib, 1969), or use assumptions that lead to high 
sensitivity values (Eddy, 1980). Because of the inverse relationship between 
sensitivity and duration values, see Figure lid, it is clear that this leads to too 
short an estimated duration of pre-clinical stages. The high value (2.4 years) 
found by Zelen and Feinleib (1969) fits within our range of 1.6-2.7 years, but 
it is based on early, incomplete results of the HIP study; use of their method 
on complete results would result in a much lower value. 
The mean duration of about 1.0-1.5 years for the state 1-2 cm in our 2-
state/2-mode model is compatible with clinical studies which show great 
variation in growth rates, but on average suggest a tumour diameter doubling 
time of about I year. 
The simulated rates in Figure lie for screen-detected cancers in the first 
round are too high at younger ages, and too low at older ages. The same 
deviations appear in screen-detection rates for repeat rounds (not shown). 
Complementary differences are found for interval cancers (Figure lif). This 
could be expected since the total number of cancers is related to the good-
fitting control group incidence. In the present model, both sensitivity and 
duration of pre-clinical breast cancer are independent of age. A longer 
duration and/or a higher sensitivity with increasing age could diminish the 
discrepancies in the youngest and the oldest age-groups. 
Olher models 
The model of Shwartz (1980,1981) is based on the concept of tumour growth 
rates, using the average doubling time of 1.1 years reported by Kusama el al. 
(\972). It leads to good agreement with HIP data. 
Very different results are obtained in the model of Eddy (1980), who uses 
the so-called "progression assumption", implying that once a cancer becomes 
detectable by a screening test, the sensitivity is 100%. The assumed mean 
duration of screen-detectable disease of about 1.4 years results in a good 
explanation of HIP data. Note that this duration compares well with the 
product of sensitivity and duration (0.68 X 2.23 = 1.52, Table II.2) in our 
model. 
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Efficacy 
The discrepancy between simulated and observed HIP case-mortality in the 
first years of follow-up is noteworthy. The more slowly evolving difference 
between study and control group in the model simulation results is in 
agreement with the findings from recent trials in Sweden and in the UK 
(Tabar et al., 1989; Andersson et al., 1988; Roberts et al., 1990). The early 
reduction in mortality in the HIP study could possibly be ascribed to chance 
variation. 
The overall reduction in mortality in the HIP study group is statistically 
significant (Shapiro, 1977), but the confidence range (I %-34% reduction) 
reflects the still great uncertainty about the amount of reduction. No clear dif-
ference in reduction can be observed between age-groups (Habbema et al., 
1986). Therefore, in the model, the efficacy of early detection is assumed to 
be independent of age. This assumption is supported by the results of a 
statistical reanalysis of the HIP study of Chu et al., 1988; who demonstrate a 
significant mortality reduction in women below age 50 at entry in addition to 
the already established significance of the mortality reduction in the higher 
age-groups. However, these favourable results in women under 50 have not 
(yet) been reproduced in the recent trials. 
Extensions to the model 
Further extensions of the model have not been explored, because of the 
limited number of cases in the HIP study. The number of breast cancers is 
already small for some of the classifications used, especially for screen-
detected cases and for deaths from breast cancer. Missing data inhibit the use 
of other subclassifications, e.g. by lymph node status. 
A related issue is the validity of some of the assumptions used in the model. 
The assumptions, such as the independence of test results, the correlation of 
the duration in the 2 pre-clinical states, or the age-independence of the mean 
duration of pre-clinical states, could have been varied easily in the MISCAN 
computer programme. Again, the limited number of cases in the HIP data was 
the main reason that this was not done. 
Other extensions of the model, e.g., radiation risks and false positive test 
results, have been left out because they are more easily analyzed separately, 
and do not interfere with the estimation of the basic parameters of the model. 
For example, the specificity of the screening tests can be directly estimated 
from follow-up data of women with positive test results. 
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Modem mammography 
An adapted version of the model has been used to analyze the results of more 
recent screening projects (Collette et al., 1984, Verbeek et al., 1984) in the 
Netherlands. Mammographic techniques have improved since the HIP study. 
The lower limit of screen-detectable tumour-diameter has decreased from 
about I Col to about 0.5 cm. Cases of intraductal carcinoma in situ are also 
increasingly detected at screening. Therefore, the model has been extended to 
a 4-state model (dCIS, and tumour sizes :5 I cm / 1-2 cm / >2 Col). The 
analysis indicates that the results concerning the average duration of the states 
are in agreement with the results of the analysis of the HIP data, at much 
higher values for the sensitivity of mammography (Chapter III). Furthermore, 
it was necessary to include age-dependence of the mean duration in the model, 
with a mean duration at age 65 being about twice the mean duration at age 40. 
When transferred to the HIP model, this same age-dependency would 
practically remove the discrepancies found in Figures lie and lif, and Figure If 
in Chapter I. These findings show the possibilities of models for comparing 
screening programmes, by explaining differences and similarities in results 
between these programmes. 
Application of the model 
Models for screening of breast cancer can be used to predict effectiveness of 
screening policies, and in making cost-effectiveness calculations regarding the 
age-range to be screened, the interval between screening examinations, and the 
type of screening test(s) to be used. Test-sensitivity, duration of pre-clinical 
stage, and efficacy of early detection are crucial parameters in comparing 
different policies, especially in relation to the screening interval. 
The extended (4-state) model has been used in a comprehensive evaluation 
of public health effects and costs of nation-wide breast cancer screening in the 
Netherlands. The impact of screening on the demand for health care facilities 
was also predicted (Van der Maas et al., 1989; De Koning et al., 1990). This 
approach to prospective evaluation of screening policies can be equally useful 
for other countries. 
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Appendix IIA. 
HIP BREAST CANCER SCREENING MODEL: 
SIMPLIFYING ASSUMPTIONS AND DIRECT ESTIMATES 
Age-dependency 
The natural history of the disease is assumed not to depend on age. The onset rates 
(the transition from NO BREAST CANCER to the first preclinical screen-detectable 
state), do increase with age. 
Onsel 
Apart from a difference in risk of breast cancer between refusers and participants, 
no other risk categories are considered in the model. As a consequence, women who 
attend all four screening rounds have the same risk as women that only attend the 
first screening. Shapiro el al. (1982) estimated relative risks of participants and 
non-participants from the observed clinical incidence in the control group and in the 
refusers (non- participants to the initial screening) in the study group. In the period 
until seven years after entry, the observed incidence rates are 2.12 and 1.75 per 
1000 woman-years, respectively. The estimated expected incidence for participants is 
then 2.31 per 1000 woman-years, and the risk ratio of participants to 
non-participants is 2.31 : 1.75. This ratio is used in specifying the preclinical 
incidence, Le. the transition rate to the preclinical screen-detectable slale, for 
participanls and non-parlicipants in Ihe simulaled cohort. 
In testing model assumplions against HIP resulls, different assumplions are made 
on Ihe total duration of Ihe preclinical slates. Depending on Ihe mean total duration, 
the age-specific preclinical incidence is approximaled from clinical incidence data on 
breast cancer, by pulling forward this incidence by Ihe assumed mean duration. For 
example, if Ihe mean duration of the preclinical slates is assumed to be 5 years, then 
the preclinical incidence can be approximated from clinical incidence figures in 
5-year age-groups by moving up all age-groups by one category. 
Preclinical disease 
Duralion in Ihe two preclinical stales is assumed 10 be 100% correlaled. The mean 
durations in each stale are essenlial paramelers of Ihe model. 
The observed clinical lumour size dislribulion of Ihe HIP conlrol group 
(30%/70% for cases with known tumour size) is used direclly in Ihe model: from 
Ihe state PRECLINICAL ,;; 2 CM., 30% will proceed 10 CLINICAL ,;; 2 CM., and 70% 
will proceed to slate PRECLINICAL > 2 CM. and will be diagnosed in slate CLINICAL 
>2CM. 
Survival 
The Iransitions from slales CLINICAL 10 DEATH FROM BREAST CANCER are 
paramelrized direclly from Ihe observed dislribution of Ihe survival lime afler 
clinical diagnosis in Ihe HIP conlrol group (relalive survival, up 10 14 years of 
follow-up). 
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Sellsitivity 
The results of mammography and of clinical examination for preclinical breast 
cancer cases are considered to be independent. Furthermore, in varying the 
sensitivity values it is assumed that a constant difference exists between the 
sensitivity of mammography alone and the sensitivity of clinical examination. From 
the distribution of screen-detected cases by mode of detection (33 % mammography 
alone, 45% clinically alone, 22% both modalities positive, it is estimated that the 
percentage of cases missed is 10% higher for mammography than for clinical 
examination. Although the data might suggest an age-relationship for this difference, 
this is neglected for the time being because it is based on rather small numbers: 
from a total of 31 cases detected below age 50, 19 were detected by clinical 
examination alone, and only 6 by mammography alone. After fixing the sensitivity 
difference at 10% for both preclinical states, only one unknown parameter remains 
that describes the quality of the screening test in a preclinical disease state: the 
sensitivity of the combined screening test. 
Allelldallce 
Table IIA.1 Participation in the HIP study, and simulated rates that are 
based on the model specifications concerning attendance. 
Participation 
ROUND OBSERVED SIMULATED 
67% 67% 
2 53% 53% 
3 49% 49% 
4 46% 45% 
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Appendix lIB. 
OBSERVED HIP RESULTS AND SIMULATED OUTCOMES. 
Table IIB.l Clinical incidence and mortality 01 breast cancer, adapted to level 
in HIP control group Irom TNCS 11975) and the New York State 
Lile Table, NCHS (1975). 
Age group Clinical Incidence Mortality 
TNCS simulated New York simulated 
25-29 0.10 0.13 0.02 0.03 
30-34 0.26 0.32 0.08 0.10 
35·39 0.60 0.69 0.17 0.23 
40-44 1.18 1.18 0.31 0.42 
45-49 1.80 1.77 0.61 0.71 
50-54 1.94 1.96 0.77 1.00 
55-59 2.17 2.24 0.99 1.17 
60·64 2.55 2.57 1.12 1.39 
65-69 2.64 2.76 1.16 1.56 
70-74 2.94 2.98 1.55 1.65 
75-79 3.33 3.45 1.74 1.88 
80·84 3.40 2.98 1.97 2.07 
All ages (25-84) 1.72 1.75 0.76 0.90 
Table IIB.2 HIP study group, participants. Screen·detected breast cancer at 
initial examination and subsequent rounds, by age at diagnosis. 
Age at Initial examination Rounds 2 - 4 
diagnosis Cases Rate p.l 000 examined Cases Rate p.l 000 
womanyears 
HIP Simulated HIP Simulated 
40-49 16 1.72 2.50 15 0.76 1.27 
50-54 12 2.61 3.13 19 1.56 1.47 
55·59 15 3.88 3.77 20 1.87 1.78 
> 60 12 4.95 4.45 23 2.67 2.24 
All ages 55 2.73 3.08 77 1.49 1.57 
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Table IIB.3 HIP study group, participants. Screen·detected breast cancer in 
repeat rounds, by round. 
Round 
2 
3 
4 
Total 
Table IIB.4 
Round 
2-4 
2,3 
4 
Total 
Cases 
32 
18 
27 
77 
Rate p. 1000 examined 
HIP Simulated 
1.85 1.66 
1.05 
1.57 
1.49 
1.43 
1.60 
1.57 
HIP study group, participants. Interval cancers, by round of the 
last screening and duration since the last screening. 
Duration Cases Rate per 1000 woman-years 
(months) HIP Simulated 
<12 14 0.71 1.05 
>12 25 1.38 0.89 
<12 32 0.75 1.97 
>12 33 1.93 1.82 
>12 68 1.95 1.78 
173 1.29 1.42 
Table IIB.5 HIP study group, participants. Interval cancers, by age at diag-
nosis. 
Age at Cases Rate per 1000 woman-years 
diagnosis HIP Simulated 
40-49 51 1.29 1.04 
50-54 38 1.17 1.25 
55-59 35 1.19 1.60 
> 60 49 1.50 1.96 
Total 173 1.29 1.42 
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Table IIB.6 HIP study group, participants. Interval cancers by duration since 
last negative screening result. 
Interval Cases Rate per 1000 woman-years 
(months) HIP Simulated 
O· 5 0.72 9 0.28 
6-12 1.16 38 1.19 
12-23 1.49 44 1.58 
2~35 1.91 34 1.67 
36-47 1.93 27 1.94 
>48 2~ 21 2.00 
Total 1.42 173 1.29 
Table IIB.7 HIP control group. Breast cancer cases by age at diagnosis. 
Age at Cases Rate per 1000 woman-years 
diagnosis HIP Simulated 
40-49 98 1.62 1.70 
50-54 109 2.21 1.96 
55-59 97 2.15 2.30 
> 60 139 2.63 2.77 
Total 443 2.13 2.13 
Table IIB.8 HIP control group. Breast cancer deaths, and case-mortality with 
underlying cause breast cancer, by age of entry. 
Age at entry Number of deaths Case mortality 
40-44 39 
45-49 43 
50-54 54 
55-59 43 
60-64 33 
Total 212 
HIP 
0.561 
0.536 
0.482 
0.555 
0.507 
0.508 
Simulated 
0.519 
0.506 
0.527 
0.512 
0.484 
0.512 
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Tabla IIB.9 HIP study group, participants. Distribution 01 screen-detected 
breast cancer according to modality, at initial screening and 
subsequent rounds. Simulated (sim) percentages as predicted by 
MISCAN. 
Physical Mammography Both positive Total 
examination only only 
HIP sim HIP sim HIP sim HIP 
N % % N % % N % % N 
Initial 24 44 40.4 21 38 29.2 10 18 30.4 55 
screen 
Repeat 36 45 43.2 23 30 29.0 19 25 27.8 Z7 
rounds 
Tabla IIB.10 HIP study, participants. Distribution 01 screen-detectad breast 
cancers according to tumour diameter. Observed numbers and 
percentages adjusted lor tumours with unknown diameter based 
on the survival experience 01 these tumours. Simulated (sim) 
percentages as predicted by MISCAN. 
!5 2 em. > 2 cm. HIP Total 
HIP s;m HIP sim known unknown 
size size 
N % % N % % N N 
Initial screen 16 40 52.8 26 60 47.2 42 13 
Repeat rounds 30 67 69.4 21 33 30.6 51 26 
Interval cancers 56 43 38.4 72 57 61.6 128 45 
Table IIB.ll HIP study. Difference in breast cancer deaths in study group and 
control group, lor lour dillerent time·periods since entry, and 
case-mortality rates at the end 01 the time period. 
Time since entry into study (years) 
0-4 5-6 7-9 10-14 
Control group deaths 63 61 50 38 
HIP case mortality 0.144 0.284 0.401 0.492 
simulated case mortality 0.148 0.265 0.398 0.512 
Study group deaths 39 42 42 42 
HIP case mortality 0.090 0.191 0.294 0.403 
simulated case mortality 0.115 0.211 0.324 0.423 
% difference (HIP) -38% -31 % -16% + 11% 
% difference (simulated) -22% -18% -16% -12% 

III. A MODEL FOR BREAST CANCER SCREENING 
Introduction 
Policy recommendations for breast cancer screening primarily address the 
eligible age-group and the interval between subsequent screening tests. The 
choice of a policy should preferably be based on the balance between expected 
health effects and costs. 
However, the relationship between the age-group and interval, and the 
health effects is far from straightforward. Even the results of experimental 
screening projects can give rise to very different recommendations. For 
example, in the Swedish randomized trials, there is not yet firm evidence for a 
mortality rate reduction for women below the age of 50. In this age-group, the 
proportion of breast cancers that had been detected by screening was 
substantially lower than in older age-groups (Tabar et al., 1985; 1987). In 
Sweden itself, it was concluded that the screening interval had been too long, 
which resulted in a recommendation for annual screening in women between 
the ages 40 and 49 and biannual screening for older women (Tabar et al., 
1988). Other recommendations, however, state that, in view of this lack of 
evidence for a mortality rate reduction, screening should not start before age 
50 except in an experimental setting (Gezondheidsraad, 1987; Van der Maas et 
al., 1989; Forrest, 1986). 
Some of the large number of factors that influence the relationship between 
screening policy and health effects are related to the natural history of breast 
cancer and the characteristics of the screening tests: the incidence of (pre-) 
clinical breast cancer, the duration of screen-detectable preclinical stages, the 
improvement in prognosis following early detection, and the sensitivity and 
specificity of mammography. Other factors determine the population coverage, 
for example, the attendance and the question of whether nonattenders 
constitute a high risk group. Neal'ly all of these factors are age-dependent. 
In view of this complexity, mathematical models, in which these factors are 
included, are indispensable for making predictions about the health effects and 
costs of different screening policies. But having a model is not sufficient. To 
obtain valid predictions, the model assumptions should be tested against 
available data of existing screening projects. 
The analysis reported here uses a model-based approach to evaluate 
screening programs, using the computer simulation package MISCAN 
(Rabbema et al., 1984; Habbema et al., 1987). This approach has been used 
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in cost-effectiveness analyses of screening for cervical cancer (Habbema ef al., 
1987) and for breast cancer (Van der Maas el al., 1989). 
In this chapter, the breast cancer screening model will be presented and dis-
cussed. An earlier model, resulting from an analysis of the data from the HIP 
study (Chapter II), is not applicable for the current situation in view of the 
great improvements in mammographic technique since the time of the HIP 
study. The major differences between the HIP model and the current model 
will be discussed. 
A detailed description of the model is presented in Appendix IlIA. 
Material 
The model-assumptions about preclinical disease and mammography were 
checked against the following results of the Dutch screening projects in 
Nijmegen and Utrecht (Verbeek el al., 1984; Collette el al., 1984): (I) 
detection rates by age and screening round; (2) incidence of interval cancers, 
by age, screening round and by time since last screening; (3) stage-distribution 
of screen-detected cancers, interval cancers, and unscreened cancers. 
For Nijmegen, the results pertain to women in the birth-cohorts (1910-
1939) invited for the first round. This wide age-range allowed for an age-
specific comparison of model outcomes and screening results. For Utrecht, 
only results for birth-cohorts from 1911 to 1925 from the city of Utrecht were 
used (Table III. I). 
Copies of the key data files from Nijmegen and Utrecht were kindly made 
available for the analysis and were used to derive the desired tabulations. The 
population files consist of records containing the participation pattern of all 
individual women, and the cancer files contain all breast cancers diagnosed in 
the study populations. 
The population data files were also used to study the participation pattern. 
The attendance figures are clearly age-dependent, with older women having 
the lowest participation rate. In Utrecht, only women attending a screening 
were invited for the next screening round. In Nijmegen, where all women 
were (and are) invited for each round, it appeared that attendance decreased 
steadily in subsequent rounds, from 85% in round I to 67% in round 4 (ages 
< 65 years). Attendance rates are high in the participants of the preceding 
round and low in the nonparticipants. These findings were incorporated in the 
model. 
The survival rates of clinically diagnosed breast cancers are based on 
tumor-size specific data from the Utrecht project (DOM, 1986), and on age-
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specific data from Sweden (Adami el al., 1986). Model-assumptions about the 
effectiveness of screening in reducing breast cancer the mortality rate were 
tested against the results of the Kopparberg I Osterg6tland trial (Tabar el al., 
1988). 
Table 111.1 Characteristics and results of the 2 breast cancer screening 
projects in the Netherlands (Verbeek et al., 1984; Collette et 
al., 1984; DOM, 1986; Collette et al., 1988). Values refer 
to cohorts and rounds that were used in the present 
analysis. 
Characteristics: 
Start year 
Cohorts invited 
age at first round 
# Women invited (total) 
Women invited in subsequent 
rounds 
# rounds 
Interval (years) 
Screening tests 
Results: 
Attendance rate, round 1 
Screen-detected round 1 
breast cancer round 2-5 
Interval cancers 
• per 1000 women examined 
" per 1000 woman-years 
Methods 
PROJECT 
Utrecht (DOM I, city) 
1974 
1911-1925 
50-64 
20,600 
attenders only 
5 
1,1%,2,4 
mammography, 
physical examination 
72% 
108 (7.2') 
81 (2.0') 
77 (1.1") 
Nijmegen 
1975 
1910-1939 
35-64 
23,000 
all women 
4 
2,2,2 
mammography 
85% 
74 (3.8') 
120 (2.6 ') 
99 (0.9") 
The MISCAN computer simulation package (Rabbema el al., 1984; Habbema 
el al., 1987) was used for simulating the screening projects in Nijmegen and 
Utrecht according to the characteristics of these projects. The differences 
between the two projects in age-groups invited, screening intervals, and 
attendance patterns (see Table III.I) have been modeled explicitly. In the 
Utrecht variant of the model, screening by mammography and physical 
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examination is simulated, and the sensitivity of the combined tests will be 
higher than in Nijmegen. Otherwise, and in particular with respect to the 
course of breast cancer and the sensitivity of mammography, the two variants 
of the model were kept identical. 
The results of the simulations of the Nijmegen and Utrecht projects were 
compared with the observed data, using chi-square goodness of fit tests and, 
when appropriate, a t-test for equality of mean values for each table 
considered. 
PRE·CLINICAL CLINICAL I-NO brent f'Q~fr br~ .. 1 canct[ 
BREAST ~ dCIS ~ < 10 mID ~ < lOmm CANCER 
PRE·CLlNICAL CLINICAL 
breut UncU .. brent calleH 
-
10·19 mm ~ IO-19mm 
PRE·CLINICAL ~ CLINICAL brelSt CIDet< bIe'" calleu r-<!: 20 mID ;!:20mm 
.I. 
MASS SCREENING 
1 
'" 
,I, J, 1 ,II 
SCREEN· SCREEN- SCREEN· DEATH r.lse SCRBIlN· DETECTED DETECTED DETECTED 
p,uUh-c DETECTED brUIt caDet! bleu! conCer brcu\ cu.eer FROM 
tullUlIl! dCIS < lOmm 10·19 10m <!:20mm BREAST 
I I I CANCER 
, 
Figure illa Structure of the disease model for breast cancer, and the stages (tumor 
diameter categories) used in the model. The possible courses of the 
disease are indicated. The state death from other causes, which can be 
attained from all other states, is not shown. 
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We decided not to summarize the test results into olle score for the overall 
goodness of fit of the model. There are many problems in combining results 
of statistical testing between tables from a screening project and between 
projects. Moreover, an overall lack of fit is not very informative; one has to 
go back to the individual tables to find the reason for the lack of fit. 
Therefore, the overall judgment of the adequacy of the fit is based on test 
outcomes for the separate tables. The tables in which a persistent lack of fit 
occurred are presented. 
Model SIlUC{Ure 
The structure of the disease model is presented in Figure IlIa. The first state is 
NO BREAST CANCER. Women reside in this state until a transition occurs to 
one of the pre-clinical states that are detectable by screening (mammography 
or clinical examination). There is one pre-invasive state, intraductal carcinoma 
in situ (dCIS). The screen-detectable invasive state (pre-clinical breast cancer), 
is subdivided according to the diameter of the tumor: < 10 mOl, 10 to 19 
mOl, and ;;, 20 0101. 
The same subdivision is used for the symptomatic clinical states (clinically 
diagnosed breast cancer) and for the SCREEN-DETECTED BREAST CANCER 
states. The state FALSE-POSITIVE TEST RESULTS refers to women with a 
positive screening examinatioll in whom no breast cancer is found at further 
assessment. 
The two end states of the model are DEATH FROM BREAST CANCER and 
DEATH FROM OTHER CAUSES. The rate of transition to this state is governed by 
the Dutch Iifetable, which is corrected for death from breast cancer (CBS, 
1985). 
The tumor diameter was given a central role in the stage distribution within 
the model because it determines the probability that breast cancer will be 
detected by screening; however is also affects the prognosis after treatment. In 
assessing screening policies, the use of the diameter-based staging will not 
only result in model-output concerning the number of cases that are detected 
early, but also concerning the stage-distribution and, thus, the prognosis of 
these cases. Additionally, it enables calculation of the impact of screening on 
the use of diagnostic and therapeutic procedures. 
Having defined the structure of the model, the task of specifying its many 
parameters remains. Some parameter values can be calculated directly from 
available data. Examples are the preclinical incidence, the stage distribution 
and survival of clinically diagnosed cancers, and the attendance patterns in the 
screening projects. However, a number of important parameters cannot be 
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obtained in this way; suitable values have to be obtained by experimentation 
with the model. These parameters are (I) the duration of screen-detectable 
invasive stages, (2) the sensitivity of the screening test, and (3) the 
improvement in prognosis following early detection. 
In model experimentation, simulated results are compared with data from 
the Utrecht and Nijmegen projects to test the parameter values. An initial set 
of parameter values, which were partly based on the HIP model, resulted in 
many discrepancies between simulated and observed data. Next, the input 
parameters of the model were varied systematically. Eventually, a set of 
model specifications was obtained that gave an adequate overall fit of almost 
all screening results from the Nijmegen and Utrecht projects. 
First, the parameter values that resulted in this fit will be presented. Then a 
comparison will be made of the simulated and the observed data. 
Model parameters 
Table m.2 summarizes the values of the key parameters of the model that 
resulted from the analysis. 
Clinical breast cancel' and survival 
The clinical incidence is based on Dutch figures from 1977 to 1982 (CBS, 
1985). The age-specific rates for more recent years are very similar, so there 
is no reason to assume important time or cohort trends for The Netherlands. 
The distribution of the tumor diameter for clinically diagnosed cancers was 
obtained directly from data on cancers diagnosed outside the screening pro-
gramme in Utrecht and Nijmegen: 10% < 10 mm, 22% between 10 and 19 
mm, and 68% ~20 mm. In the model, the distribution is independent from 
age. 
Age- and (diameter)stage-specific survival data are available in the Utrecht 
project for a limited age-range. Long-term results are still lacking. Because of 
the rather small numbers, a parametric approach was used to determine the 
fraction cured and a probability distribution function for the survival time of 
cases that will die from breast cancer. The lognormal distribution parameters 
(mean and variance) were taken from an analysis of Swedish survival data 
(Rutqvist, 1985). Overall, approximately 58% of the breast cancer deaths in 
clinically diagnosed cases are assumed to occur within 5 years from diagnosis 
and 86% within 10 years. After 10 years, there is still a considerable excess in 
the mortality rate. The average fraction cured was estimated from the Utrecht 
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data on clinically diagnosed cancers and varies with age according to the age-
specific pattern in Sweden (Adami, et al., 1986). The probability of survival 
(20-year follow-up, all stages combined) is highest (59 %) around the age of 45 
and declines with increasing age to 35% at the age of 80 (Table m.2). 
The combination of model-assumptions on clinical incidence, stage dis-
tribution, and survival result in a good fit for the mortality rate for breast 
cancer in the Netherlands at all ages. When age-dependency of the survival is 
not taken into account, the simulated mortality for older women will be far too 
low: in the age groups 75 to 79, 80 to 84, and older than 85, the difference 
would be 5%, 17%, and 36%, respectively. 
Table 111.2 Key assumptions of the breast cancer screening model. 
Parameter 
Preclinical incidence 
Clinical stage distribution 
< 10 mm. 
10·19 mm. 
'" 20 mm. 
20'years survival of clinically diagnosed 
breast cancers (diagnosis at age 55) 
< 10 mm. 
10-19 mm. 
'" 20 mm. 
Duration of preclinical 
invasive stages 
Age 40 
Age 50 
Age 60 
Age 70 
Sensitivity of mammography 
dCIS or < 10 mm. 
'" 10 mm. 
Impact of early detection: mortality 
reduction for screen-detected cancers 
Assumption 
Based on Dutch clinical 
incidence, 1977-82 
% in stage 
10% 
22% 
68% 
Survival 
83% 
68% 
51% 
Average dura-
tion (years) 
1.6 
2.1 
3.0 
4.7 
Sensitivity 
70% 
95% 
Reduction 
52% 
Independent 
from age 
Age-dependent 
(see text) 
Independent 
from age 
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Duration of preclinical stages 
The average duration of the preclinical stage is proportional to the ratio 
between the detection rate in the initial screening round and the clinical 
incidence rate. This ratio clearly increases with age: in Sweden, from 1.9 in 
the age group from 40 to 49 years to 3.5 in age group from 60 to 69 years 
(Day el al., 1988), and in Nijmegen from 2.1 to 3.1 for the same age groups. 
When searching for appropriate model-assumptions about the relationship 
between the average duration and age, the model was tested against the age-
specific detection rates and the age-specific incidence of interval cancers as 
observed in Nijmegen. A reasonable fit was obtained using the following as-
sumptions and parameter values: 
1. The average total length of the preclinical period, as given in Table III.2. 
2. Ratios 4:6:7 for the average durations of the disease in the preclinical 
stages < 10 mm : 10 to 19 mm : ;;" 20 mm. 
3. The duration of the preclinical stages follows an exponential distribution. 
This distribution has been proven to give an adequate fit in the HlP 
model (see Chapter II), as in other model-based analyses (Walter and 
Day, 1983; Day and Walter, 1984). 
4. For the stages dCIS and preclinical < 10 mm, the sensitivity of mammo-
graphy is 70%. For tumors;;" 10 mm in diameter, the value is 95%. 
The data from Utrecht and Nijmegen show that 12% to 15% of the cancers 
detected in the initial screen and 6 % to 7 % of those detected in the subsequent 
rounds were dCIS. It is (rather arbitrarily) assumed in the model that 5% of 
invasive breast cancers are preceded by a screen-detectable dCIS stage and 
that this stage lasts 7 years on average. Note that this is approximately three 
times as long as the preclinical invasive duration around ages 50 to 60 (see 
Table III.2) , and thus, the proportion of dCIS in the prevalence of all 
preclinical stages will be approximately 15%. 
It is assumed that all screen-detectable dCIS cases are progressive, i. e., 
they eventually develop into an invasive form of breast cancer. This 
assumption cannot be justified on the basis of available data. One could just as 
readily assume that some fraction of dCIS cases are nonprogressive and still 
obtain a good fit by shortening the average duration. The 100% progression 
assumption is just made to complete the model. In application of the model to 
predict effects of different screening policies, this is one of the parameters for 
which a sensitivity analysis should be carried out. The proportion of dCIS in 
the cancers diagnosed outside mass screening is considered to be negligible 
and is assumed to be zero. 
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The age-specific incidence of the preclinical stage is obtained by shifting the 
clinical incidence rate to younger ages, by a number of years corresponding to 
the average (age-specific) total duration of the preclinical stages. This implies 
100% progression of preclinical disease and excludes overdiagnosis by 
screening (except for inevitable cases in which women die from other 
independent causes in the period between screen-detection and clinical 
diagnosis without screening). This assumption is in agreement with findings 
from the randomized trials (Chu el al., 1988; Tabar el al., 1987). 
The specificity of the screening test can be estimated directly from observed 
results of screening projects, for example e.g., from Utrecht and Nijmegen. 
The model-assumptions used in cost-effectiveness calculations are given 
elsewhere(Van der Maas el al. 1989). 
lmprovemelll in prognosis following deleclion by screening 
In the model, the (age-stage specific) survival of interval cancers and cancers 
diagnosed in nonparticipants is the same as the survival of clinically diagnosed 
cancers in the absence of screening. A decrease in the mortality rate in a 
screened popUlation is a result of improvement in the prognosis of screen-
detected cancers. This improvement has been estimated from the results of the 
8-year Kopparberg/Ostergiitland trial. When using the number of breast cancer 
deaths (153) among breast cancer cases in the control group in the trial for 
comparison with the study group, a correction has to be made for differences 
in size between both groups (Tabar el al., 1988). After correction, 175 deaths 
would have been expected for the study group in the case of no screening. The 
total observed deaths in the study group is only 124 cases, 47 of which 
occurred in screen-detected cancers. If it is assumed that the difference of 51 
deaths is due to the early detection and treatment, then the reduction in the 
breast cancer mortality rate for the screen-detected breast cancers is: 51 I 
(51 +47) = 52%. 
This 52% improvement in prognosis could not be explained entirely by the 
shift in tumor size category that results from early detection. The simulated 
decrease in the breast cancer mortality rate among screen-detected women is 
then only 40%. The additional improvement undoubtedly results from the 
tendency that also wilhin a size category, screen-detected cases are detected 
relatively early (This especially applies to the highest tumor size category). 
Support for this hypothesis is given by the finding that within a size category, 
the observed proportion of node metastases is slightly lower in screen-detected 
cases (Tabar el al., 1987). The same phenomenon can be observed in the 
Nijmegen and Utrecht data. 
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After combining the shifts within and between the screen-detected invasive 
stages, reduction factors have been obtained that express the reduction in risk 
of dying from breast cancer compared to this risk when the cancer had been 
diagnosed (possibly in a higher tumor size category) in the absence of 
screening. In the model, for stages < 10 mm, 10 to 19 mm, and ;,,20 mm, 
reduction factors of 0.75, 0.45, and 0.15, respectively, are assumed, and no 
risk of dying from breast cancer for screen-detected dCIS. Using these 
assumptions, the simulated reduction in the mortality rate after 5 to 8 years of 
follow-up observation is approximately 24 % to 27 %, which is within the 
range (23%-29%) reported for Kopparberg/Osterg6t1and (Tabar et al., 1985; 
Tabar et al., 1988). 
Comparison of simulated and observed results 
Figures IIIb-e compare the simulated results with the actual values from the 
projects in Utrecht and Nijmegen. The solid line in each figure represents the 
simulated values, and the dots give the actual values observed. The vertical 
lines through each point give the 95 % confidence interval for the observed 
data using a normal approximation for the cases that are assumed to be 
governed by a Poisson distribution. 
The model shows a good fit of the detection rate by screening round 
(Figure IIIb(l)) and by age-group (Figure IIIc) in Nijmegen, with the 
exception of the youngest age-group. The deviation in this age-group is 
statistically significant, although the number of cancers is relatively small. 
This discrepancy cannot be corrected by simply shortening the preclinical 
duration at younger ages, since this would cause a rise in the already too high 
interval cancer rate in this age-group, see Figure IIId. Assuming a lower 
sensitivity would have the same effect. It appears, however, that the simulated 
detection rate for the 35 to 44 age-group is approximately at the level that has 
been reported for rounds 5 and 6. (These data were not yet available for the 
present analysis.) 
The same model-assumptions about the course of the disease and the sensiti-
vity of mammography that gave good fitting results for Nijmegen, could not 
fit the detection rates analyzed from the Utrecht project, see Figure IIIb(2). 
We tried to obtain a better agreement between the model and the Utrecht data 
by varying the model-assumptions about the preclinical stage of breast cancer 
and the sensitivity of the screening tests. However, no assumptions could be 
found that resulted in a reasonable fit. 
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Figure IIlb Detection rates by screening round. Comparison of model 
results and the results from the projects in: 
(1) Nijmegen (birth cohort 1910-1939); PCh;>0.5, PT>0.5. 
(2) Utrecht (DOM I, city of Utrecht); PCh;<0.001, PT> 0.2 
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Figure IIIc Detection rate by age. Comparison of model results and the 
results from the Nijmegen project, birth cohort 1910-1939. 
PChi> 0.1, PT> 0.5. 
The lack of fit can to some extent be explained by the characteristics of the 
Utrecht project. For example, in the model, the result of a screening is 
dichotomous: either preclinical cancer is suspected, and the woman is referred 
for further diagnostic assessment, or not. In Utrecht, there were, however, 
two intermediate stages ("brief note to G.P." and "check-up message") that in 
a few cases led to the diagnosis of breast cancer some time later (Collette 
1988). In addition, after the first round, only one view per breast was taken 
per screening, which may have affected the sensitivity. Both factors could 
have contributed to the low detection rates in rounds 2 through 4. However, 
these factors cannot explain such large differences between the model and 
observation in rounds I to 4. 
The incidence rates for interval cancers show a good fit with the Nijmegen 
data, both in relation to age (Figure IIId) and to the length of time since the 
last screening (Figure lIIe(I». This comparison in particular gives a good in-
dication of the accuracy of the model-assumptions about the duration of the 
preclinical stages of the disease. 
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Figure IUd. Incidence rate of Interval cancers, by age. Comparison of 
model results and the results from the Nijmegen project, 
birth cohort 1910-1939. PChi>0.5, PT>0.5. 
The same comparison for the Utrecht data shows again some deviations, see 
Figure IIIe(2). When these data are compared for each of the screening rounds 
separately (not shown), it appears that the simulated incidence of interval 
cancers is too high after rounds I and 2, and the simulated screen-detection 
rates in the immediately following rounds 2 and 3 are also too high (Figure 
IIIb(2)). For subsequent rounds, however, the too high simulated detection 
rate is counteracted by a too low simulated incidence of interval cancers. 
Table III.3 presents a comparison between the simulated stage distribution 
of breast cancers and the distribution recorded in Nijmegen and Utrecht. The 
cancers are grouped according to the mode of detection. In general, there is 
either a fairly close correspondence between the model and the observed 
values, or else the simulated values lie between the values for Nijmegen and 
those for Utrecht. The simulated distribution for screen-detected cancers in the 
follow-up rounds is slightly too favorable in comparison with both projects. 
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The reverse is true for the interval cancers, especially for Utrecht, i.e., there 
are too many tumors in the simulation with a diameter;:: 20 mm. 
Table 111.3 Distribution of the breast cancers by stage of the disease at 
diagnosis. 
Comparison of simulated and observed distributions for Nijmegen and 
Utrecht. 
o = observed, S = simulated. True interval cancers: diagnosed before 
next screening round; Pseudo interval cancer: diagnosed after 
non participation in a screening round. 
Source: Data-files of the two screening projects. 
Mode of detection Total number dCIS s 9mm 10-19 
'" 20 
mm mm 
A. Nijmegen 
screen-detected 
round 1 0 74 12% 16% 32% 39% 
S 10% 25% 36% 29% 
round 2-4 0 120 8% 25% 43% 24% 
S 8% 37% 39% 16% 
true interval cancers 
round 1-4 0 99 9% 7% 28% 56% 
S 21% 24% 55% 
unscreened 
0 107 2% 21% 19% 59% 
S 12% 24% 64% 
B. Utrecht (DOM I, city) 
screen-detected 
round 1 0 108 14% 25% 40% 21% 
S 10% 23% 37% 30% 
round 1-4 0 81 6% 32% 46% 16% 
S 6% 39% 42% 13% 
true interval cancers 
round 1-4 0 77 10% 14% 38% 38% 
S 24% 25% 51% 
pseudo-interval 
0 73 4% 11 % 27% 58% 
S 16% 24% 60% 
unscreened 
0 172 2% 8% 33% 58% 
S 11% 23% 66% 
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Figure lIIe. tncidence rate of interval cancers, by duration since last 
screening examination. Includes "pseudo" interval cancers detected after 
non participation to a screening round. Comparison of model results and 
the results from the projects in: 
(1) Nljmegen (birth cohort 1919-1939); PChi > 0,5, Pr> 0.2, 
(2) Utrecht (DOM I, city of Utrecht); PChi> 0.1, Pr> 0.1. 
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The model-assumption that dCIS can only be detected by mass screening 
conflicts with the observed data for the interval cancers. It is, however, 
difficult to find an explanation for the observed percentage (approximately 
10%) of dCIS in interval cancers, which is very high in comparison with the 
low percentage of dCIS in unscreened women. When dCIS is combined with 
the stage invasive cancer < 10 mm, then there is only a slight difference 
between the model and the observed data. 
Discussion 
The fit of the model to the breast cancer screening data is quite satisfactory, 
with one major and a few minor exceptions. The major exception is the lack 
of fit for the detection rates in the five screening rounds of the Utrecht project 
(see Figure IIIb(2)). Only data from the DOM I project in the city of Utrecht 
were included in the comparison. Results from the other projects in the city 
and the suburbs of Utrecht (Collette et al., 1988) were not yet available. It is 
noteworthy, however, that at the first informal inspection, the outcomes of the 
model seem to be in much better agreement with the results reported from 
these other projects. 
The lack of fit for the Utrecht project is not due to the simultaneous 
analysis of the data from Utrecht and Nijmegen. Independent parameter 
variation for Utrecht did not result in a better fit. 
The improvement in prognosis is crucial in assessing the effects of 
screening. The case-control studies in Nijmegen and Utrecht estimate a 
reduction of 50% and 70% in the breast cancer mortality rate in screened 
women compared to unscreened women, respectively. (Verbeek et al., 1984; 
Collette et at., 1984). This is much higher than the 29% reduction from the 
Kopparberg-Ostergotiand study in Sweden that was used in fitting the model. 
Indeed, a portion of the breast cancers in the Kopparberg-Ostergotiand study 
group occur in unscreened women, but since the attendance rate is approxi-
mately 90%, this can only explain a few percent of the difference in mortality 
reduction. 
From a methodologic point of view, the Swedish results should be 
preferred, because they stem from a randomized trial. In the Nijmegen and 
Utrecht case-control studies, part of the difference between screened and 
unscreened results might have resulted from selection effects. 
Apart from the questions about differences between Sweden and the Nether-
lands regarding the quality of the screening or data collection, and the clear 
difference in attendance levels, the screening situation in both countries is 
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similar in many respects. For example, the Kopparberg/Ostergotland policy 
closely resembles the one used in Nijmegen, and the proportion of cancers 
below 20 mm. in diameter is 43% in Sweden (Tabar el 0/., 1987) and 42% in 
the Netherlands (Table III.3). 
More important, the results of the project in the United Kingdom (UK Trial 
of Early Detection of Breast Cancer Group, 1988) and the trial in Malmo 
(Habbema el 0/., 1986), published after completion of the analysis reported 
here, both show more modest reductions in the mortality rate, even less than 
the Kopparberg/Ostergotland study. This brings the estimate used in the model 
to the comfortable position of being an intermediate estimate. 
A number of presuppositions are made in the model. The clinical stage 
distribution (tumor diameter) is assumed to be constant for all ages. This is 
probably not correct, but the practical implications are minor since the impact 
on prognosis is already incorporated in the age-dependent survival. 
From a prognostic point of view, refinement of the present stage 
distribution into lymph node/tumor diameter stages is attractive. However, the 
model would become more complicated, and finding appropriate parameters 
for the preclinical stages would become even more tedious. The current 
approach in which the improvement in prognosis is corrected for shifts within 
diameter stages is more feasible. 
The sensitivity of the screening test depends on the tumor diameter but is 
assumed not to depend on the age of the woman. It is difficult to distinguish 
between the concepts of sensitivity and duration of screen-detectable stage. 
Model assumptions of a shorter duration of preclinical disease at younger ages 
can to some extent be exchanged for assumptions stating that the sensitivity is 
lower in these age groups. 
Another important issue is the effect of screening for women under 50 
years of age. Thus far, the results for younger women are inconclusive (Tabar 
el 0/., 1988; Chu el of., 1988; Habbema el of., 1986; Andersson el 0/., 
1988). In the model, the improvement in prognosis in screen-detected women 
is independent of age. However, since the preclinical duration is shorter at 
younger ages, and the survival of clinically diagnosed cancers is highest 
between the ages of 40 and 50, the model will predict a lower reduction (%) 
in mortality below the age of 50 than for older women. Given the ambiguity 
of current empirical results for effectiveness below the age of 50, the model 
should be used with care in these age groups. The lower incidence below age 
50 further detracts from the desirability of screening in these ages. 
In the model, there is no difference in the risk of breast cancer between 
participants and nonparticipants. In the HIP study, the risk in nonparticipants 
was estimated to be lower than average. In the Netherlands, a more indirect 
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comparison between Nijmegen and the nearby city of Arnhem where no mass 
screening took place led to the conclusion that there was no clear indication 
for a difference in risk (Verbeek et 01., 1984). The same can be concluded 
from the Utrecht project by comparing the incidence in nonattenders with the 
incidence in the years before screening started. 
The assumptions made for dCIS in the model are highly speculative, but are 
compatible with the findings in screen-detected cancers. The assumption of no 
dCIS among clinically diagnosed breast cancers is an oversimplification, 
especially for interval cancers. The importance of dCIS may well increase 
with additional improvement in screening techniques. For example, figures 
from Nijmegen for screening rounds 5 and 6 show a percentage of 
approximately 19% dCIS in screen-detected breast cancers. 
Comparison with the analysis of HIP study 
The MISCAN approach was also used to analyze the results of the HIP study 
(see Chapter II). However, the model consisted of two tumor diameter classes 
only, since tumors below I cm. in diameter were not screen-detectable at that 
time. No age-dependency was assumed for the average duration. Although the 
data suggested some age-dependency, the number of screen-detected cases in 
the HIP study did not allow for conclusive estimates. The average duration of 
the preclinical screen-detectable stage derived in the HIP analysis was 2.2 
years (age group 40-70 years). This is the same as the average total duration 
of the dwelling time for tumors in the stages of 10 to 19 mm and ;,,20 mm in 
the present model for women aged 55. The estimated sensitivity of 
mammography for the HIP model was only 50% (Chapter II) which is much 
lower than the 95 % in the present model. 
These comparisons show the potential power of modeling: the parameter 
values for the invariant part of the natural history of preclinical breast cancer 
are indeed the same, whereas the increase in the sensitivity reflects the 
improvement in mammography. Taking the obvious differences between HIP 
and Nijmegen into account, the model shows that there is a good correspon-
dence between the screening data from these studies. Exploratory simulations 
of the projects in the UK and Sweden seem to indicate the promising prospect 
of fitting these studies as well. 
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Comparison with results from other models 
The findings about the duration of preclinical disease and the sensitivity of 
screening can be compared with results from other modeling approaches. A 
review of these approaches is given by Prorok (prorok, 1988). 
The statistical model of Day and Walter (1984) has been applied to the 
results of several screening projects (Day et al., 1988; Walter and Day, 1983; 
Verbeek et al., 1988). In its original version, this model consists of a single 
preclinical stage, for which a probability distribution function for the dwelling 
time is specified. The parameters of this function, the sensitivity of the 
screening test, and the clinical incidence of breast cancer can be estimated 
from screening data. In some applications, the clinical incidence is fixed to a 
"known" value, e.g., the incidence in the control group when a randomized 
study is analyzed. The model is confined to the detection of breast cancer; the 
effects on mortality rate are not taken into account. One advantage of this 
model is that it is relatively simple to obtain an approximate confidence 
interval for the parameter values. 
This model was applied to data from Utrecht by Day et al. (1988). The 
study reports a good fit of the model (chi-sqnare of 7.2 and 7 degrees of 
freedom [d/]), when assuming a sensitivity of 99% and a mean duration of 2.8 
years. It is not indicated exactly what data from Utrecht were used, but it is 
clearly a less detailed subset of the data that we used for testing model as-
sumptions. When we simulate this simplified model with a mean duration of 
2.8 years and 99% sensitivity and test the outcomes against the screen-detected 
cases in the five screening rounds of the Utrecht data (DOM I project, city of 
Utrecht), the chi-square rises to 16.0. When the interval cancers are also 
added to the analysis, the chi-square value becomes 50.9 for 22 df, indicating 
a very bad fit of the model. The largest deviations occur in rounds 3 and 4 
(screen-detected and interval cases), so probably these have not been included 
in the analysis of Day et al .. It is important to note that this simpler model 
also fails to give a good description of the results from Utrecht. 
An adapted version of the Day and Walter model was applied to the 
Nijmegen data (Verbeek et al., 1988). In general, the estimated parameters 
are comparable to the values found in the MISCAN approach presented here, 
especially regarding age-dependency of the estimated duration of the 
preclinical stage. However, the reported average duration is somewhat shorter, 
e.g., 2'h years in the 50 to 64 age group (compare Table lII.2). This 
difference may be due to the fact that the sensitivity in the cnrrent model 
varies within the preclinical stage, which will result in an increase of the 
average duration. 
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Other model-based evaluations of breast cancer screening have been 
published (Eddy, 1980; Shwartz, 1978; Eddy et al., 1988). However, in these 
evaluations not much attention is devoted to the subject of fitting the model to 
empirical data from large screening studies. The model of Shwartz is based on 
a biological formulation of tumor growth; parameter estimates for this model 
cannot be compared directly with our approach. 
Adaptation of the model for cost-effectiveness calculations 
The model presented here has subsequently been used in predicting the effects 
and costs of different screening policies for breast cancer. For this purpose, 
some adaptations and extensions are needed, but the core of the model, i.e. 
model-assumptions about preclinical disease, sensitivity of screening, and 
improvement in prognosis remains unchanged. 
The adaptations mainly refer to the population studied: instead of specifying 
the Utrecht and Nijmegen populations, now the entire Dutch female population 
is considered, taking the expected dynamics in the forthcoming decades into 
account. During this period, the average attendance is assumed to remain 
constant at 65 % in the age group of 50-69 years. The attendance pattern is 
modeled according to the experience in Nijmegen. 
The clinical part of the model was extended, by linking schedules for 
diagnostic and treatment procedures to the screen-detected and the clinical 
states and to the state "false positive test result". Treatment of advanced 
disease is linked to the state "death from breast cancer". This extension is 
useful in determining the change in demand for diagnostic and therapeutic 
facilities following the introduction of mass screening (De Koning et al., 
1990). 
Finally, cost estimates for all activities related to screening, diagnosis, and 
treatment have been linked to the model. This enabled calculation of costs and 
savings of different screening policies. The main conclusion from these 
calculations is that in terms of costs per life-year gained, biannual 
mammographic screening of women older than 50 years of age compares 
favorably with other health care facilities (Van der Maas et a/., 1989). 
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Appendix IlIA. 
DETAILED OVERVIEW OF THE MODEL SPECIFICATIONS. 
This appendix gives the full parameter quantification of the breast cancer screening 
model. Details on the simulation method can be found in the description of the 
MISCAN model (Rabbema et al., 1984). 
Demography 
Women die from other causes according to the Dutch Iifetable for 1982-83, in which 
breast cancer deaths have been excluded. 
AGE Proportion dead 
35 0.0149 
40 0.0204 
45 0.0280 
50 0.0389 
55 0.0558 
60 0.0829 
65 0.1273 
70 0.1996 
75 0.3128 
80 0.4759 
Risk groups 
The female population is assumed to be homogeneous with respect to risk of 
breast cancer. Apart from the obvious factor age, no other risk factors are 
taken into account. A consequence of this assumption is that participation at 
screening is independent from risk. 
Disease model 
Note: the description in this section applies to the situation in which there is 
no screeni ng. 
Stages: 
The stages involved in the disease process are represented in Figure IlIa. In 
addition, transitions to the stage DEATH FROM OTHER CAUSES are possible 
from all stages except DEATH FROM BREAST CANCER. These transitions are 
governed by the lifetable (see I). 
Preclinical incidence. 
The preclinical incidence is described by a piecewise linear probability 
distribution function, with a constant probability density within 5-year age-
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groups. The preclinical incidence is estimated from the reported clinical 
incidence data. It is shifted to younger ages according to the assumptions 
about the transitions and durations in the preclinical stages. The relation 
between clinical incidence Ii in each of the N age-groups i and the preclinical 
incidence Pj in preceding age-groups j is given by: 
; 
1;=L;D(i,})Pj , i=i,Oo,N j.1 
A deterministic auxiliary model was used to calculate the matrix D(i,j) 
representing the probability of clinical diagnosis for women who entered the 
first preclinical stage in age-group j. The Pj values are then calculated by 
solving the set of N equations. 
The preclinical incidence rates are: 
Age group 
35-39 
40·44 
45·49 
50-54 
55-59 
60-64 
66-69 
70-74 
75-79 
80-84 
Preclinical course. 
Preclinical incidence 
(per 100,000) 
94 
163 
216 
221 
264 
297 
345 
421 
472 
464 
From the preclinical incidence, 5% pass through the preclinical screen-detect-
able stage dCIS. The dwelling time in this stage follows an exponential 
distribution with mean 7 years. Transitions between stages are described by 
transition probabilities PT, the dwelling time distribution in a stage is 
conditional on the next stage and follows an exponential distribution. The 
mean durations mea) are age-dependent according to the formula (m50 is the 
mean duration at age 50): 
0.3 11150 
lII(a) 
(1.0-0.9a)2 
a= age 
100 
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From To Pr m60 
PRECLIN < 1 0 mm PRECLIN 10-19 mm 0.9 0.58 
PRECLIN < 1 0 mm CLiN < 10 mm 0.1 0.68 
PRECLIN 10-19 mm PRECLlN;;: 20 mm 0.75 0.86 
PRECLIN 10-19 mm CLiN 10-19 mm 0.25 0.85 
PRECLIN ;;: 20 mm CLiN ;;: 20 mm 1.0 1.00 
Survival. 
Survival is described by a fraction cured and a survival time distribution for 
women who are at risk of dying from breast cancer. Values for the mean and 
variance of the log-normal survival time distribution are adopted from an 
analysis reported by the Swedish Cancer registry (Rutqvist, 1985). The 
fraction cured in each clinical stage, as estimated from survival data from 
Utrecht, is: 
Stage 
CLiN < 10 mm 
CLiN 10-19 mm 
CLiN ;;:20 mm 
Fraction cured 
0.757 
0.702 
0.407 
Mass screening: ages, recall scheme, participation 
Nijmegell variallt 
The age distribution of the population invited for the first screening round is 
specified by giving the relative size of the (5-year) age-groups involved. Total 
number invited: 23,000. 
Age distribution and attendance, Round 1 
Age group Relative size Attendance 
35-39 0.119 0.875 
40·44 0.171 0.872 
46·49 0.172 0.870 
50-54 0.179 0.852 
65-69 0.169 0.852 
60·64 0.160 0.814 
65+ 0.040 0.708 
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Recall scheme: all women in the original cohort are invited for rounds 2-4. 
The interval between rounds is 2 years. The attendance in a round was found 
to differ especially between participants and non-participants in the preceding 
round. 
Attendance, rounds 2-4. 
Round Interval Attendance Attendance 
years participants nonparticipants 
2 2 0.853 0.155 
3 2 0.807 0.192 
4 2 0.820 0.191 
Screening test: mammography. 
Utrecht variant. Total number invited: 20,600. 
Age group 
50-54 
55-59 
60-64 
Age distribution and attendance, round 1. 
Relative size 
0.360 
0.323 
0.317 
Attendance 
0.762 
0.726 
0.650 
Recall scheme: only participants at the preceding round are invited for a new 
round. 
Attendance, rounds 2-4. 
Round Interval Attendance 
(years) (participants) 
2 1.0 0.808 
3 1.5 0.860 
4 2.0 0.844 
5 4.0 0.714 
Screening tests: mammography and physical examination. 
Sensitivity 
The sensitivity of the screening tests is defined for each "true" stage of the 
disease. Mammography and physical examination are assumed to be 
independent, i.e. the overall sensitivity in stage 10-19 mm. is 0.95 in 
Nijmegen and 0.975 in Utrecht. 
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Sensitivity 
State Mammography Physical 
examination 
dCIS 0.7 0.0 
< 10 mm. 0.7 0.0 
10-19 mm. 0.95 0.5 
"' 20 mm. 0.95 0.7 
Improvement in prognosis 
The improvement in prognosis resulting from early detection by screening is 
highest in the early stages. 
Stage 
dCIS 
< 10 mm. 
10-19 mm. 
"' 20 mm. 
Testing the goodness of fit. 
Reduction in lethality from 
breast cancer. 
1.0 
0.75 
0.45 
0.15 
Simulated and observed are arranged in a number of tables, for example the 
tables for detection rate by round which correspond to Figures IIIb(l) and 
IIIb(2). 
In comparing the simulated rates s and observed rates r, which are based on q 
and p cases, respectively. allowance should be made for the variance in the 
simulated rate which is inherent to the method of microsimulation (Habbema 
et al., 1987). Each rate is tested using the formula: 
z r-s 
Vr2lp+s2lq 
When simulating a sufficiently large number of life-histories, q> > P and 
var(s) < < var(r), and total variance is dominated by the variance of the 
observed data. For each table, a chi-square value was calculated by adding the 
sum of squares of the Z values in the categories in the table, with the number 
of degrees of freedom equal to the number of categories. A t-test for the mean 
value of the rates in a table is directly based on the Z value. 
In figures IIIb-e, the vertical lines denote confidence intervals of the observed 
rates. Variability of simulated rates is not displayed in the figures. 

IV. EPIDEMIOLOGICAL EVIDENCE FOR AGE-DEPENDENT 
REGRESSION OF PRE-INVASIVE CERVICAL CANCER 
Introduction 
Regression of pre-invasive cervical cancer is still a controversial issue. The 
possibility of regression, which may not occur at the same rate at all ages, is 
important for decision making about screening policies and about management 
of these lesions. A high regression rate would mean that many screen-detected 
lesions are diagnosed and treated unnecessarily. This would influence the 
balance between favourable and adverse effects of screening. 
In the analysis of the screening data from the British Columbia cohort 
study, a considerable amount of regression was found. The regression is 
concentrated in lesions detected at younger ages (Boyes et al., 1982). This 
finding was based on a comparison of the estimated cumulative incidence of 
pre-invasive lesions with the prevalence of these lesions and with the 
cumulative incidence of clinically diagnosed invasive cervical cancer. 
However, no explicit hypotheses about regression were tested. A model based 
approach would allow for using the detailed age-specific data from the cohort 
study in testing the assumptions. Earlier modelling efforts, e.g. by Coppleson 
and Brown (1975) also pointed at the existence of regression, but used a 
combination of data from widely different sources. 
For breast cancer, Day and Walter (1984) proposed a simplified model that 
can be used in analyzing data from screening programs. In this paper we 
propose a simplified model for cervical cancer, and use the model to test 
hypotheses about regression against data from the screening program in British 
Columbia. 
A model for cervical cancer is more complicated than for breast cancer, 
because of the long duration of pre-invasive stages and the possibility of 
regression. The proposed model contains the essentials of screening for 
cervical cancer: incidence of pre-invasive lesions, dnration, progression and 
possible regression of these lesions, and sensitivity of the Pap smear. 
Three hypothesis about regression of pre-invasive lesions are tested: (A) no 
regression, (B) a constant rate of regression at all ages, and (C) different 
regression rates for lesions that occur in young and middle-aged women, 
respectively. 
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Material and methods 
The data used in testing the hypotheses are all derived from the report of the 
British Columbia cohort study (Boyes et at., 1982). This study analyzed the 
records of the screening program in British Columbia in the period 1949-1969, 
for two cohorts of women, born in 1914-18 and 1929-33, respectively. A full 
overview of the data is presented in Appendix IVA, Table IVA. I. 
The age-specific incidence of clinical cervical cancer is based on data for 
the total female population between ages 20-24 and 60-64 in British Columbia 
in 1955-1957. Cervical cancer screening started already around 1950 in British 
Columbia, but only on a very limited scale. The impact on clinical incidence 
in the first years of screening has presumably been negligible. Thus, the 
incidence in 1955-57 is considered to represent the situation without screening. 
We converted the clinical incidence into an incidence rate for the female 
population at risk of cervical cancer by correcting for the cumulative hys-
terectomy rates recorded in the two cohort study populations. 
A distinct advantage of the data from British Columbia is that age-specific 
rates are available over a broad age-range, both for clinically diagnosed 
cancers and for screen-detected lesions. The two cohorts together span the 
age-range 20-54 in the study period. In the overlapping age-group 35-39, 
results from the younger cohort are used because of the larger numbers in this 
group. It is assumed that the cross-sectional clinical incidence data and the 
longitudinal screening data are comparable. Differences between these data 
sets could be caused by cohort effects, but cohort differences were not found 
in the cohort study (Boyes el al., 1982). 
Regression is supposed to occur only in pre-invasive lesions. The observed 
detection rates of pre-invasive lesions (dysplasia and carcinoma in situ) of a 
first smear are included in estimating and testing the assumptions about 
regression (see Table IVA. I). In the results of the second and subsequent 
smears the pre-invasive and early invasive lesions are pooled, because of the 
small numbers in the latter category. On basis of the tables in the report of the 
cohort study, these results are classified by age at midpoint between the first 
and second smear, and by the time since the preceding Pap-smear. 
The clinical incidence rates in the unscreened parts of the cohorts are also 
used in testing the model. An important reason for including these data in the 
analysis is that they contain information about the difference in potential risk 
for cervical cancer between participants and non-participants in screening. 
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Figure IV. a Schematic representation of the model. 
The model 
The model consists of 5 states: No CERVICAL CANCER, PRE-INVASIVE 
CERVICAL CANCER, PRE-CLINICAL INVASIVE CERVICAL CANCER, SCREEN-
DETECTED LESIONS, and CLINICAL CERVICAL CANCER, see Figure IV.a. Death 
from other causes and hysterectomies for other reasons than cervical cancer 
are treated as independent exogenous factors that have no influence on 
incidence rates in the "at risk" population or on screen-detection rates. 
Survival of screen-detected and clinical cervical cancer and death from 
cervical cancer are not considered in the model since they do not relate to the 
problem of regression. 
The model is stochastic, i.e., the disease process is described in 
probabilistic terms. The transitions between stages are described by probabil-
ities, and the dwelling time within the stage PRE-INVASIVE CERVICAL CANCER 
is governed by a probability distribution. 
The onset of pre-invasive screen-detectable stages corresponding with 
dysplasia and Carcinoma in Situ is reflected in the transition from No 
CERVICAL CANCER to PRE-INVASIVE CERVICAL CANCER. This onset is assumed 
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to be age-dependent and starts at age ao. Women who participate in screening 
are assumed to have a relative risk r/' in comparison with the total population. 
From PRE-INVASIVE CERVICAL CANCER, the lesion may regress sponta-
neously (i.e., return to No CERVICAL CANCER) or it may progress into PRE-
CLINICAL INVASIVE CERVICAL CANCER. The proportion of cases in which pro-
gression occurs is age-dependent. The state PRE-CLINICAL INVASIVE CERVICAL 
CANCER consists of micro-invasive lesions and occult tumours. The duration in 
this state, i.e., the time between invasion and clinical diagnosis of cervical 
cancer, is assumed to be the same in all women. All invasive lesions are 
assumed to be progressive. This chain of probabilities will result in the (age-
dependent) clinical incidence rate. 
The lesions in stages PRE-INVASIVE CERVICAL CANCER and PRE-CLINICAL 
INVASIVE CANCER can be detected when a Pap smear is made. The sensitivity 
of this screening test is sp for pre-invasive and s/ for invasive lesions, 
respectively. The detection rates for women who have a Pap smear will 
depend on their age, on the rank of the smear, and on the time since the 
preceding smear. The formulae for the clinical incidence rate and the detection 
rates at first, second, and subsequent Pap-smears are given in Appendix IVB. 
In order to make the model more parsimonious, a number of simplifications 
are made. First, both the onset rate of pre-invasive lesions and the proportion 
of progressive lesions are assumed to have two levels. Onset rate /'/ and 
proportion progression p / apply to younger women (between ages ao and a I)' 
and levels /'2 and P2 apply to women of age a/and older. 
Second, the pre-invasive duration is described by a Weibull probability 
distribution which has two parameters: mean duration III and shape (or 
concentration parameter) b. The Weibull distribution is a generalisation of the 
exponential distribution. The additional concentration parameter allows for 
changing the variance in the duration independently from the mean, higher 
values indicating less variability. 
Third, the duration of the preclinical invasive stage and the sensitivity in 
this stage are assessed directly from the clinical incidence rates and detection 
rates of the first smear, see Table IV AA. (Note that these detection rates are 
not included in testing the modeL) The ratio of the two rates, shown in the 
last column of the table, represents an estimate for the product of sensitivity 
and duration (approximately 3.6 years). The sensitivity for invasive lesions 
was fixed at s/ = 0.90, and the duration was set a 4 years. A last 
simplification was used in calculating the detection rates at second and 
subsequent smears, see Appendix IVB for details. 
In analyzing the data, three models A, B, and C are compared. In model A, 
it is assumed that all pre-invasive cases progress (P,=P2= 1.0). In models B 
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and C only a certain proportion of pre-invasive lesions will progress to 
invasive cancer. In model B, this proportion is independent from age (p] =P2)' 
In model C, the proportion of progressive lesions differs between young and 
middle-aged women (p] ~P2)' 
Model A has 8 parameters: the relative risk (rr) , the ages and rates of the 
incidence of pre-invasive lesions (00 ' a] , r1 ' 1'2 ), the duration of pre-
invasive lesions (m, b), and the sensitivity of the Pap smear (sp), that are to 
estimated. By including the progression parameters (p 1 and P2)' model C has 
10 parameters, while model B has only 9 independent parameters because the 
progression parameters are equal. 
Estimation procedure 
The cohort study data on clinical incidence (8 age-categories after combining 
20-24 and 25-29 because of very small numbers), detection rates at the first 
smear (7 categories), detection rates at the second and at subsequent smears ( 
2 x 4 x 3 categories), and the clinical incidence in unscreened parts of the 
cohorts ( 6 categories ), are all arranged into a single table (see Table IVA. I) 
with 45 entries. 
For each set of parameter values, expected number of cases according to 
the model are calculated. Both a Pearson Chi-square test statistic for the 
goodness of fit and the Likelihood are calculated from the expected and 
observed numbers of cases. For each model, best-fitting parameter estimates 
are obtained by maximization of the likelihood. The Likelihood-Ratio test is 
used to compare the models A, B, and C, and also in finding one- and two-
dimensional confidence regions for the parameters. More specific details on 
the estimation and testing procedures are given in Appendix IVB. 
Results 
The best fitting parameter values for the three models (A, Band C) are 
presented in Table IV.!. The goodness-of-fit test for the assumption that all 
pre-invasive lesions will progress to become invasive cancers (model A) shows 
that it is not possible to fit the data from British Columbia with this 
assumption. 
Especially the results of second and subsequent smears show large 
discrepancies between observed data and the model (See Appendix IVA, 
Table IV A.I). The clinical incidence and the detection rate of the first screen 
are fitted fairly well. This obviously requires quite surprising parameter 
estimates: a very long average duration (33 years) of pre-invasive lesions, 
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coupled with an incidence rate of 1.3xlO-3 between age 15 and 33 which is 
much higher than the clinical incidence rate_ After age 33, few pre-invasive 
lesions start developing_ Because of the low estimate (66 %) for the sensitivity 
of the Pap smear, the model gives too high detection rates for smears made 
within a short interval after the preceding smear. And the relatively low 
incidence rate of new lesions results in much too low detection rates for 
smears made after an interval of more than 3 years since the first or second 
smear. 
Table IV.1 Parameter estimates for pre-invasive lesions of cervical 
cancer, and goodness of fit of the three models. 
Model 
hra__ ABC 
Incidence of pre-invasive 
lesions (rates xl(P woman years): 
start at age ao: 
change at age a I: 
incidence rate 1'1 (before age a I) 
incidence rate '2 (after age al) 
relative risk rr of participants 
Duration and progression 
of pre-invasive lesions: 
mean duration //I (years) 
shape of distribution b 
progression PI (before age a I) 
progression P2 (after age a I) 
Pap smear: 
sensitivity sp 
GOODNEss OF FIT: 
p-value 
No 
regression 
15 
33 
I.31 
0.16 
0.80 
33.3 
2.06 
1.00 
1.00 
0.66 
0.0001 
Regression, 
constant 
15 
33 
1.46 
0.54 
0.75 
21.5 
2.37 
0.47 
0.47 
0.70 
0.005 
Regression, 
age-dependent 
18 
34 
2.11 
1.06 
0.74 
11.8 
1.58 
0.16 
0.60 
0.80 
0.7 
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With a shape parameter of 2.1 the variability in duration is rather low, and 
only 24% of the pre-invasive lesions will have a duration of less than 20 
years. In other words: although no explicit regression is assumed in model A, 
this very long duration, with a considerable amount of (very) slow-progressing 
lesions, can be interpreted as a compensating mechanism. 
The assumption of an equal proportion regression at all ages (model B) 
results in an estimate of 53 % for the proportion regression among pre-invasive 
lesions, see Table IV.1. The estimates for the onset after age 33, the mean 
duration of pre-invasive lesions, and the sensitivity of the Pap smear differ 
considerably from the case with no regression (model A). Although model B 
gives a statistically significant (p<O.OOOI) better fit than model A, the 
goodness of fit test against the cohort study data still yields a p-value smaller 
than 0.01. The same discrepancies with observed data found in model A exist 
in model B; they are only less extreme. 
The difference in log-likelihood between the model (A) with no regression 
and the model (C) with age-dependent regression indicates that a clearly 
significant (p< <0.0001) improvement is brought about by adding age-
dependent regression. Moreover, model C gives a good fit of the observed 
data from British Columbia. Between age 18 and 34, the incidence of pre-
invasive lesions is high, and the estimated proportion of regression among 
these lesions is 84 %. The proportion regression over age 34 is 40 %. From all 
lesions developing before age 65, an average of 62 % is regressive. Estimates 
for the other parameters show considerable differences compared to the case 
with no regression (model A, see Table IV.I). In women older than 34 years, 
there is a substantial onset rate of new pre-invasive lesions. The estimates for 
the duration of pre-invasive lesions imply that the large majority (85 %) of all 
new progressive lesions will turn into invasive lesions within 20 years. In 
combination with the higher sensitivity (0.80) of the Pap smear, these changes 
lead to a considerable improvement in the fit of the detection rate of second 
and subsequent smears. The relative risk of participants is 0.74, indicating that 
unscreened women constitute a high risk group. 
For model (C), assumptions about average duration, sensitivity, progression 
rate, and the shape have been varied to find 95 % confidence limits for these 
parameters, see Table IV.2. The mean duration of pre-invasive lesions is be-
tween 9.8 and 14.4 years. Mean durations of less than 9.8 years result in 
clinical incidence rates becoming too high at older ages, durations longer than 
14.4 years will conversely result in too high detection rates at older age. The 
range for the shape parameter of the distribution means that the standard 
deviation is between 5.9 and 12.1 years. The sensitivity of the Pap smear for 
pre-invasive lesions is between 76% and 85%. Other values will especially 
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deteriorate the fits of detection rates by interval at second and subsequent 
smears. The range for progression in lesions starting before age 34 is 8%-
24%, indicating that at most a quarter of these lesions will become invasive. 
The lower bound is imposed by the clinical incidence at young ages. The 
upper bound is imposed by an overall tendency in all detection rates to 
become too low if progression is over 30%. The range for the proportion 
progression over age 34 is rather wide (42%-88%). Since 100% progression is 
not included in the range, the model supports the hypothesis that regression 
also occurs in lesions that develop at higher ages. 
We also considered alternative values for the ages (ao and aJ) at which the 
onset rate and progression change. The confidence range for the age at which 
the onset starts is from 17 to 20 years, and the onset changes between ages 32 
and 36. Outside both confidence ranges the fit deteriorates rapidly. Note that 
in Table 18 in Boyes el al. (1982) already a clear difference was shown 
between estimated incidence rates of dysplasia before and after age 35. 
Table IV.2 Maximum likelihood estimates (MLE) and confidence ranges 
for the parameters of model C with age-dependent 
progression of pre-invasive lesions. 
Parameter MLE Range 
Incidence of pre-invasive lesions (per 103 
woman years): 
incidence rate, age < 34 (ro) 
incidence rate, age> 34 (r ,) 
relative risk of participants (rr) 
Duration and progression of pre-invasive 
lesions: 
mean duration m (years) 
shape of distribution (6) 
progression, age < 34 (p ,) 
progression, age> 34 (P2) 
Pap smear: 
sensitivity (sp) 
2.11 
1.06 
0.74 
11.8 
1.58 
0.16 
0.60 
0.80 
1.75 - 2.83 
0.80 - 1.38 
0.62 - 0.85 
9.8 14.5 
0.92 2.12 
0.08 0.24 
0.42 - 0.88 
0.76 - 0.85 
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Figure IVb Two-dimensional confidence regions for parameters of pre-
invasive cervical cancer, model C. "Progression" is the proportion of 
progressive lesions among new cases developing before age 34. The points 
+ mark the best-fitting combinations of two parameters. 
(1) progression and onset rate of pre-invasive lesions before age 34; 
(2) progression and mean duration of pre-invasive lesions; 
(3) progression and sensitivity of Pap smear in pre-invasive stages. 
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Only slightly wider ranges are found when two-dimensional confidence 
regions are considered, see Figure IV.b. For example, even when the 
sensitivity would be known to be 77 %, then the upper limit for progression is 
still only 27 %. From the figure it can be seen that variation in one parameter 
may be compensated by changing other parameters as well. For example, a 
high proportion of regression is possible when the onset rates are high, the 
mean duration short, and the sensitivity high. 
Discussion 
In the original analysis of the British Columbia cohort study, it was concluded 
that regression is part of the natural history of dysplasia and carcinoma ill situ, 
and that regression is more likely to occur at younger ages (Boyes et al., 
1982). Our analysis combines comprehensive data from this screening project 
with a modelling approach in which the essential aspects of the natural history 
of cervical cancer and screening are incorporated. The results show that it is 
possible to obtain an adequate fit of the screening data set by assuming that 
regression of pre-invasive lesions is age-dependent, with a higher proportion 
of regressive lesions developing before age 34. It is estimated that at least 
three quarters of these lesions in young women and about one-third in middle-
aged women will regress spontaneously. We also analyzed a model which 
100% progression is assumed in middle-aged women. This will give a 
statistically satisfactory fit of the cohort study data. However, the fit improves 
significantly by assuming that regression also occurs in lesions that develop 
after age 34. Assuming equal regression probabilities at all ages, or no 
regression at all, will give rise to large discrepancies between the model and 
the data from the cohort study. 
Using Occam's razor in formulating the model has a clear advantage, since 
it allows for testing of hypotheses in a statistical framework. As a 
consequence, the resulting model inevitably contains some biologically 
implausible aspects. For example, age-related changes in the incidence and 
natural history of pre-invasive lesions will occur gradually, and not briskly at 
one specific age (34). Thus, the model should be regarded as a filtered version 
of a more smoothly operating process. 
Both the sensitivity and the duration of pre-invasive lesions are assumed to 
be independent from age. Possibly, there could be more fast growing lesions 
at increasing age, but testing assumptions about age-dependent duration is 
hampered by the absence of screening data from age 54 onwards. It is difficult 
to predict the consequences of such assumptions for the estimated proportion 
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regression, because of the confounding effects of other parameters that will 
also take different values (as could be seen in Figure IV.b). 
The average duration of regressive and progressive pre-invasive lesions is 
assumed to be equal. A shorter duration for regressive lesions would probably 
result in an even higher proportion of (new) regressive lesions. 
In model (C) with age-dependent regression, the confidence interval for the 
concentration parameter governing the variability in the duration of pre-
invasive lesions includes the value b = 1.0 which represents an exponential 
distribution, see Table IV.2. This means that the current model is just not 
significantly superior (0.05 < p < 0.1) to a further simplified model with 
exponential dwelling time in the pre-invasive stage. We also considered a log-
normal distribution of the duration of the pre-invasive state as an alternative 
for the Weibull distribution. The resulting parameter estimates are almost 
exactly the same as those for the Weibull distribution. Only the mean and 
variation of the duration of the pre-invasive state both give higher values, but 
it appears that these differences are necessary to have about equal probabilities 
for durations between 0 and 10 years. The goodness of fit does not improve 
for model C, and appears to be considerably worse for the models with 
constant regression or no regression (A and B). 
For the preclinical invasive stage we assumed a fixed duration of 4 years 
and a sensitivity of the Pap smear of 90% in order to arrive at the observed 
ratio between detection rate and clinical incidence, see Table IV A.4. Other 
assumptions about preclinical invasive cancers may as well fit the data. For 
example, a different but still "simplified" assumption is that the duration of 
pre-invasive and preclinical invasive stages are 100% correlated. This means 
that lesions with a short dwelling time in the pre-invasive state will also have a 
relatively short dwelling time in the preclinical invasive stage. It appears that 
with this assumption, model C results in a equally good fit of the observed 
data from the cohort study. The values for most parameters are not very 
different from those listed in Table IV.1. Only for the concentration parameter 
(b) a different value (2.0) is estimated, but this means that the variability in 
the duration of the total pre-clinical period is about the same for both 
assumptions. 
There is general evidence that risk and participation to cervical cancer 
screening are associated (Koopmanschap el al., 1990b). The decision to 
include the relative risk parameter in the model was supported by the clearly 
higher clinical incidence rates in the unscreened parts of the cohorts in 
comparison with the clinical incidence in the total population in the 
"unscreened" situation in 1955-57. It was noted by Boyes el al. (1982) that the 
accuracy of the clinical incidence rates in the cohorts may suffer from 
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problems in determining the actual size of the unscreened "at-risk" population. 
However, if these data are not used in the estimation procedure, and the 
relative risk is given a fixed value assuming either no difference in risk 
between participants and unscreened women or a relative risk of 0.8 for 
participants, the resulting parameter estimates are still within the confidence 
ranges for the full model C as presented in Table IV.2. 
Since the period covered by the British Columbia cohort study, there have 
been clear developments in diagnostic techniques (colposcopy) and follow-up 
guidelines of early cytological abnormalities. In the early seventies, 
colposcopy was introduced in British Columbia, hampering continued model-
based evaluation of the two study cohorts (Anderson el at., 1988). Given the 
tendency towards treatment of very early abnormalities, and the impossibility 
to discern regressive from progressive lesions, it seems probable that the 
proportion of regressive lesions among those treated after detection by 
screening will become larger as a result of these developments. 
Estimates for the proportion regression based on follow-up of untreated 
cases of carcinoma in situ show great variations, see Brinton (1986) for an 
overview. For carcinoma in situ lesions, Kottmeier (1961) reported 71 % 
progression to invasive cancer after 12 years of follow-up. In contrast to this 
figure is the 36 % regression after 5 years of follow-up, as reported by Kinlen 
and Spriggs (1976). They also found that regression was confined to women 
aged less than 40 at the time of the initial smear. These follow-up periods are 
short if compared with the duration of preinvasive stages. The principal value 
of these studies is thus the support for the existence of spontaneous regression. 
Our estimate that a considerable proportion of pre-invasive lesions will 
progress to invasive stage does not prove a causal relation between dysplasia 
and carcinoma ill silll and invasive cervical cancer. Evidence for such a 
relation is given by the results of a combined analysis of data from major 
screening programmes (IARC Working Group, 1986), indicating a strong 
reduction in risk of invasive cervical cancer in the first 5-10 years after one or 
more negative Pap smears. We have analyzed the TARC data with model C, 
using the quantification given in Table TV.1. Despite the apparent difference 
between the long average duration of 11.8 years and the relatively short 
duration of the protective effect reported by the TARC study, we found that 
the model gives a good fit of this reduction in risk (see Chapter V). 
Among the models for evaluation of cervical cancer screening (see Prorok, 
1986, for an overview), a number of other "simplified" models for analysis of 
screening data have been published. Coppleson and Brown (1975) use data on 
age specific clinical incidence and detection rates of a first smear. This is a 
much more limited data set than we used, and their model shows some 
Regression of pre-Invasive cervical cancer 97 
differences with our model. However, they also found that the possibility of 
regression should be included in the model in order to explain the observed 
data. 
Albert (1981) tried to fit annual data concerning number of cases with CIS, 
pre-clinical invasive, and clinical invasive cancer in British Columbia. No 
distinction is made between first and subsequent smears, and false negatives 
are neglected. In our opinion, too many important aspects (age-dependencies, 
difference between first and subsequent smears) are neglected in this model, 
and it is not suited for testing assumptions about regression of CIS. 
Brookmeyer and Day (1987) proposed an extension of the model that Day 
and Walter developed for breast cancer screening, which is similar to our 
extension. They analyzed data from a case-control study addressing the 
question of the relative risk of invasive cancer for women who had a negative 
smear from. The data come from one of the screening programmes involved 
in the IARC study (IARC working group, 1986). Detection rates at successive 
smears are not taken into account, and therefore the proportion of regression 
can not be estimated from these data. The sensitivity of the Pap smear and the 
mean duration of the pre-clinical stage are estimated and have a large 
confidence region that includes our estimates. 
Gustafsson and Adami (1989) used a model that is similar to ours, but 
includes mortality as an additional final stage. Swedish population based 
incidence (CIS and invasive cancer) and mortality rates are used to obtain 
estimates for regression and duration of the preclinical stages. The estimated 
mean duration of the pre-invasive stage is 13.3 years, which compares well 
with our estimate. Further similarities are found for the variability of the 
duration (40% of new lesions will become invasive within 10 years, compared 
to 47% in our model) and the mean duration (3.9 years) of pre-clinical 
invasive lesions. However, the proportion progressive lesions is estimated to 
be lower (12%) than in our model, and is found to be independent from age, 
resulting in a marked difference with our model at higher ages. This low 
proportion might be due to the fact that in analyzing of the Swedish data, no 
distinction could be made between results of first and subsequent smears, see 
van Oortmarssen and Habbema (1990) and Adami and Gustafsson (1990). 
Other models for cervical cancer screening are comprehensive rather than 
simplified, and try to give a realistic description of the processes involved. 
Such models are less useful for estimation of parameters or testing of 
hypotheses. Typically, these models aim at evaluation of different screening 
policies (Knox, 1973; Eddy 1981). 
We conclude that the present analysis gives evidence for the existence of a 
considerable proportion of regression, especially at young ages. The 
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implications of this finding for cervical screening policies can best be 
considered in a cost-effectiveness framework. Such an analysis, based on this 
and other model-based analyses of screening data has been carried out for the 
present situation regarding the epidemiology and early detection and treatment 
possibilities for cervical cancer. The medical findings are reported in Van 
Ballegooijen et al. (1990), and the economic aspects in Koopmanschap et al. 
(1990a). The results point out that frequent screening at young ages gives rise 
to an unfavourable balance between favourable and adverse effects. It is also 
inefficient when comparisons of the cost-effectiveness ratio are made with 
screening at higher ages. 
Appendix IVA. 
Table IVA-1. (see page 99) 
Overview of the data from the British Columbia cohort study (Boyes et at., 
1982). and the fit between expected numbers for models A,B,C and 
observed numbers: (a) Clinical incidence of invasive cervical cancer 1955·7; 
(b) Clinical incidence in the unscreened part of the cohorts; (c) First smear: 
pre· invasive cancers; (d) Second smear by age at midpoint; (e) Third and 
subsequent smears by age at mid·point; (f) Second smear by interval since 
first screening; (g) Third and subsequent smears by interval since preceding 
smear . 
• significant difference, p<O.05 
•• significant difference, p<O.01 
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Cases Observed data Expected number of cases 
Age Rate x 106 Cases Model A Model B Model C 
(a) Clinical 20-29 3_2 9 8_9 7_9 9.8 
Incidence 30-34 10.1 15 20.9 21.1 23.2 
35-39 23.6 36 39.4 40.9 35.5 
40-44 29.8 40 51.2 52.6 43.7 
45-49 45.7 49 51.2 50.1 46.8 
50-54 53.5 43 43.2 38.7 42.0 
55-59 53.6 37 38.9 30.8 40.0 
60-64 55.5 35 35.0 24.6 • 38.4 
(b) Unsereened: 25-29 6.8 15 12.3 11.3 14.7 
Clinical 30-34 22.7 27 20.8 22.1 24.4 
incidence 35-39 53.2 15 17.7 21.3 18.8 
40-44 42.3 85 79.4 82.4 68.5 • 
45-49 56.5 55 59.5 61.7 58.0 
50-54 141.6 39 32.0 32.7 36.3 
(c) First smear 20-24 700 7 4.8 5.3 4.7 
25-29 880 106 96.5 104.3 110.5 
30-34 1190 402 367.8 385.4 406.4 
35-39 1150 215 209.9 218.2 220.1 
40-44 1030 150 155.1 158.1 148.3 
45-49 930 223 232.7 229.6 212.9 
50-54 780 81 91.5 88.1 85.6 
(d) Second smear 25-29 182 34 32.5 32.2 33.4 
by age 30-34 216 24 118.1 114.2 112.7 
35-39 126 25 40.4 •• 39.5 33.5 
40-44 125 31 37.1 35.9 31.1 
45-49 122 53 62.4 59.1 52.9 
50-54 109 12 16.8 15.5 14.2 
(e) Third + smear 25-29 157 9 7.7 7.5 8.9 
by age 30-34 165 96 91.0 86.5 96.3 
35-39 105 63 61.9 64.2 64.2 
40-44 140 16 9.2 • 9.8 10.2 
45-49 101 59 46.7 49.0 52.2 
50-54 70 30 35.6 36.7 40.1 
(f) Interval s 11 409 23 30.0 28.2 23.0 
second smear 12-35 224 94 107.0 102.4 93.0 
(eoh 2) 
'" 36 136 66 54.6 55.8 64.2 
s 11 270 9 16.2 14.6 10.5 
(coh 1) 12-35 150 47 65.8 60.5 49.5 
'" 36 90 40 34.2 35.4 38.2 (g) Third + smear s 11 248 45 44.7 42.3 38.8 
(eoh 2) 12-35 119 98 101.3 99.8 107.0 
'" 36 105 25 14.6 • 16.1 • 23.6 (coh 1) s 11 160 25 27.7 • 26.6 23.6 
12-35 88 66 58.3 60.7 65.7 
'" 36 63 14 5.5 8.3 13.2 
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Table IVA-2_ 
Goodness of fit 
Chi-Square 
D.F. 
p-value 
Deviance 
p-value 
Table IVA-3. 
Models 
A-B 
B-C 
A-C 
Table IVA-4. 
Chapter IV 
Goodness of fit of the three models A, B, C 
Model 
A B C 
73.3 
33 
0.00007 
69.4 
0.0002 
Comparison between models A, Band C. 
2 Log Likelihood Ratio (Chi-
square) 
14.2 (1 d.!,) 
30.9 (1 d.!,) 
45.1 (2 d.!,) 
56.0 
32 
0.005 
55.2 
0.007 
P-value 
24.4 
31 
0.8 
24.3 
0.8 
< 0.0001 
< 0.0001 
< 0.0001 
Comparison of screen-detection rates at first smear, and 
clinical incidence of invasive cancers. 
Clinical incidence Screen-detected invasive cancers 
Age Cases Rate (xl 05) Cases Rate (xl 05) Ratio 
(INC) (PCI) PCI:INC 
20-24 0.8 0 0 n.a. 
25-29 8 5.6 2 17 3.0 
30-34 15 9.9 23 68 6.9 
35-39 36 22.7 18 97 4.3 
40-44 40 27.4 16 110 4.0 
46-49 49 40.2 35 146 3.6 
50-54 43 45.5 11 105 2.3 
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Appendix IVB 
TIlE FORMULAE OF TIlE MODEL. 
In this appendix, we will give the formulae Ihat have been used in calculating Ihe 
expecled incidence rales and delection rates as shown in Table IV A.I, on basis of 
Ihe 10 paramelers of the model: ao' aI' r 1, r2, rr, Ill, b, PI' P2, S p (see Table 
IV.!). 
Functionsf(z) and F(z) are the probability density and dislribntion, respectively, of 
the duration z of Ihe pre-invasive stage. The Weibull dislribution for F(z) is 
characlerized by Iwo paramelers, scale c and shape b: 
F(Z) = I - e _(ve)b (1) 
The scale parameler c can be oblained from Ihe mean Ill, since III c r(l + lib), 
where ro is Ihe Gamma function. 
The probability density and dislribution funclions for Ihe duralion y=z+q of the 
lotal preclinical state is denoled by g(y) and G(y), respeclively, where q is Ihe 
duration of Ihe preclinical invasive slage. The Iwo varianls for the relation belween 
F(z) and G(y) are: 
I. Fixed duration q of Ihe preclinical invasive slage: 
G(y) = F(y-q), and g(y) =f(y-q) for y>q, G(y) = o and g(y) = Oolherwise. 
2. 100% correlation belween z and q. Here v = 1II/(III+q) is Ihe average 
proportion of Ihe preclinical duration in the pre-invasive slage: 
G(y) = F(v.y), and g(y) = v.f(v.y) for all y>O. 
The clinical incidence Ira) al age a is derived from Ihe onsel rale R(a-y), Ihe 
proportion of progressive lesions p(a-y) and Ihe dislribulion g(y) of Ihe lotal duralion 
y=z+q of the two pre-clinical slages: 
a-ao 
lea) = r g(y)p(a-y)R(a-y)dy (2) 
The clinical incidence applies 10 Ihe lotal female populalion al risk, which by 
definition has a relative risk equal 10 1.0. For known values of Ihe relalive risk rr of 
the screened population, the relative risk of the unscreened population ru(a) is age-
dependent via the fraclion screened ..-(a): 
rll(a) = 1-7f(a).rr 
I ,,(a) 
(3) 
The incidence in the unscreened part of Ihe cohorls is ru(a) . Ira) and can be derived 
from expressions (2) and (3). 
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For convenience, we introduce N(a), the rate at which cases leave the PRE-
INVASIVE stage: 
0-°0 
N(a) = ! Jtz)R(a-z)dz (4) 
Now the detection rate of pre-invasive lesions at a first screening at age a is: 
a 
Pp(a) = rr Sp ! (R(x)-N(x))dx (5) 
And the detection rate of invasive pre-clinical lesions: 
a 
Pia) = rrsl !(N(X)-I(X))dx (6) 
The detection rate of pre-clinical lesions for a second smear at age 112 depends on 
the age III at which the first smear was made. 
''2 
S(III'UV = f rrR(a)[Sp{I-F(lIr a)} + sIP(a)(F(lIr a)-G(1I2-a)}j(l-sp)"<a'da 
aO (7) 
The notation (I_sp)a<a, is used to indicate that the false negative rate at the first 
screening should be taken into account only in cases where the onset occurred before 
age Ill' 
For the detection rates of second and later smears, a further simplifying 
assumption was made to reduce numerical complexity: the false negative rate at the 
subsequent smear(s) is assumed to be 1.0-s p for all screen-detectable lesions. Thus, 
the expression for the false negative rate is an approximation, neglecting the lower 
false negative rate 1.0-s I in cases who are in stage PRECLINICAL INVASIVE already 
at age 112' This will result in a slight exaggeration of the detection rate, since lesions 
that are in stage PRE-CLlNlCAL INVASIVE CERVICAL CANCER at preceding smears 
would have a false negative rate of 112' 
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The detection rate at a third screen at age 113 depends on the ages III and 112 of the 
preceding smears: 
"I 
T(ul,u2,U3) = f rr R(a)(l-sp)2 [Sp{I-F(1I3-a)} + SIP(a){F(1I3-a) - G(lIra)}] da 
"0 
''2 
+ f rr R(a) (I-sp) [Sp(I-F(1I3-a)} + sIP(a){F(U3-a) - G(U3-a)}] da 
"I 
"3 
+ f rr R(a) [Sp(I -F(1I3-a)} + sIP(a){F(1I3-a) - G(U3-a)}] da 
''2 
The simplifications in R(a) and p(a) are: 
R(a) = { 
rl 
r2 
p(a) = {
PI 
P2 
(8) 
Expressions (2), (5), (7) and (8) can now be simplified considerably. The resulting 
expressions are used to calculate expected rates for a given set of parameter values. 
The clinical incidence /(a) and the deteclion rate of a first smear are calculated for 
I-year age-groups and then aggregated to the classes used in the testing procedure. 
The detection rates S(III,1I2) of a second smear are calculated for a matrix of "ages 
at mid-point of the interval" and intervals. The same method is used for detection 
rates T(1I1 ,112 ,113) of third and subsequent smears, assuming that the interval 
between the first and second smear is I, 2, 3 or 5 years with probabilities 0.40, 
0.30, 0.15 and 0.15, respectively (based on woman-years in the published tables for 
the second smear). These rates are also aggregated, after dividing the rates by the 
length of the interval to obtain rates that have woman-years as denominator. 
Expected numbers of cases are obtained by multiplying expected rates and observed 
denominators (woman-years or number screened). 
The log-likelihood is based on the assumption that the observed cases are a 
realisation of a Poisson-distribution with mean = expected number of cases. The 
likelihood is maximized using a downhill simplex multidimensional optimization 
routine (press et ai, 1988). 
The total number of classes is 45, the number of degrees of freedom for the Pearson 
Chi-Square test for the goodness of fit of the model is 41 minus the number of free 
parameters that were varied in deriving the maximum likelihood estimates. The 
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number of degrees of freedom equals the number of categories minus 4, since in 
each cohort both expected and observed sum of cases detected with the second smear 
and with subsequent smears is the same for the two subclassifications (by age and by 
interval since first smear), as can be seen in Table IVA-I. The deviance, i.e. the 
likelihood ratio test statistic for comparing a model with the complete model, is also 
inspected in assessing the goodness of fit. 
Comparisons between models are based on the Likelihood-ratio test. Also, 95% 
confidence regions for 1 and for two parameters are obtained by inverting the 
Likelihood-ratio test, i.e. by searching for parameter values for which the log 
likelihood is 3.84 + 2 respectively 5.99 + 2 lower than the log-likelihood of the 
optimal model. One- and two-dimensional confidence regions (Table IV.II, Figure 
IV.b) are computed by repeatedly applying the downhill simplex optimization routine 
in combination with a root-finding algorithm. 
V. THE DURATION OF PRE-CLINICAL CERVICAL CANCER 
AND THE REDUCTION IN INCIDENCE OF INVASIVE 
CANCER FOLLOWING NEGATIVE PAP-SMEARS. 
Introduction 
The results of three decades of cervical cancer screening have been analyzed by 
different methods in order to assess the effectiveness of early detection and 
treatment, and to make recommendations about the screening intervals. The most 
convincing direct evidence for the effectiveness of screening is given by the 
mortality trends in countries with different levels of screening (Lililril el at., 
1987). However, such a comparison does not allow conclusions about the optimal 
screening interval. This is an important question in view of both the large 
resource implications of cervical cancer screening, and the striking diversity in 
policy recommendations. 
In analyzing the interval between Pap-smears, two methods are being used: a 
direct epidemiologic exposure-incidence approach and a more indirect model-
based approach. 
In the direct approach, the potential impact of different screening intervals is 
derived from the gradual increase of the incidence of invasive cervical cancer in 
women after one or more negative Pap-smears. This incidence can be estimated 
directly by linking screening register data and cancer register data, an approach 
which has been used by an IARC working group in a combined analysis of 
results from large screening programs in 8 countries in Europe and North 
America (Hakama el at., 1986, IARC, 1986). The IARC group reported the 
results as "relative protection", i.e. the ratio of the incidence in unscreened 
women to the incidence following negative smears. We prefer the term "risk 
reduction" to avoid the suggestion of active protection given by Pap-smears. In 
the first years after a negative Pap smear, the relative risk is less than 25 percent 
of the level in unscreened women, and within 6-10 years it increases to 
approximately 50 percent of the unscreened level (Hakama el at., 1986). 
The second approach uses a "deep" model of the pre-clinical course of the 
disease, which is fitted to screening results, and subsequently used to predict the 
favourable and adverse effects of screening policies. Examples include Coppleson 
& Brown (1975) and Gustafsson & Adami (1989,1990,1992). We have developed 
a model to analyze the epidemiological data and the detailed screening results 
from British Columbia, see Chapter IV. One would expect that the duration of 
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low risk in the 'risk reduction' approach would be approximately equal to the 
duration of the pre-clinical stages in the model-based approach. However, model-
based estimates are consistently higher, with a mean total duration of dysplasia, 
carcinoma in situ (CIS), and pre-clinical invasive stages of 15 to 20 years 
(Coppleson and Brown, 1975, Gustafsson and Adami, 1990, and Chapter IV) and 
a median of about 15 years. 
In the IARC study both clinically diagnosed cancers and screen-detected 
invasive cancers have been used in determining the risk reduction, see page 17 
of the report (Hakama el al., 1986). We will investigate whether this inclusion 
of screen-detected cancers can give an explanation for the seemingly 
contradictory outcomes of the two approaches. The implications for the choice 
of the screening frequency will be discussed. 
Material and methods 
Our epidemiologic model describing the pre-clinical course of cervical cancer and 
the intervention by screening, which was used to analyze comprehensive data 
from the British Columbia cohort study of cervical cancer screening, will be used 
to analyze the incidence of invasive cancer following negative smears as 
calculated in the IARC study. 
model. 
The British Columbia cohort study (Boyes el al., 1982) is based on cervical 
screening data collected between 1949 and 1969, in two cohorts born between 
1914-18 and between 1929-33, respectively. The parameters of our cervical 
cancer screening model were estimated from the cohort study data, which include 
age-specific detection rates at first screening and at subsequent screenings by 
interval since preceding smear, the clinical incidence in the population before 
screening started, and the clinical incidence in unscreened women. The resulting 
model quantification shows a good fit of the data, see Chapter IV. 
The model consists of six stages, see Figure Va. The model neglects death 
from cervical cancer and from other causes and hysterectomy for other reasons 
than cervical cancer. These stages can be excluded, since comparison between 
observed data and outcomes of the model are based on rates, and it is assumed 
that the risk of death from other causes or hysterectomy for other reasons than 
cervical cancer is independent from the risk of cervical cancer. 
From the initial stage NO CERVICAL CANCER, transitions to the stage PRE-
INVASIVE CERVICAL CANCER (which includes Dysplasia and Carcinoma in Situ) 
occur at two different rates, for younger and for older women, respectively. The 
duration of this stage is governed by a probability distribution function which is 
characterized by the mean duration (estimated value: 12 years) and the variability 
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of this duration which is considerable: 20% of new progressive lesions will enter 
the stage PRE-CLINICAL INVASIVE CANCER within 5 years_ The estimated 
probability of spontaneous regression is 84% for younger women and 40% for 
older women_ 
In the absence of screening, all invasive cancers will eventually be diagnosed 
clinically (stage CLINICAL INVASIVE CERVICAL CANCER)_ The duration of PRE-
CLINICAL INVASIVE cancers is assumed to be constant, and estimated to be 4 
years. Thus, the total average duration of (progressive) screen-detectable stages 
is between 14 and 20 years. The probability of detecting a pre-clinical lesion by 
a Pap-smear is estimated to be 80% in PRE-INVASIVE CERVICAL CANCER and 90% 
in PRE-CLINICAL INVASIVE CANCER. Screening participants constitute a group 
which has below-average risk of developing cervical cancer; the estimated 
relative risk is 74%. Confidence regions of the parameter estimates and other 
details of the analysis of the British Columbia data and the resulting model are 
given in Chapter IV. 
Pre-clinical Clinical 
Pre-invasive ~ invasive ~ invasive No ~ cervical cancer cervical cancer cervical cancer 
cervical 
cancer 
1 
Pap smears 
~ Screen-detected Screen-detected 
pre-invasive invasive 
cervical cancer cervical cancer 
Figure Va. Schematic representation of the cervical cancer screening model 
The model is used to predict the build-up of incidence of invasive cancers 
following negative smears which can be compared with the eslimates of the IARC 
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study for the relative protection against invasive cervical cancer following one 
negative smear and two or more negative smears, respectively (see Tables III and 
IV in IARC, 1986). This relative protection was calculated by dividing the 
incidence in unscreened populations (taken from Cancer Incidence in Five 
Continents, volumes II and III) by the observed incidence of invasive cervical 
cancer in screened women in the screening programs involved in the IARC study. 
Comparing the model with IARC fil/dings 
The model has been used to predict the initial fall and subsequent rise in 
incidence of invasive cervical cancer following a first or second negative smear. 
Women who had negative Pap smears are likely to have further preventive 
smears at which invasive cancers may be detected in addition to the clinically 
diagnosed (symptomatic) cancers. In the studies that are based on complete cohort 
data, the total incidence of invasive cervical cancer is a function of age and time 
since last negative smear, number of negative smears, and screening intensity 
after the last negative smear. The numerator of the incidence is composed of the 
clinically diagnosed cancers and the product of the screening intensity and the 
screen-detection rate of invasive cancers (see Appendix). 
The main results from the IARC study concern the relative risk following two 
or more negative Pap smears in women aged 35-64. The interval between two 
smears is approximately 3 years in most of the programs that participated in the 
IARC study, with a range from 2-3 years to 5 years (Hakama et al., 1986). We 
assumed an interval of 3 years between the last 2 negative smears. The 
contribution of screen-detected invasive cancer to the total incidence depends on 
the screening intensity for which we assumed that each year 33 percent of the 
women will have a Pap smear. Reports of the participating programs indicate that 
the average age of the women in age-group 35-64 is approximately 45 years 
(Hakama et al., 1986). Therefore, model predictions for age 45 will be compared 
with IARC outcomes, which are predominantly based on complete cohort data 
(114 of the 162 cases of invasive cancer, or 70%). The remaining 48 invasive 
cases are from case-control studies. In principle, these case-control data would 
require a separate treatment in the model because of the different consequences 
of pooling screen-detected and clinical cases, and the absence of high-risk non-
participants in these studies. 
IARC results for the relative risk following a single negative smear have only 
been presented for women below age 35 (IARC, 1986), and are fully based on 
cohort data. Most women concerned are in the 30-34 age-group. We take screen-
detected invasive cancers at a second smear into account, again assuming that 
each year 33 percent of the women will have a next Pap-smear. 
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Results 
In Figure Vb(/), the risk reduction following two negative smears as predicted 
by the model is compared with the observed results of the IARC study (women 
aged 35-64)_ Confidence ranges for the IARC outcomes are given_ The predicted 
relative risk of clinically diagnosed cervical cancer is much lower than the 
observed IARC level. During the first 4 years the predicted risk is very low 
because of the assumed fixed 4-year duration of preclinical invasive stage and the 
10% false negative rate in this stage at each screening. At 4 years, an abrupt 
(small) increase in risk occurs because of the higher false-negative rate (20%) of 
pre-invasive lesions, and from this moment also cervical cancers which started 
developing after the last smear can be diagnosed. Note that part of the risk 
reduction predicted by the model results from the difference in risk between 
participants and non-participants, which would give a relative risk of74% even 
if Pap-smears had no effect at alL 
Much better agreement between model predictions and IARC outcomes is 
obtained when screen-detected invasive cancers are included in the prediction. 
The contribution of screen-detected invasive cancers in year y is equal to the 
prevalence of preclinical invasive cancers (which is roughly 4 x the average 
clinical incidence in years y to y+4 because of the 4-year duration of the 
preclinical invasive stage), multiplied by the screening intensity (0.33) and the 
sensitivity (0.9). Note that this rather high screening intensity will lead to a rapid 
decline in the number of women-years at risk after the first few years. In these 
first years, the predictions are slightly too low, which might be due to the 
simplified model assumption of the fixed duration of the pre-clinical invasive 
stage. Comparison for other ages within the 35-64 range shows that the predicted 
relative risk decreases gradually with age. We conclude therefore that the 
predictions for age 45 as shown in figure Vb(2) probably give a good account of 
the build-up of incidence following negative smears in the age-group 35-64. 
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Figure Vb. Comparison of estimated relative risks (mean and 95% 
confidence interval) of cervical cancer according to the IARC study (lARC, 
1986), and model predictions based on the best fitting estimates of the British 
Columbia data: (1) women aged 35-64 who had two or more negative smear; 
(2) women under 35 years who had one negative smear. The IARC estimates 
in (1) and (2) are adapted from Table V.3 and VA in (IARC, 1986). 
no further screening: only clinically diagnosed cancers, no further 
with further screening: 
screening. 
both clinically diagnosed cancers and invasive 
cancers detected at further screening. 
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In Figure Vb(2), the model predictions and IARC outcomes are compared for 
women below age 35 who had had one negative smear. Because of the smaller 
impact of a single negative smear, the relative risks in the first years after the 
negative smear are higher than in Figure Vb(J). The predicted trend for clinically 
diagnosed cases starts at a relative risk of 7.4 % in the first four years following 
the negative smear which results from the 10% false negative rate and the 74% 
relative risk of participants. The model-predicted relative risk of clinically 
diagnosed cancers is lower than the IARC outcomes, and is below the lower limit 
of the confidence interval for nearly all IARC outcomes. Inclusion of screen-
detected invasive cancers will give a much better agreement. The model 
predictions are shown for age 35. For younger ages higher relative risks are 
predicted, because of the larger proportion of fast growing lesions at these ages. 
The predictions for age 30 are well within the confidence ranges of the rARC 
outcomes, however. 
Discussion 
The results of the model can be used to draw conclusions about the risk reduction 
after negative screening tests, and about the duration of (progressive) preclinical 
stages of the disease. 
A first conclusion is that the estimated relative risks of the rARC study should 
be interpreted with caution because of the inclusion of screen-detected invasive 
cancers. These cases cause an early increase in the risk of invasive cancer, as can 
be seen from the predicted curves "no further screening" and "with further 
screening" in figure 2. The difference between the curves depends only on two 
assumptions: the duration of pre-clinical invasive cancer, and the frequency of 
screening. 
The 4-year duration of pre-clinical invasive cancer is derived directly from 
comparison of detection rates at first screening and clinical incidence in 
unscreened women in British Columbia, see Chapter IV and Boyes el at. (1982). 
Similar durations have been obtained in Sweden (Gustafsson and Adami, 1992) 
and from a large pilot study of cervical cancer screening in The Netherlands. 
From equations (I) and (4) in Appendix V A it can be seen that the difference 
between "clinical only" and "all invasive" is proportional to the screening 
intensity. Given the mix of the different screening intervals obtained by pooling 
the data from the separate programmes in the rARC study, an average frequency 
of 33 % per year between 2 and 6 years after the last negative smears is 
reasonable. 
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A second conclusion is that accounting for the impact of further screening can 
resolve the apparent discrepancy between the results of the IARC study, which 
might suggest a median duration of 5-8 years of pre-clinical cancer, and 
estimated median durations of 15 years and more derived with statistical models. 
This conclusion is based on our statistical model, with parameters which had been 
estimated directly from comprehensive screening data from British Columbia. 
The only parameter that had to be added to the British Columbia model in 
analyzing the IARC data is the screening frequency. We tested the implications 
of alternative assumptions about the interval between smears. Other intervals, for 
example 2 or 4 years in stead of 3 years, will still result in a good 
correspondence with IARC findings and model predictions concerning relative 
risk after two negative smears, provided that similar assumptions are made for 
the duration between the two smears and the duration between the second and a 
possible subsequent third smear. A shorter interval between the two negative 
smears will give more reduction in the clinical incidence of invasive cancers, but 
this is compensated by the associated higher screening frequency following the 
second smear which will increase the number of screen-detected invasive cancers. 
Similarly, a longer first interval can be compensated by a lower screening 
frequency following the second smear. The predicted relative risk after one 
negative smear is more sensitive to changes in assumptions about a possible 
second smear. Assuming that each year only 25 percent of the women (who had 
a first negative smear) are screened would lead to a lower value of the predicted 
relative risk, but most values remain within the confidence limits of the IARC 
data. If 50 percent of the women would have a smear each year, then the 
predicted relative risk is clearly too high, especially in the first 5 years following 
the negative smear. 
A restriction with respect to the comparison for two or more negative Pap 
smears (Figure Vb(l)) is that the way in which the model results are calculated 
applies to the 70% of the cases that stem from cohort-based incidence data. The 
remaining 30 % of cases stem from two case-control studies in which the relative 
risk is calculated as the average risk for screen-detected and clinically diagnosed 
cases, in stead of taking the sum. This would lead to a lower model prediction 
for this group of cases, which would however be partly compensated by deleting 
the attenders risk of74% which is not applicable since persons that have not been 
screened are not included in the case-control studies. 
We also tested the robustness of our second conclusion, that the apparent 
discrepancy between the results of the IARC study and the estimates of statistical 
models can be resolved by accounting for the impact of further smears, by 
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investigating alternative quantifications of our statistical model that still give a 
good fit of the British Columbia data. 
The assumption of a fixed 4 year duration of pre-clinical invasive cancers is 
a simplification. In reality, this duration will show variation, and might be 
correlated with the duration of the pre-invasive stage. We investigated the 
extreme opposite assumption that the duration is fully correlated with the duration 
of this preceding stage. In this case, the average duration of the invasive stage 
is 5.7 years. The only parameter which is seriously affected by this alternative 
assumption is the variability of the duration of the pre-invasive stage: only 10% 
of new progressive lesions will become invasive within 5 years. This alternative 
model gives an equally good fit of the British Columbia data see Chapter IV. 
The alternative model predicts relative risks of clinically diagnosed cervical 
cancer following one or two negative smears that are similar to those predicted 
by the basic model, and are again clearly below the observed outcomes of the 
IARC study. In the case of one preceding negative smear, inclusion of screen-
detected cancers will result in a good agreement between the model-predicted and 
the observed risk reduction. For two negative smears, the predicted relative risk 
shows a larger discrepancy and is 20-30 percent too low if compared to the IARC 
results. A much better fit can be obtained by increasing the standard deviation of 
the duration from 5.9 to 7.3 years, which implies more fast-developing lesions. 
A standard deviation of 7.3 years is still within the confidence limits derived 
from the British Columbia data. 
Another simplifying assumption in the model concerns false-negative test 
results. Test results in a woman are assumed to be independent, whereas in 
practice it is likely that after a false-negative smear the sensitivity of a subsequent 
test is relatively low. After two negative smears (Figure Vb(l», this would imply 
a higher starting level of the relative risk. The change in the contribution of 
screen-detected invasive cancers will depend on the precise assumptions made 
about the association between test results. 
The self-selection relative risk r=0.74 is a model estimate based on the British 
Columbia data. It is mainly based on ratio of incidence in unscreened women to 
incidence in historical controls, and as such, can be questioned. A further 
question is whether it would apply to other regions and countries as well. 
The model quantifications for duration and progression closely resemble 
estimates from a model which was based on data from the Swedish cancer 
registry on carcinoma in situ (CIS) and invasive cancers (Gustafsson & Adami, 
1989). This model only considers CIS, but in the Swedish classification practice 
this probably includes most cases of severe dysplasia as well. In our model the 
pre-invasive stage represents both CIS and dysplasia, but dysplasia only plays a 
minor role in British Columbia in the period considered. In the Swedish model, 
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the estimated average duration of progressive CIS is 13-14 years with a 
confidence interval of 4 years, and approximately 40 percent of new progressive 
pre-invasive lesions will become invasive within 10 years, which is nearly equal 
to the value (39 percent) for our alternative model. The part of the Swedish 
model which describes progressive lesions is very similar to our model. 
Differences occur in the proportion and the duration of regressive lesions, but 
they do not influence the estimated reduction in incidence of invasive cancer. 
The assumptions of our model differ markedly from the assumptions made in 
the cervical cancer model of Eddy that has been claimed to be compatible with 
the IARC results (Eddy, 1987). This model has not been fitted to actual screening 
data, but was composed on basis of literature data and has been used for making 
recommendations about screening policies (Eddy, 1981; Eddy, 1990). 
Apparently, no provision is made for pre-clinical invasive cancers that are likely 
to be detected at screening tests. The average duration of the pre-clinical stage 
is 8 years, which is only half of the estimated value derived directly from 
detailed data analyses by our model and the model of Gustafsson. 
In the introduction we described two approaches to making inferences about 
the natural history of pre-clinical cervical cancer and the difference in their 
outcomes: a direct exposure-incidence approach, and a model based approach. 
Our analysis shows that the seemingly conflicting results of the two approaches 
can be explained by the observation that women who have had negative smears 
are likely to have subsequent smears at which invasive cancers can be detected 
early. Indeed, for women without further smears, the model predicts a relative 
risk of at most 40 % after 10 years following two negative smears, whereas 
inclusion of screen-detected invasive cases will after 10 years result in a risk 
which is approximately equal to an unscreened population (see Figure Vb(l». 
The "exposure-incidence" approach has the convenience of giving a direct 
estimation of risk of invasive cancer following negative smears from 
epidemiologic data. Uncertainties about some of the parameters of the model-
based approach, notably the proportion of regressive cases among screen-detected 
pre-invasive lesions, are avoided in this approach. The problem, however, is that 
the risk estimates may be severely biased, depending on the actual frequency of 
subsequent Pap-smears. 
Morrison (1982) already discussed this potential bias in the outcomes of case-
control studies of cancer screening, emphasizing that case definition should be 
based on disease manifestations that develop only after the lead-time interval. 
Including all screen-detected invasive cases will give rise to too pessimistic 
estimates of the efficacy of screening. For example, the IARC group stated that 
"the interval between screening should be three year or less" (IARC, 1986). This 
recommendation is based on the consideration that an acceptable interval should 
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at least give a 90 percent reduction in the cumulative incidence of invasive 
cervical cancer in the age group 35-64_ However, a considerable proportion of 
these invasive cancers is detected by screening, and have a much better prognosis 
than clinically diagnosed cancers_ The outcomes of the "exposure-incidence" 
approach can therefore not be applied to situations with a different intensity of 
screening, or for making recommendations about screening intervals_ 
Exclusion of the screen-detected cases from the analysis is not a very useful 
alternative, not only because the mode of detection is not known in part of the 
programmes that participated in the IARC study, but especially because the 
results would then only apply to situations in which screening is stopped. 
The model based approach for epidemiologic evaluation of cervical cancer 
screening has two advantages. First, it takes more epidemiologic data into 
account in analyzing results of screening programs. The resulting model 
quantification will thus be compatible with detection rates of first and subsequent 
screening tests, incidence of interval cancers, incidence in unscreened women 
(Chapter IV). Indeed, it is an explanatory model for the findings of a screening 
program, that can be used to show the additional reduction in risk of death from 
cervical cancer which is incurred by the favourable prognosis of screen-detected 
invasive cancers. The second, related, advantage is that the model can be used 
for making predictions of the effects of screening policies, in which both the 
prevention of invasive cancer and the early detection of (micro-)invasive cancer 
contribute to the favourable effects by choosing mortality as end-point. On basis 
of data regarding the survival of screen-detected cancers, our model predicts that 
a 90 percent reduction in mortality may be achieved with screening intervals of 
5 years, see Chapter VI. A detailed cost-effectiveness analysis based on an 
extended version of the model presented in this paper, indicates that reducing the 
screening interval to three years or less gives an unfavourable shift in the balance 
between beneficial effects and adverse effects when compared with longer 
screening intervals (Van Ballegooijen et al., 1992), and are also far less efficient 
in terms of cost-effectiveness (Koopmanschap et al., 1990). 
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Appendix V.A 
CALCULATION OF THE REDUCTION IN INCIDENCE 
FOLLOWING NEGATIVE SMEARS. 
Chapter V 
Mathematical descriptions of screening for cancer have been presented before, both for 
one stage and two-stage models (Louis el al., 1978; Day & Walter, 1984; Brookmeyer 
& Day. 1987; Alexander, 1989). The following description applies to relative risks that 
are calculated on the basis of data from a complete cohort, i.e. from incidences based 
on number of cases and number of woman-years. 
Consider women who have had one negative smear. The total reported incidence of 
invasive cervical cancer J(a,y) for women of age a, at y years following the negative 
smear, is the sum of the clinical incidence C(a,y) and the detection rate of invasive 
cancers at a second smear D(a,y) multiplied by the screening intensity k (smears per 
woman per year) in the period since the negative smear: 
J(a,Y) ~ C(a,y) + k D(a,y) (1) 
For women of age a who did not yet have a second smear, the clinical incidence 
C(a,y) at y years after one negative smear is: 
(1-), (I 
C(a,y) ~ (1 -s(Y») ! r RpCt) g(a-/)dr + Lr Rp(r) g(a-r)dr (2) 
where g(t) is the probability density function of the total preclinical duration, and 
R/z) the onset rate of progressive pre-invasive lesions at age z, and s(y) the test 
sensitivity of the smear at y years before clinical diagnosis. If yS:4 years, then 
the cancer was already invasive and s(y) = sT' ify>4 years the cancer was pre-
invasive and s(y) = sp. Parameters sp = 0.8 and sT = 0.9 denote the sensitivity 
of the Pap smear in detecting pre-invasive and invasive lesions, respectively. A 
relative risk r is introduced to reflect the lower incidence of cervical cancer in 
participants becallse of selective participation in screening. The first part of the 
equation represents the contribution of false-negatives, the second part represents 
lesions that developed after the negative smear. 
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At y years after the negative smear, the detection rate of invasive cancers D(a,y) 
at a second smear made for women of age a is: 
a-y 
D(a,y) = si1-S(Y»)! r Rp(l) (F(a-I) -G(a-I»)dt + 
(3) 
a 
+ sl f r Rp(t) (F(a-I) -G(a-I»)dl 
a-y 
where F(I) and G(t) are the probability distribution functions of the durations of 
the pre-invasive and the total pre-clinical stage, respectively. 
In a situation of "no further screening", the relative risk is the ratio of the clinical 
incidence C(a,y) following a negative smear to the clinical incidence B(a) in 
un screened women of the same age a: 
a 
B(a) = ! R/I) g(a-I)(/I (4) 
If screen-detected cases are included, the relative risk is the ratio of l(a,Y) to 
B(a). Similar equations are used for the case of two preceding negative smears. 
These equations are used for the general case of women who had at least two 
negative smears; the effect of the additional negative smears is assumed to be 
negligible. 

VI. PREDICTING MORTALITY FROM CERVICAL CANCER 
AFfER NEGATIVE SMEAR TEST RESULTS 
Introduction 
The International Agency for Research on Cancer (IARC) working group on 
evaluation of cervical cancer screening programmes has analysed data from 
large screening programmes in Europe and North America (Hakama el al., 
1986). Protection against cervical cancer after negative smear test results was 
measured by the risk of invasive cancer. The relative protection - that is, the 
ratio of the risks in unscreened and screened women - decreases with 
increasing time since the last smear. Analysis of this decreasing trend may be 
useful in deciding about the interval between smears. The IARC group 
concluded that the intervals between screening should be three years or less 
(IARC, 1986). 
The primary aim of cervical cancer screening is to prevent death from 
cervical cancer. Using death rather than invasive cancer as the criterion will 
result in different estimates for the protection after negative smear test results. 
Women who have had negative smear test results are likely to have further 
smear tests, and invasive cancers may not only surface clinically but also be 
detected by these subsequent smears. On average, these invasive cancers 
detected by screening have a much better prognosis than those that are 
clinically diagnosed. When comparing women who had one or more negative 
smear test results with unscreened women, the relative protection against 
mortality from cervical cancer will therefore be higher than the relative 
protection against invasive cancer. We investigated the size of the difference 
between these two relative protection rates, and the implications for 
recommendations about the screening interval. 
Methods 
The aim of screening for cervical cancer is to reduce the risk of diagnosing an 
invasive cancer that would eventually result in death from the disease. The 
next screening should therefore be scheduled when the risk of lethal invasive 
cancer is considered to have become too high. We therefore used protection 
against lethal invasive cancer as an indicator for protection against mortality. 
Information on the survival of patients with invasive cancers was not 
available in the IARC study. We therefore used a model for progression of the 
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disease which links the risks of lethal invasive cancer to the data on risk of 
invasive cancer obtained in the TARC study. We constructed a model which 
has four stages: no cervical cancer, preinvasive cervical cancer, pre-clinical 
invasive cervical cancer, and clinical invasive cervical cancer. We used data 
from the cohort study of cervical cancer screening in British Columbia (Boyes 
et af., 1982) to estimate the parameters of this model (Chapter TV). The 
preinvasive stages dysplasia and carcinoma in situ together had an estimated 
mean duration of 12.3 (95% confidence interval 9.7 to 14.7) years with a 
standard deviation of 5.8 (4.6 to ll.l) years. The estimated mean duration of 
preclinical invasive stages was five years. The sensitivity of the smear test was 
estimated at 80%. These values fitted the data from British Columbia well, 
and agreed with similar analyses of more recent screening data from the 
Netherlands (Habbema et af., 1988) and Sweden (Gustafsson and Adami, 
1989). 
To be consistent with the TARC study, we included screen detected invasive 
cancers in the calculations for the model. On the basis of the TARC report we 
estimated that each year 33 % of women who have already had two or more 
(negative) smear test results will have another smear test (Hakama et al., 
1986). We used this estimate in the model, to predict the relative risk of 
invasive cancer; these predictions agreed with the TARC group finding of 50% 
reduction in risk after 6-10 years after (at least) two negative smear test 
results. The fit of the TARC results could be improved further by increasing 
the standard deviation of the duration of preinvasive lesions to 7.3 years, 
which is still well within the confidence limits of the British Columbia 
estimates, see Chapter V. The resulting best fitting model was used to 
translate the protection against invasive cancer PI into protection against lethal 
invasive cancer PM. The model gives the proportion (s) of the invasive cancers 
that are screen detected. On the basis of estimates of the average lethalities qs 
and qc of screen detected and clinically diagnosed invasive cervical cancers, 
we used the following formula to calculate the protection against lethal 
invasive cancer: 
We assumed a relative five year survival rate of 90% for screen detected 
invasive cancers, which we derived from combining stage distribution of 
screen detected invasive cancers and stage specific five year survival data (Van 
der Graaf, 1987). Assuming a 60% five year survival for clinically diagnosed 
cervical cancers gives a 1:4 lethality ratio (q/qc=0.25). Some studies have 
reported survival statistics for clinically diagnosed cancers in the range 
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65%-70% (Van der Graaf, 1987; Cancer Registry of Norway, 1980; 
Hakulinen et al., 1983), but these figures are higher because stage IA and IB 
cancers detected by screening were included. We assumed that the 1:4 
lethality ratio after 5 years of follow up persisted in the long term; we also 
considered a lethality ratio of 1:3. 
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Figure Via Comparison of relative protection against all invasive cervical 
cancers as estimated by the IARC group (lARC, 1986) with 
model predictions of protection against lethal invasive and against 
all invasive cervical cancer, after two negative smear test results 
(three years apart) in 45 year old women. It is assumed that each 
subsequent year 33 % of women who have not yet had a third 
smear will have one. The lethality ratio of screen detected to 
clinically diagnosed cancers is assumed to be 1 :4. 
Results 
Figure Via shows the relative protection against invasive cancer and against 
lethal invasive cancer predicted by our model for a 45 year old woman who 
has had two negative smear test results at an interval of three years assuming a 
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1:4 lethality ratio between screen detected and clinically diagnosed cancers. 
The points give the relative protection against invasive cervical cancer for 
35-64 year old women estimated by the IARC study group (IARC, 1986). The 
dashed curve shows the model fit of the observed results. The model predicted 
protection against mortality from cervical cancer after negative smear results 
was about 50% higher than the protection against invasive cancer. If a more 
conservative lethality ratio of 1:3 was assumed, the relative protection against 
mortality from cervical cancer was still about 30-40% higher than the IARC 
estimates would suggest. 
In the model, the durations of preclinical invasive lesions have an inherent 
one to one relation with the durations of preinvasive lesions. This assumption 
implies that fast growing preinvasive lesions will also develop rapidly when 
they have become invasive. Screening tends to pick up slow growing lesions 
and to miss fast growing lesions (length biased sampling). Shortly after two 
negative smear results some women will already have fast growing lesions that 
may later be diagnosed clinically, resulting in a small proportion of screen 
detected cancers and a low prediction of the relative protection against lethal 
invasive cancers (see formula). This effect is strongest in younger age groups. 
In the model, most cervical cancers occurring at younger ages are assumed to 
be fast growing lesions that have a lower probability of being detected by 
regular screening. Thus, the relative protection against lethal invasive cancer 
in women under age 30 is predicted to be much lower than for women 
between ages 35 and 65, for whom predictions are similar to those presented 
in the figure. 
We also considered a model with a fixed four year duration of the 
preclinical invasive stage. The fit for the two data sets (British Columbia and 
IARC) was as good as with the former model. The length biased sampling 
phenomenon did not occur in this model, and therefore it predicted that a 
higher proportion of invasive cancers will be detected by screening. As a 
result the relative protection against lethal invasive cancer in the first years 
since the last negative smear test result was almost 100% higher than the 
protection against all invasive cancers. 
In reality, the development of preclinical invasive cancer will be in between 
the extreme situations assumed in the two models and the relative protection 
against lethal invasive cancer will be between 50% and 100% higher than for 
all invasive cancers. 
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Screening frequencies 
The IARC working group calculated the reduction in cumulative incidence of 
invasive cervical cancer for different screening frequencies in women aged 
35-64. It assumed that all women participate in screening. For example, the 
figure shows that the incidence of all invasive cancers in the first three years 
after a second negative smear test result is between 10 and II times lower on 
average than in a situation without screening resulting in an estimated 90.4% 
reduction in cumulative incidence between the ages 35 and 64 with a three 
year screening interval. We used the model to derive corresponding figures for 
the reduction in cumulative incidence of lethal invasive cancer (Table VI.!). 
The IARC statement that the screening interval should be three years or less 
corresponds with a reduction of at least 90 %. If this same percentage is 
applied to reduction in mortality from cervical cancer our model calculations 
show that an interval of five years is still acceptable. More frequent screening 
will give little additional benefit. For example, changing from a five year to a 
three year interval implies that all efforts (taking smears, cytological analysis, 
follow up, etc) increase by two thirds, whereas the benefits increase by less 
than 5 %, resulting in a 14 times worse marginal cost effectiveness ratio. 
Table Vt.l. Percentage reduction in the cumulative rate of cervical 
cancer incidence and mortality in women aged 35-64 for 
different frequencies of screening *. 
% reduction in: 
Interval between cumulative cumulative cumulative 
screenings (years) incidence incidence mortality (A) (8) (C) 
93.5 95.4 96.9 
2 92.5 93.3 95.3 
3 90.4 91.0 93.7 
4 88.4 •• 88.3 91.8 
5 83.6 85.2 89.7 
10 64.1 68.1 80.0 
• (A): calculated by the IARC working group. see Table V in the IARC 
paper (lARC, 1986); (8) and (C) are model based predictions. 
"Calculated from Table III in the IARC paper (lARC. 1986) 
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In an earlier analysis we used a more detailed model based on Dutch 
epidemiological, medical, and economic data to predict the effects and costs of 
cervical cancer screening policies (Habbema et al., 1988). For the Netherlands 
we calculated a cost effectiveness ratio of about £8000 per life year gained for 
a screening policy with five yearly invitations between the ages of 37 and 62, 
assuming an average attendance rate of 65% (Habbema et al., 1988, 
Koopmanschap et al., 1990a). In this model the additional effects of a policy 
with more frequent invitations (three yearly between ages 36 and 63) are 
higher than in the case with 100% attendance because of irregular participation 
patterns. The marginal costs per life year gained with the three yearly policy 
in comparison with the five yearly policy were about £25 000. Whereas the 
cost per life year gained of £8000 for a five yearly interval may be considered 
acceptable, the marginal costs per life year gained by screening every three 
years are high in comparison with the costs of many other health care 
facilities. In addition, we found that increasing the screening frequency will 
worsen the balance between favourable and adverse health effects (unnecessary 
treatment of women with false positive results and regressive lesions) of 
screening (van Ballegooijen et al., 1990). 
Our analysis is based on published data from studies that are now more than 
10 years old. Reports of an increasing incidence and mortality, especially in 
younger women, do not influence our results since our estimates are 
predominantly determined by the duration of preinvasive stages and the 
sensitivity of the screening test. These factors could also change over time 
(Elliot et al., 1989), stressing the need for continuous re-evaluation of the 
protection afforded by negative smear test results. 
Conclusion 
The most serious negative effects of cervical cancer are early death and the 
serious morbidity associated with advanced disease. Therefore, reduction of 
the risk of death from cervical cancer should be the primary criterion in 
evaluating screening policies. Reduction in incidence of invasive cancer carries 
an additional benefit since some major therapeutic procedures and their 
associated morbidity will be avoided, but this should be considered in 
conjunction with the negative health effects of diagnostic and therapeutic 
procedures that are induced by screening (van Ballegooijen et al., 1990). 
The use of reduction in incidence as a proxy for reduction in mortality is 
appealing. However, we have shown that protection against invasive cancer 
underestimates protection against mortality. The two criteria will lead to 
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different recommendations: screening intervals based on mortality are about 
50 % longer than those based on incidence. This difference is caused by the 
good survival of women with screen detected invasive cancers. On the basis of 
our calculations of the reduction in cervical cancer mortality we conclude that 
screening intervals of five years are appropriate. Regular screening at this 
interval in the age group 35-64 is expected to give about 90% reduction in the 
risk of dying from cervical cancer. More intensive screening will give little 
additional benefit, and should be discouraged in view of the adverse effects 
and the high costs. 

VII. DISCUSSION AND CONCLUSION 
The main goal of the project "decision making about screening for cancer" has 
always been to support decision making by predicting the public health effects 
and other consequences of screening. In making these predictions, it is 
important that all factors that may influence the effects of screening, and 
interrelations between these factors, can taken into consideration (Rabbema et 
01., 1978). Some of these factors can be controlled or influenced by the 
screening policy. For example, persons may be invited at certain ages, and the 
quality of the screening test may be influenced favourably by adequate training 
of personnel and by a quality control system. The impact of policy decisions 
on the effects of screening is far from straightforward and depends on charac-
teristics of the diseases and of the screening tests. An important secondary 
goal of the project is therefore to acquire a better understanding of these 
underlying processes on basis of available empirical data. Because of the 
complicated dynamic relations involved, modelling is indispensable in decision 
analysis of screening. 
In this thesis, which focuses on the secondary goal, I have described the 
first steps in model-based evaluation of screening for cancer. These steps 
include: 
• a survey of existing knowledge and data and of the main issues in cancer 
screening (Chapter I, see also Rabbema et.al., 1982ab), 
• detailed analysis of data from screening projects (see Rabbema et 01., 1983, 
1986) 
• development of quantitative modelling tools (Van Oortmarssen et 01., 1981, 
Rabbema et 01., 1984,1987), 
• model-based analysis of data related to breast cancer screening (Chapters II 
and III) and cervical cancer screening (Chapters IV, V and VI, see also 
Rabbema et 01., 1985). 
The practical relevance of this work with respect to decision making about 
screening is expressed in the subsequent cost-effectiveness studies of breast 
cancer screening and cervical cancer screening, and has been reported in two 
PhD theses (De Koning et 01., 1993, Koopmanschap et 01., 1994) and in a 
number of publications and reports. 
I will discuss two topics in this chapter: the methodology of model 
development and model validation and the applications to breast and cervical 
cancer screening. Attention will be given to the remaining issues that may be 
addressed in future model-based analysis of cancer screening. 
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Model development 
The first step in applied modelling of disease control programmes is to 
identify the key factors that determine the results of such programmes, and to 
establish the main relations between these factors and the results (Habbema 
and van Oortmarssen, 1994). This step involves review of the literature, 
inspection of data from screening programmes, and consultation of experts, 
and has resulted in definition of a basic structure of an epidemiometric model 
for cancer screening. This model consists of a number of modules describing 
the preclinical, screen-detectable stage of the disease (with parameters 
duration, regression and progression), the treatment (parameters survival and 
improvement in prognosis as a result of early detection), the screening test 
(parameters sensitivity and specificity), and the characteristics of a screening 
policy (age groups to be screened, screening intervals, participation rates). 
Refinements and extensions to this basic model have been identified, e.g. 
multiple disease stages, more than one screening test, association between risk 
and participation in screening. 
A general framework has been described (Habbema et al., 1984) which has 
proven to be applicable to breast cancer screening and to cervical cancer 
screening. The core of the framework is a single one-dimensional disease 
history consisting of a number of successive disease states. A model for a 
specific disease is specified by defining its states and the transitions between 
states. State definitions are generally chosen on basis of classifications used in 
available data: the model is data-driven. Transitions are defined by declaring 
dwelling time distributions in states that are independent of the preceding 
states and transitions (Semi-Markov property). In reality, staging of the cancer 
is based on more than one dimension, for example tumour size, node 
involvement, distant metastases, and diagnosis (yes or no). In the models 
described in this thesis, and especially in the breast cancer screening models 
described in Chapters II and III, these dimensions could be combined readily 
in defining the disease states. However, in further extensions to these models, 
and in modelling screening for other cancers, for example cancer of the 
prostate, colorectal cancer, and lung cancer, the one-dimensional Semi-
Markov approach may well lead to restrictions because not all dependencies 
between the variables involved can be adequately translated into the Semi-
Markov transitions and durations. For example: lymph node status depends on 
tumour size, and clinical detection depends on tumour size and lymph node 
status. 
One way out of this problem would be to refrain from the disease stages, 
and build a model which only considers events, such as start of the preclinical 
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screen-detectable stage, clinical diagnosis, detection at a screening test, death 
from the disease. The model is specified by describing the functional relations 
between these events. This type of models has been proposed by David Eddy 
(1980,1981,1988,1989,1990). The disadvantage of this event-driven approach 
is that important information in the data is neglected, for example about the 
differences in stage distribution between screen-detected cases, interval 
cancers, and clinically diagnosed cancers. 
A better alternative would be a disease history which consists of interacting 
parallel processes such as tumour growth, node involvement, presence of 
clinical symptoms. This approach, which was used in the breast cancer model 
of Shwartz (1978ab, 1980, 1981, 1992), may be extended further to model 
interaction between different disease processes. This would be useful in 
modelling the interaction between HPV infection and progressive preinvasive 
cervical cancer, and in modelling the risks of developing malignant colorectal 
cancer depending on the presence of benign polyps developing in different 
parts of the colon and that may be detected by different screening tests. 
Collaboration with epidemiologists and other experts of screening programs 
and access to data of such programs has proven to be essential in building 
well-founded and useful models. Members of our research group participated 
in the Evaluation committee of the Dutch pilot projects of cervical cancer 
screening (Evaluation Committee, 1989), in the IARC working group on 
evaluation of cervical cancer screening programmes (Hakama el al., 1986), in 
the Dutch evaluation study of the cost and effects of breast cancer screening 
(Van der Maas, el al., 1989). At present, we are participating in the 
evaluation teams of the national screening programmes for breast cancer and 
cervical cancer (LETB, 1992, 1993, 1994). In developing the models, we 
analyzed data-sets of major screening projects: the statistical data set of the 
HIP study (Habbema el al., 1983, 1986), the tape of the British Columbia 
Cohort Study (Van Oortmarssen and Habbema, 1986), and several datasets of 
the DOM and Nijmegen projects for breast cancer screening and of Dutch 
projects for cervical cancer screening. 
In our implementation of the cancer screening models into computer 
programs, two approaches emerged: a general and comprehensive micro-
simulation MISCAN approach, and a simplified numerical-statistical approach 
which has to be developed from scratch for each specific application. 
Initially, much emphasis was put on the requirement of taking all (possibly) 
relevant factors into consideration in evaluation of screening policies. To meet 
this requirement, the MISCAN microsimuialioll computer programme has been 
developed for simulating models that comply to the general framework. The 
choice of microsimulation was mainly based on previous experience with the 
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macrosimulatioll model SCRMOD developed by E.G. Knox (1973,1975). 
Being the best comprehensive cancer screening model at that time, it 
nevertheless turned out that intrinsic properties of macrosimulation seriously 
limit the number of interrelations that can be included in the models. Both 
memory usage and simulation time will increase tremendously when new 
independent variables are added to the model. Microsimulation offers greater 
freedom for including interactions, and implementation of model extensions to 
the computer programme is quite easy. Memory usage and simulation time 
will only increase more or less linear when adding variables to the model. 
Complex invitation schedules and screening patterns can be incorporated easily 
in MISCAN. For example, the history of opportunistic and organised cervical 
cancer screening in The Netherlands, including its long-term effects, has been 
taken into account in predicting the impact of different future screening 
policies. And in evaluating breast cancel' screening in The Netherlands, a 
practical complication such as the gradual build-up of the nationwide program 
has been explicitly included in the model. This flexibility of microsimulation is 
especially useful in making detailed predictions of the effects and costs of 
different screening policies in the setting of a real population. All cost-
effectiveness calculations have been solely based on MIS CAN calculations. 
In model-based analysis of screening data, use of (MISCAN) micro-
simulation enabled detailed simulation of experimental screening projects, for 
example the randomized breast cancer screening trials in New York (HIP 
study), and the pilot projects in Utrecht and Nijmegen. An important 
advantage of microsimulation in analyzing screening data is that the 
characteristics of the project design and the data can easily be included 
explicitly in the model. Examples are the age-distribution at entry in a study, 
different durations of intervals between screenings, definition of cases in 
randomized trials and in case-control studies, and the precise calculation of 
person(-year)s at risk. Moreover, output of the model can be produced in the 
same format that is used in the projects, enabling direct comparisons between 
model and observed data. 
However, use of microsimulation in data analysis has a number of 
drawbacks that are related to the variability of the simulation output (see also 
Chapter f). In estimating model parameters from the observed data of a 
screening project, the standard maximum likelihood approach cannot be 
applied. Moreover, the estimation procedures will take much computer time 
because of the relatively long duration of a single simulation run, which needs 
to be large to reduce the variability of the output), and also because special 
optimization procedures are required that take random variation in the model 
Discussion and Conc/usion 131 
output into account, and that are be less efficient than standard optimization 
procedures for deterministic models. 
A statistical-numerical model based on maximum-likelihood methodology 
will often be worth consideration. The choice between microsimulation 
(MISCAN) and the statistical-numerical approaches depends on the objectives 
of the analysis, the characteristics of the data under study, and the amount of 
time available for the analysis. Screening models used in statistical-numerical 
data analysis are generally simpler than MISCAN models, either by 
concentrating on particular aspects of the screening process or by giving a 
simplified description of the overall model. Modification or extension of the 
model structure will in general require a substantial effort in deriving 
mathematical equations and implementation in a computer program - if 
possible at all. An attractive option is to combine the two approaches, starting 
with a formal statistical analysis of part of the data with a limited model, and 
extending the analysis to other data by implementing the full model in 
MISCAN. 
Milestones in the statistical-numerical modelling of cancer screening are the 
"one stage - one test - one examination" of Zelen and Feinleib (1969), and the 
"one stage - one test - multiple examinations" model for progressive screen-
detectable cancer developed by Walter & Day (1983). The latter model is very 
useful for a quick combined analysis of detection rates and interval cancers for 
cohorts with specified screening patterns, yielding estimates of the mean 
duration of the screen-detectable stage and the sensitivity of the screening test, 
and has been used as an auxiliary tool in the MISCAN analysis of breast 
cancer screening data (Chapters II and III). The model of Walter and Day has 
been extended to two screening tests and two progressive stages (Alexander, 
1989), which already requires substantial mathematical and programming 
efforts. 
For a cervical cancer screening model aimed at analyzing detection rates 
and interval cancers, further refinements are necessary. First, the proportion 
of (pre-invasive) screen-detectable lesions that will regress spontaneously 
cannot be neglected when detection rates are included in the analysis. Second, 
age has to be included explicitly in the model because of the long duration of 
screen-detectable stages and because of considerable age-dependencies in the 
model. The resulting models lead to a rather complicated set of equations (see 
Chapter IV), and the computer implementation is specific for the data 
available. The data from British Columbia used in Chapter IV are relatively 
straightforward, describing two birth cohorts that are assumed to have the 
same basic risk of developing cervical cancer. A similar analysis of Dutch 
data is complicated by a number of factors: missing data, mix of opportunistic 
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and organized screening, apparent risk differences between cohorts, etc. In 
view of these complications, a MISCAN approach was chosen for analyzing 
the Dutch data. One of the starting points was the disease model which 
resulted from the British Columbia analysis reported in Chapter IV. Other 
starting points are an Age-Period-Cohort analysis of (pre-screening) cervical 
cancer mortality data, and estimation of age-dependent survival probabilities 
on basis of Dutch incidence/mortality ratios and survival data from literature. 
This example shows that in modelling screening for cancer, several tools 
can be combined fruitfully. Microsimulation is then used in the stages in 
which integrated analyses are being carried out and in making predictions for 
the effects and costs of screening strategies. But when a microsimulation 
model like MISCAN is already available, it can also be used in data analysis, 
especially in exploratory analyses of the data, or in exploring the robustness of 
the findings of statistical-numerical models. 
Validity of the model 
A model is only a highly simplified representation of the complex processes 
involved in mass screening for cancer. The validity of a model is limited by 
statistical uncertainty, reliability of the data, correctness of the computer 
programme, misspecification of the model, and uncertainties related to transfer 
of the model in space and time. 
I. The statistical uncertainty caused by the limited number of observations 
that were used in estimating and testing the model will influence the 
goodness of fit score, and it will also be reflected in the size of the 
confidence region for the values of the model parameters. In the analyses 
presented in Chapters II, III and IV, we used all data available in order 
to narrow down the size of the confidence regions. However, this implies 
that no independent data were available for formal validation of the 
models. 
In using microsimulation, the additional uncertainty caused by the 
variability of the simulation results had to be taken into account in 
calculation goodness of fit or confidence regions. 
2. Reliability of the data. Available data that are used in quantification of 
the model may be affected by various sources of bias. In the context of 
screening for disease, special types of bias occur that have been 
discussed in Chapter I: lead-time bias, length biased sampling, 
overdiagnosis bias, and self selection bias. The mechanisms leading to 
these biases are often automatically included in the model (lead time and 
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length biased sampling) or can easily be added to the model. Models are 
very useful in studying their implications, for example lead time and 
length biased sampling have been investigated with the "one stage - one 
test" model of Zelen and Feinleib (1969). 
More cumbersome are problems caused by the quality of the data, for 
example caused by incomplete registration, errors in data processing, or 
changes in classification procedures or in diagnostic or treatment 
protocols. Sometimes, the latter biases lead to quite drastic 
inconsistencies that can be detected. For example, a change in the 
referral policy with respect to cytologic classification "moderate 
dysplasia" in the Dutch pilot projects of cervical cancer screening caused 
an sudden increase in detection rates of histologically confirmed 
abnormalities. And the mortality trends of cervical cancer as reported by 
the Dutch Cental Bureau of Statistics (CBS) show a dip between 1964 
and 1971, that might be interpreted as an early start of the decreasing 
trend in later years. Further inspection revealed that a similar decrease 
was found for "uterus corpus" and a considerable increase in mortality 
classified as "uterus, unspecified", reflecting a temporary change in 
classification of these cancer sites. Close contact or collaboration with 
investigators from screening projects is important for correct 
interpretations in model-based analysis of the data. 
3. Reliability of numerical implementation of the model. Of course, the 
computer programme should be properly validated. Validation of a 
microsimulation programme can profit from the individual histories that 
can be checked. But the variability in the simulation outcomes may 
sometimes lead to problems. More than once we have incorrectly 
interpreted unexpected outcomes resulting from random variation as 
caused by errors in the input specification or in the programme code. 
The use of different approaches (including manual calculations, micro-
simulation, and numerical integration methods) is the best (but time-
consuming) way for checking the outcomes of a model. 
4. Possible misspecification of the model. 
A model which gives a good fit of the data is not necessarily a correct 
model. For example, certain crucial aspects might be neglected in the 
model, or incorrect assumptions might be made. These misspecifications 
may result in erroneous parameter estimates and confidence regions, and 
incorrect results in extrapolation of the model. For example, predictions 
about different screening policies based on incorrect estimates of the 
underlying disease and screening processes will most likely also lead to 
incorrect recommendations. 
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Misspecification of a model may be a deliberate choice, for example 
motivated by lack of time or because lack of sufficient data for testing 
further refinement of the model. But misspecification can also occur by 
accident, by overlooking alternative explanations of the data. 
The HIP results had been analyzed with two (highly) simplified models. 
Walter and Day (1983) only considered the duration of preclinical 
screen-detectable stage and the sensitivity of the screening examination 
without making a distinction between the outcomes of the two screening 
tests (mammography and physical examination). Goldberg and Wittes 
(1978) only considered the test sensitivities on basis of the cross-
tabulation of outcomes of the two tests, neglecting the information 
provided by the interval cancer rate and the trend in detection rates at 
subsequent tests. The two analyses gave quite different point estimates 
and confidence intervals of the sensitivity of the screening examination. 
Our analysis of the HIP breast cancer screening data (Chapter II) showed 
that adding more details to a model will narrow down the confidence 
interval for estimates of the mean duration of preclinical stages and 
sensitivity of the two screening tests (mammography and physical 
examination). The estimates for mean duration are longer, and for 
sensitivity lower than in the Walter & Day model. The confidence region 
is roughly equal to the intersection of the ones found by Walter & Day 
and by Goldberg & Wittes. 
Age-specific comparisons between the model and HIP results suggested 
age-dependency of sensitivity and/or of duration of preclinical stages, but 
a model with age-dependent duration did not give a significant 
improvement of the fit, and we decided to assume a constant duration. 
This is an example of misspecification caused by lack of data, since all 
analyses of more recent datasets indicated a significant increase of the 
mean duration with age, see for example Chapter III. 
The possibility of serious misspecification can never be ruled out, but it 
can be minimized by performing extensive robustness analyses regarding 
the parameter estimation (see the discussioll section of the cervical cancer 
model presented in Chapter IV). A potential remaining source of 
misspecification in the cervical cancer model is discussed in the 
Applicatioll section of the present chapter. 
5. Uncertainty because of transfer in space and/or time. 
This problem relates to analysis of different screening datasets with a 
single model or with models which have a number of assumptions in 
common. The additional problem of transferring model assumptions in 
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time is especiaJly relevant when models that have been fitted to local data 
are being used for making predictions. 
In the cancer screening model, a distinction is made between the 
"general" biological factors and "local" factors that are influenced by the 
specific conditions in a region or country. However, the extent of 
variability between areas is not known precisely, and factors that are 
assumed to be biological or otherwise invariable may in reality be differ 
between areas or vary with time. For example, in the analysis of risk 
reduction after negative Pap smears (Chapter V) we assume that the 
relative risk of participants in cervical cancer screening, estimated to be 
0.74 in British Columbia, applies to the other screening projects as well. 
But it is likely that the distribution of risk of cervical cancer, and its 
association with participation, differs considerably between countries. 
The MISCAN models have been repeatedly transferred between 
screening projects. In such a transfer, model specifications concerning 
local characteristics of the projects (for example: the level of incidence 
and mortality, the screening policy, the participation rate) are adapted, 
whilst the parameters of the underlying processes are preserved. For 
example, the breast cancer screening model was first constructed on basis 
of the HIP data, and then transferred and modernized on basis of data 
from the Utrecht and Nijmegen projects. The resulting model was 
transferred to the Swedish trials in Kopparberg/Osterg5tland and Malmo 
for estimation of the effect of early detection and treatment on mortality, 
and finaJly to the national situation in the Netherlands for making cost-
effectiveness predictions of screening policies. This breast cancer model 
has been transferred and adapted to the local characteristics of other 
countries (e.g., Australia, Italy, Germany) for evaluating cost-
effectiveness of breast cancer screening (Carter el al., 1993, Van Ineveld 
et a/., 1993, Paci el al.(in press), Beemsterboer et al., 1994). 
Similarly, the cervical cancer model based on data from British Columbia 
(Chapter IV) has been transferred to the situation in the Netherlands, and 
was extended and calibrated to the specific Dutch circumstances. This 
model has also been used to make future predictions about cost-
effectiveness of screening in The Netherlands (Van BaJlegooijen el al., 
1993) and in Italy. 
The advantage of modelling is that the potential biases resulting from 
uncertainty about local or future parameter values can be addressed by 
performing sensitivity and uncertainty analyses. An example of the 
potential usefulness of models is in addressing problems of transferring 
observed screening effects is in meta-analyses. Several meta-analyses of 
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RCT's for breast cancer screening have been published, but in all 
analyses the overt differences between the studies are neglected. Models 
can be used to control for the local characteristics, and investigate the 
remaining variability between projects. 
Funher work 
The limitations posed by the assumption of a one-dimensional semi-Markov 
disease process are beginning to cause problems in implementing extensions to 
the breast and cervical cancer models, and will presumably also lead to 
problems in modelling colorectal cancer screening. A more general framework 
in which a number of interdependent processes can be modelled deserves 
serious consideration. This could lead to a new general-purpose version of 
MISCAN. An alternative would be to build special models for each disease on 
basis of a common library of subroutines. 
Complete revision of the MISCAN programme has another potential 
advantage. In the past, we have been asked regularly for a copy of MISCAN. 
For a number of reasons, we have always been reluctant in distributing 
MISCAN. An important reason in this respect is that we developed as a tool 
for our own research activities, which means that it includes a number of 
peculiarities, that some options that had been built in (but not used) have never 
been tested and checked, and that only crude documentation is available. In 
revising MISCAN, it could be tried to develop a core version for distribution. 
However, this would require a considerable additional effort, and it will 
probably be difficult to get necessary funding. 
Two natural extensions of our microsimulation work are currently being 
considered. 
First, microsimulation can be used to generate fictitious data sets on basis 
of assumptions about effects of screening, which can be used to investigate 
study designs and methods for analyzing data. At the moment, a project is 
going on in collaboration with the National Cancer Institute (USA) to study 
the methodology of case-control studies for analyzing the effects of screening 
for breast cancer. 
The second extension of microsimulalion is being developed in collaboration 
with the International Institute for Applied Systems Analysis (IIASA). The 
objective is to develop and implement a method for optimization of screening 
strategies, i.e. finding strategies that give the best balance between costs and 
effects for a given number of screening invitations. Highly simplified models 
can be optimized by writing down the equations and using conventional 
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optimization techniques. Models that take the principal factors into account, 
such as the cervical cancer screening model described in Chapter IV, are 
already too complicated for these techniques. Models of medium complexity 
can optimized with methods that do not require computation of derivatives, 
such as the downhill simplex method, see for example Press et al. (1988). 
This method was used for optimization of cervical cancer screening policies by 
Gustafsson and Adami (1992) and by Verhoeven (1994). A promising 
alternative for stochastic simulation models is the Stochastic Quasi-Gradient 
(SQG) technique, which can be regarded as a special form of microsimulation. 
Starting from a given screening strategy, the strategy is iteratively adjusted 
after each simulated life history. After a large number of histories, the 
resulting strategy is expected to be very close to the real optimum (as in the 
case of normal microsimulation, the outcome is an estimate of the true value). 
The SQG method requires strict regularity conditions, and cancer screening 
models require considerable reformulation, seeOortmarssen & Ermoliev 
(1994). The main advantage of SQG optimization is that it is very fast when 
compared to alternative optimization methods. 
It remains to be seen whether the SQG approach can also be applied to 
comprehensive models for breast cancer and cervical cancer that are used for 
cost-effectiveness calculations, and whether it can be applied in estimating 
values of the model parameters from screening data. An alternative option is 
to use general optimization routines for stochastic models, that operate as a 
shell around MISCAN and can both be used for data analysis and policy 
optimization, without the need for reformulating the disease/screening model. 
A computer package MINIMIZE containing five different optimization 
methods for stochastic models is under development at our department and is 
currently being tested for various model applications. 
Application to screening for cancer 
Breast callcer 
In discussing misspecification errors in the previous section, I explained that 
our model-based analysis of the HIP study (Chapter II) can be regarded as an 
integration of two simplified models. Additional refinements in our HIP model 
include a distinction between two tumour size categories which differ in level 
of sensitivity, and the introduction of age as one of the variables of the model. 
The screening results from the Dutch pilot project in Nijmegen, where all 
women were invited from age 35 onward, allowed for analyzing the age-
dependency of preclinical dwelling times which was suspected but could not 
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be demonstrated from the HIP data. A good fit of the data from Nijmegen was 
obtained by assuming increasing mean duration with age (from 1.6 years at 
age 40 to 4.7 years at age 70). The improvement in mammographic techniques 
is reflected in much higher estimates for the sensitivity in comparison with the 
HIP analysis. Most data from the other Dutch pilot project in Utrecht, which 
had an entirely different invitation scheme, could be fitted with the same 
assumptions about preclinical disease and test sensitivity. 
The breast cancer model has been extended to include clinical aspects 
(diagnostic assessment and treatment), economic aspects (cost of screening, 
diagnosis and treatment), and quality of life information. The resulting cost-
effectivelless models have been used for predicting the effects and costs of 
different screening policies in the Netherlands (Van der Maas et al., 1989, De 
Koning et al., 1991). 
In recent years, the breast cancer model has been refined further in 
comparison with the description given in Chapter III. The subdivision in 
tumour diameter categories of invasive cancers has been changed from < 10, 
10-19, 20+ mm. into :;;5, 6-10, 11-20, >20 mm. in order to be compatible 
with the TNM staging system, and a further subdivision has been made into 
lymph node negative and positive stages, using an ad hoc extension to 
MISCAN. Other refinements include a distinction in the test-sensitivity and 
improvement in prognosis in women under and above age 50, and a revision 
of age-dependent duration of preclinical stages at old ages (65+). For details 
see Chapter 7 in (De Koning et af., 1990b), and Chapter 6 in the third 
evaluation report of the National Evaluation Team (LETB, 1994). The model 
has been transferred to the situation in Germany, and this German version has 
been fitted to available incidence, mortality, and screening data (Beemsterboer 
et af., 1994). Similar studies of the costs and effects of screening have been 
done for Australia and Florence (Italy). Recently we started another evaluation 
of screening in Catalonia (Spain). 
The present model, which is in good agreement with the data from the 
Dutch pilot studies regarding the detection rates and interval cancers, has been 
used to make detailed predictions of detection rates, interval cancer rates, and 
stage distribution in the Dutch national screening programme. Thus far, the 
results of the programme are in agreement with these predictions (LETB, 
1992, 1993, 1994), with one exception: the models predicted that the stage 
distribution at a repeat screening is better than in the first round, but in 
practice the distributions are similar. Two possible explanations are false 
reassurance - negative screening results might lead to disregarding of early 
symptoms - and a more complex natural history than assumed in the model, 
with fast growing cancer spending relatively much time in advanced stages. 
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The model is roughly compatible with the Swedish randomized trials 
regarding the reduction in breast cancer mortality: it predicts the average 
mortality reduction of these trials when allowing for the specific characteristics 
of the trials (age-groups, screening intervals, duration of follow-up). The 
improvement in prognosis following early detection is a crucial parameter of 
the model, and further analysis of the Swedish trials including the detection 
rates, interval cancer rates, and stage distributions, would contribute to the 
credibility of the model. 
The most important question in breast cancer remains at present the 
reduction in mortality resulting from screening women below age 50, which 
we addressed on basis of the HlP data (Habbema et at., 1986). The debate 
concerning interpretation of the HlP results is still continuing, but is of limited 
relevance for present day decision making because of the major improvement 
in mammographic techniques since the late 1960's, and the marked trend 
towards a more favourable stage distribution of clinically diagnosed cancers. 
On basis of the favourable HlP findings for women below age 50, one 
could have expected a clear reduction in the modern trials in view of the 
improvement in technique. However, after 6-12 years of follow-up, the trials 
in Sweden only show a non-significant 10% reduction in mortality in this age-
group (Nystrom et al., 1993), and the Edinburgh trial also shows a small non-
significant reduction at 10 years of follow-up (UK trial, 1988, Roberts et al., 
1990, Fletcher et at., 1993). In the 50+ group, a significant mortality 
reduction occurs in some of the separate Swedish projects and also in the 
pooled Swedish results (Nystrom et at., 1993). A smaller reduction in 
mortality in younger women may be explained by the shorter average duration 
of pre-clinical stages, a lower sensitivity of mammography, and the more 
favourable prognosis of clinically diagnosed cancers (Adami et at., 1986). 
Note however that a considerable proportion of the breast cancers detected at 
repeat screenings in the age group < 50 at elll1Y will have been diagnosed at 
ages over 50 years. Indeed, MISCAN simulations of the pooled Swedish 
projects, in which we assumed no effect for cases diagnosed below age 50 and 
a constant level of mortality reduction after this age, predicted a mortality 
reduction of almost 10% in the age group <50 at entry. 
It is still possible that the history of the HlP study, in which the initially 
small difference in younger women only became significant in the long run, 
will repeat itself. In the mean time, it is hard to justify mass screening for 
women below age 50 in view of the uncertainty about favourable effects, and 
the inevitable adverse effects of which some are relatively important at 
younger ages (false positives, radiation risk). A more appropriate use of 
additional resources would be to intensify screening above age 50. Indeed, one 
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may argue that there should be a moratorium on all mammography for 
symptom-free women below age 50 outside randomized controlled trials 
(Lancet, 1991). New randomized trials in the age group 40-49 have started in 
the UK (Vessey, 1991), and may be followed by other countries. 
Another important question concerns the effectiveness and the balance 
between favourable and adverse effects and costs of screening above age 70 
(Boer et al., submitted for publication). A related issue is the potential 
increase in "opportunistic" screening in these age-groups as a result of 
frequent organized screening in the 50-69 age-group, and the hazards of 
radiation in young women. Improvements in therapeutic possibilities and an 
autonomous trend towards earlier clinical diagnosis might reduce the 
favourable effects of screening in all age groups. 
Cervical cancer 
Until recently, no complete model of cervical cancer screening existed that 
had been carefully tested against available data. See Prorok (1986) for an 
overview of models for cervical cancer screening. Modelling work by Knox 
(1973), Coppleson and Brown (1975), and Parkin (1985,1986) suggested a 
long mean duration and considerable amount of regression of pre-invasive 
stages, but did not include formal parameter estimation or testing of 
hypotheses. Brookmeyer and Day (1987) presented a simplified model and 
estimated parameters related to detection of progressive pre-clinical stages, but 
did not use a substantial part of available data: detection rates of pre-invasive 
cancer. 
The simplified model that I developed can be regarded as a generalisation 
of the latter model. All major factors playing a role in cervical cancer 
screening are covered by the 10 parameters of this model, and it gives a good 
fit of detailed data from British Columbia. The estimated parameter values 
indicate that regression is especially important in lesions which develop in 
young women. This supports the conclusions from a conventional 
epidemiological analysis of the British Columbia screening data by Boyes et 
al., 1982. The surplus value of the model is that it also gives estimates for the 
duration (mean and variability) of pre-invasive lesions and for the sensitivity 
of the Pap smear, which are crucial parameters in comparing screening 
policies. An important presupposition of the model is the use of a single 
distribution for the duration of both progressive and regressive pre-invasive 
cancers, which is also independent of age. 
Similar estimates, based on modelling Swedish cervical cancer screening 
data, were published by Gustafsson and Adami (1989, 1990). 
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The model (including parameter values derived from the British Columbia 
data) has been used to analyze the findings of the IARC collaborative study 
concerning reduction in risk of invasive cancer for women who have had one 
or more negative smears (Chapter V). This analysis shows that the risk 
reduction reported by the IARC group might be too pessimistic, since it 
includes invasive cancers that are detected by screening. The model is used to 
calculate the risk reduction for clinically diagnosed cancers, using assumptions 
about the frequencies of further smears and the duration of the preclinical 
invasive stage of cervical cancer. It appears that when the influence of screen-
detected invasive cancers is taken account, good agreement exist between 
model assumptions about the duration of preinvasive stages and the findings of 
the IARC study. These findings are used to challenge the recommendation 
from the IARC study group that the screening interval should be three years 
or less (Chapter VI). This recommendation was based on the risk reduction 
for invasive cancers, which means that the favourable effect of early detection 
of (micro-) invasive cancers is ignored. In our view, reduction of cervical 
cancer mortality should be the criterion for evaluating the effect of screening. 
Screening intervals of 4 or 5 years will already give a 90 % reduction in 
mortality in the age groups involved. More frequent screening will lead to a 
high marginal cost-effectiveness ratio, and also give lead to an increase of the 
adverse effects of screening: treatment of women with false positive test 
results and regressive lesions. 
A refined version of the simplified model was implemented in MISCAN, 
and has been used in analyzing the British Columbia data (yielding similar 
results) and screening data from the Netherlands. Detailed analysis of the 
Dutch data from the pilot regions (1976-1985) was hampered by many 
problems: clear risk differences exist between birth cohorts, Pap smears are 
being made both within and outside the organized programme, classification of 
smear results and follow-up policies in case of abnormalities were changed in 
the course of the pilot studies, etc. Still, the parameter values derived in the 
British Columbia analyses gave a reasonable overall fit of the Dutch data (see 
Habbema el al. 1988: annex C). 
This MISCAN cervical cancer screening model has been used for 
calculating the costs and (favourable and adverse) effects of screening 
strategies (Van Ballegooijen el al., 1990, Koopmanschap el al., 1990a). The 
conclusion of this evaluation was that screening should be extended to both 
younger and older age groups. It was felt that a further analysis of data for 
age groups (35- and 55 +) was indicated. This analysis resulted in small 
adjustments to the model, but reinforced the conclusions about screening 
strategies (Van Ballegooijen el al., 1993). 
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At present, the most important issue is the Human Papilloma Virus (HPV)-
based screening test. Potentially, introduction of this test could reduce the 
number of screening examinations in the population, and possibly also 
discriminate between progressive and regressive preinvasive lesions. HPV 
stages and the HPV test have been added to the model, which will be 
quantified on basis of available data. Evaluation of screening policies is now 
complicated because of the possibilities to use either of two tests (Pap or 
HPV) or the combination. Another issue that deserves continued attention is 
balance between adverse and favourable effects in detection and treatment of 
early lesions (CIN IIII). 
Modelling of breast and cervical cancer will continue as part of the 
evaluation of nationwide screening programmes in The Netherlands. 
Complementary studies are being carried out of breast cancer screening in 
Catalonia, and of the HPV-based screening for cervical cancer. Other model-
based evaluation studies address prostate cancer screening, and genetic 
screening. Modelling of colorectal cancer screening is under serious 
consideration. 
Conclusion 
Model-based analysis of some of the best available datasets of screening has 
resulted in a better understanding of natural history of breast and cervical 
cancer and of the impact of screening. Our analyses of breast cancer screening 
data have shown that detection rates, interval cancer rates, and stage 
distributions of different projects can be fitted reasonably well with a fairly 
simple model, with age-dependent duration of preclinical screen-detectable 
stages. Analysis of cervical cancer screening data strongly supports the 
existence of regressive lesions, and resulted in estimates for the duration of 
preinvasive lesions. A reasonable explanation of complicated epidemiological 
trends in The Netherlands during the past decades was obtained. 
Model-based analyses of screening projects is one of the building blocks for 
prospective evaluation of costs and effects of screening. The outcomes of 
evaluation of breast cancer screening have had a noticeable influence on the 
decision to start nationwide screening in The Netherlands. And the extensive 
comparison of screening policies for cervical cancer has contributed to the 
recent decision to change from a 3-years to a 5-years screening interval. The 
main objective of the project, supporting decision making about screening for 
cancer, has been realized. 
SAMENV ATTING 
Achtergrond van de stu die 
In Nederland vindt al sinds 1977 op landelijke schaal bevolkingsonderzoek op 
baarmoederhalskanker plaats, en is sinds kort begonnen met een landelijk 
bevolkingsonderzoek op borstkanker. Deze twee kankers vormen voor 
vrouwen tussen 30 en 65 jaar een belangrijke doodsoorzaak gezien het feit dat 
ze rond 20% van de totale sterfte in deze leeftijdsgroep veroorzaken. Het doel 
van deze bevolkingsonderzoeken, waarbij jaarlijks enige honderddllizenden 
vrollwen uitgenodigd worden om zich te laten onderzoeken ("screenell"), is 
om de kankers in een vroeg stadium op te sporen en te behandelen. Hierdoor 
wordt volgens de thans beschikbare kennis de kans om aan een van deze 
ziektes te overlijden aanzienlijk verminderd. 
Aan bevolkingsonderzoek zijn echter naast de verminderde kans om aan 
kanker te overlijden ook andere effecten verbonden, waaronder een aantal 
ongunstige. Voorbeelden van ongllnstige effecten zijn de ongerustheid die het 
bevolkingsonderzoek veroorzaakt bij de uitgenodigde vrouwen (vooral in de 
tijd tussen een uitnodiging en het bekend worden van de uitslag), en het 
ontdekken en in sommige gevallen behandelen van afwijkingen die nooit 
zouden zijn uitgegroeid tot een kanker die aan de hand van klachten wordt 
gediagnostiseerd. Hiertegenover staan echter ook gunstige neveneffecten: 
vee1al zal na vroege opsporing met een (veel) minder ingrijpende behandeling 
kunnen worden volstaan, en in samenhang met de verminderde kans op sterfte 
aan de kanker neemt ook het risico af op recurrentie en uitzaaiing na de 
primaire behandeling. 
Organisatie van bevolkingsonderzoek is een zaak van de overheid, 
kankercentra en ziekenfondsen. Bij de beslissing om bevolkingsonderzoek te 
starten of te continueren spelen naast de verwachting over de effecten ook de 
kosten een belangrijke rol. Ter illustratie: de jaarlijkse kosten van een bevol-
kingsonderzoek op baarmoederhalskanker zijn vele malen hoger dan de totale 
kosten van diagnostiek en behandeling van baarmoederhalskanker patienten. 
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Evaluatie van bevolkingsonderzoek 
Bij besluitvorming over bevolkingsonderzoek zijn onder meer de volgende 
vragen aan de orde: 
1 zijn de gunstige effecten met voldoende zekerheid aangetoond? 
2 wat is de verwachte verhouding tussen gunstige effecten, ongunstige 
effecten en kosten? 
3 welke leeftijdsgroepen dienen te worden uitgenodigd, en hoe vaak? 
De eerste vraag kan aileen worden beantwoord aan de hand van bevindingen 
van experimentele bevolkingsonderzoeken. De ideale opzet is een gerandomi-
seerde proefstudie (randomized controlled trial, afgekort RCT). In een RCT 
wordt een welomschreven populatie vrouwen via aselecte keuze ingedeeld in 
twee groepen die weI of niet worden uitgenodigd. Vervolgens wordt de sterfte 
in beide groepen vergeleken. Om een duidelijk verschil in sterfte te kunnen 
aantonen hebben deze proefstudies een zeer grote omvang nodig (tienduizen-
den of honderdduizenden uitgenodigde vrouwen) en een lange looptijd (meestal 
wordt pas na 6-8 jaar een verschil in sterfte verwacht). 
Antwoorden op de vragen 2 en 3 kunnen niet rechtstreeks uit de resultaten 
van proefstudies worden afgeleid. Ten eerste zal men deze resultaten willen 
aanpassen in verband met verschillen in omstandigheden ten opzichte van de 
proefstudies: verschillen in het voorkomen van de kanker en de sterftekans, 
verschillen in de deelnamegraad aan bevolkingsonderzoek, etcetera. Ten 
tweede zal men alternatieven willen overwegen voor in de proefstudies ge-
bruikte oproepschema's (Ieeftijden, intervallen). Ten derde zal het vaak zo zijn 
dat de voortschrijdende medisch-technische ontwikkeling aanpassing nodig 
maakt, immers de resultaten van proefstudies weerspiegelen de situatie van 
zo'n 10 jaar voordien. 
Gezien het ingewikkelde samenspel van ziektebeloop, screeningsonderzoe-
ken, en verandering van overlevingskansen zijn de consequenties van deze 
aanpassingen aileen met behulp van modellen te berekenen. De constructie van 
dergelijke modellen voor bevolkingsonderzoek op borstkanker en baarmoeder-
halskanker is het onderwerp van dit proefschrift. Dit omvat het verzamelen 
van gegevens, het opstellen van het model, het schatten van de parameters van 
het model, en zo mogelijk validatie van het model aan de hand van gegevens 
die niet bij de schatting zijn gebruikt. 
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Modellering van bevolkingsonderzoek 
De constructie van de modellen ten behoeve van evaluatie van bevolkings-
onderzoek is een onderdeel van het project "Besluitvorming over Bevolkings-
onderzoek" wat in 1977 op het Instituut Maatschappelijke Gezondheidszorg is 
gestar!. Binnen dit project heb ik meegewerkt aan de ontwikkeling van het 
computersimulatieprogramma MISCAN waarmee vroege opsporing van kanker 
kan worden doorgerekend. De met behulp van MISCAN geconstrueerde 
modellen zijn vervolgens gebruikt bij kosten-effectiviteits-studies van 
bevolkingsonderzoek op borstkanker en baarmoederhalskanker. 
Bevolkingsonderzoek op borstkanker 
Voor het bevolkingsonderzoek op borstkanker is allereerst een analyse 
gemaakt van de eerste gerandomiseerde proefstudie, het HIP project!, dat 
begon in 1964. De resultaten van het HIP project zijn met behulp van MIS-
CAN geanalyseerd (Hoofdstuk II). Hierbij is een model voor borstkanker-
screening ontwikkeld dat goed in overeenstemming is met de resultaten van 
het HIP project met betrekking tot via screening (mammografie en/of licha-
melijk onderzoek) ontdekte kankers, intervalkankers en sterftedaling. De beste 
overeenkomst werd bereikt via een model met een gemiddelde duur van 2.2 
jaar voor de preklinische stadia, en een gemiddelde sensitiviteit van 68% voor 
de combinatie van de twee screeningsmethoden. Hierbij moet worden 
aangetekend dat deze waarden gelden voor de stand van zaken in de tweede 
helft van de jaren zestig. Twee factoren zijn sinds die tijd aanzienlijk 
veranderd: de stadiumverdeling van via k1achten ontdekte borstkankers is gun-
stiger geworden door de grotere opmerkzaamheid van vrouwen en artsen ten 
aanzien van symptomen, en de techniek van de mammografie is sterk 
verbeterd. 
Deze veranderingen kwamen naar voren in de MISCAN analyse van de 
proefstudies voor bevolkingsonderzoek op borstkanker in Nijmegen en Utrecht 
(Hoofdstuk III). De veranderde stadiumverdeling blijkt uit de gegevens over 
borstkankers die zijn aangetroffen bij niet uitgenodigde vrouwen. De 
verbetering van de mammografie komt tot uiting in het aandeel van k1eine 
tumoren (diameter kleiner dan 10 mm.) in de door screening ontdekte kankers. 
De MISCAN analyse wijst op een toename van 30 % voor de gemiddelde duur 
van de stadia waarin invasieve borstkankers via screening te ontdekken zijn. 
IHIP: Health Insurance Plan of Greater New YOI*, een verzeke-
ringsmaatschappij voor ziektekosten. 
146 Samenvatting 
Aangezien volgens onze analyse ook de sensitiviteit van de screeningstest 
aanzienlijk is toegenomen, is de kans op vroegtijdige ontdekking bij een scree-
ningsprogramma op borstkanker sterk vergroot. Dit geldt met name voor 
oudere vrouwen, omdat we bij stijgende leeftijd een toename vonden van de 
gemiddelde duur van de vroege stadia van borstkanker: van minder dan 2 jaar 
op leeftijd 40 tot ongeveer 5 jaar op leeftijd 70. 
Het model wist de resultaten van de proefprojecten in Nijmegen en Utrecht 
goed te reproduceren, met uitzondering van de percentages bij screening 
ontdekte borstkankers in het eerste deelproject (DOM-I) in de stad Utrecht. 
Voor de verschillen tussen model en werkelijkheid die hier optreden ontbreekt 
een afdoende verklaring. 
Ook de uit vroege opsporing bij bevolkingsonderzoek voortvloeiende 
reductie van de kans om aan borstkanker te overlijden is gevoelig voor de 
ontwikkelingen die sinds het HIP project hebben plaatsgevonden: een betere 
klinische stadiumverdeling vermindert het potentiele effect van bevolkings-
onderzoek, terwijl daarentegen de verbeterde mammografie via nog vroegere 
opsporing het effect zou vergroten. De effectiviteit is opnieuw geanalyseerd op 
basis van uitkomsten van de Zweedse gerandomiseerde proefstudies in Kop-
parberg/Ostergotland en Malmo. Allereerst bleek dat het model dat was 
gebaseerd op de gegevens uit Nijmegen en Utrecht ook de resultaten 
betreffende via screening ontdekte kankers en intervalkankers uit deze 
Zweedse projecten redelijk goed wist te reproduceren. Vervolgens is de 
prognoseverbetering als gevolg van vroege ontdekking geschat. 
Bevolkingsonderzoek op baarmoederhalskanker 
Bij screening op baarmoederhalskanker via het uitstrijkje wordt getracht niet-
invasieve voorstadia van deze kanker op te sporen. Deze voorstadia kennen 
een lange gemiddelde duur. Wij hebben een aantal analyses verricht op de 
gegevens uit British Columbia (Canada). Deze gegevens zijn in zoverre uniek 
dat ze een complete registratie omvatten gedurende de eerste 20 jaren dat in 
die provincie screening plaatsvond (1949-1969). Deze lange peri ode maakt het 
in principe mogelijk om gefundeerde schattingen te maken over de duur van 
de voorstadia. Hierbij is opnieuw gebruikt gemaakt van het MISCAN 
simulatiepakket. 
Tevens is een speciaal gesimplificeerd model ontwikke1d wat het mogelijk 
maakt om standaard statistische technieken (maximum-likelihood schatting, 
likelihood ratio test) te gebruiken voor het schatten van modelparameters en 
het toetsen van hypotheses over het natuurlijk beloop van de niet-invasieve 
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voorstadia van baarmoederhalskanker (Hoafdstuk IV). Valgens dit gesim-
plificeerde model zal met name voar bij jange vrouwen ap te sparen 
voarstadia gelden dat een aanzienlijk deel (±84%) weer spantaan zau verdwij-
nen (in regressie gaan). Bij audere vrauwen (de grens ligt in dit 
gesimplificeerde model bij een leeftijd van 34 jaar) is in veel mindere mate 
sprake van regressie. De gemiddelde duur van de niet-invasieve stadia is 
geschat op 12 jaar. Tussen het antstaan van invasieve kanker en de antdekking 
ervan aan de hand van symptomen verlaapt gemiddeld za'n 4 a 5 jaar. Met 
deze aannames warden de resuitaten die in British Columbia werden 
waargenamen uitstekend daar het madel gerepraduceerd. 
Een werkgraep van het IARC2 (waarin wij participeerden) heeft een 
gecombineerde analyse uitgevaerd van gegevens uit 8 landen over bevolkings-
onderzoek op baarmoederhalskanker. Er werden schattingen gemaakt over de 
afname in het risico op invasieve baarmoederhalskanker die voigt op een af 
meerdere uitstrijkjes met een negatieve uitslag. Wij hebben het 
gesimplificeerde model gebruikt om deze "relatieve beschermingsgraad" te 
berekenen. Hierbij bleek allereerst dat de resultaten van de rARC analyse 
belnvloed worden daor invasieve kankers die via een uitstrijkje zijn ontdekt. 
Aileen als hiermee in de modelberekeningen rekening wordt gehouden geeft 
het model resultaten die gaed overeenkomen met de uitkomsten van de rARC 
analyse (Hoafdstuk V). 
Hoewel de kans om aan baarmoederhalskanker te overlijden bij de via 
bevolkingsonderzoek ontdekte invasieve kankers niet is uitgesloten, is deze 
tach duidelijk geringer dan bij via k1achten ontdekte kankers. Daarom zal het 
effect van bevolkingsonderzoek op de incidentie van invasieve kankers minder 
graot zijn dan het effect op de sterfte ten gevolge van baarmoederhalskanker. 
Wanneer bij vrouwen tussen 35 en 64 jaar iedere 3 jaar een uitstrijkje wordt 
gemaakt, dan vermindert volgens het model - in overeenstemming met de 
IARC uitkomsten - het risico op een invasieve baarmoederhalskanker tot 10% 
van het risico bij niet-gescreende vrouwen. De sterfte aan baarmoederhals-
kanker reduceert volgens ons model sterker, en wei tot 6%. Bij 5-jaarlijkse 
uitstrijkjes zijn de percentages respectievelijk 16% en 10% (Hoofdstuk VI). 
Aan een uitstrijkje zijn ook negatieve effecten verbonden, zoals het gegeven 
dat een deel van de ontdekte voorstadia vanzelf zou verdwijnen en dus 
"onnodig" behandeld wordt. Bij een kart screeningsinterval nemen deze 
ongunstige effecten veel sterker toe dan de gunstige effecten. Hetzelfde geldt 
vaor kosten die aan het maken van uitstrijkjes zijn verbonden: bevolkings-
2IARC: IlIIemat;ol/al Agel/CY for Research 011 Cal/cer, een 
intemationaal instituut voor kankeronderzoek in Lyon. 
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onderzoek is bij een 3-jaars interval grofweg 66% duurder dan bij een 5-jaars 
interval. In dit Iieht bezien valt de aanbeveling van de IARC werkgroep dat 
minstens eenmaal in de 3 jaar een uitstrijkje dient te worden gemaakt moeilijk 
te reehtvaardigen. 
Evaluatie van de effecten en de kosten van bevolkingsonderzoek 
De in dit proefsehrift besproken modellen voor bevolkingsonderzoek op borst-
kanker en baarmoederhalskanker hebben gediend als rekenmodellen bij 
uitvoerige evaluatiestudies naar de kosten en effeeten van deze bevolkings-
onderzoeken. 
De lIitkomsten voor bevolkingsonderzoek op borstkanker bevestigen de 
keuze om vrouwen tussen leeftijd 50 en 70 iedere 2 jaar uit te nodigen. Naar 
verwaehting zal dit op lange termijn de jaarlijkse sterfte aan borstkanker in 
Nederland met 650 verminderen. De kosten-effeetiviteit wordt gesehat op 7600 
gulden per gewonnen levensjaar, dil is gllnstiger dan voor veel andere 
medisehe voorzieningen waarvoor dit bepaald is. 
De bevindingen voor het bevolkingsonderzoek op baarmoederhalskanker 
zijn minder positief over de hllidige gang van zaken waarbij een flink deel van 
de uitstrijkjes bij vrij jonge vrouwen wordt gemaakt, vaak met een korte 
tussenpoos. Volgens onze berekeningen zou bevolkingsonderzoek het best 
kunnen beginnen rond de leeftijd van 30 jaar, waarna vrouwen met een niet te 
kort interval worden uitgenodigd voor een uitstrijkje. Deze uitnodigingen 
zouden ook na het 55e jaar nog moeten doorgaan. In het meest gunstige geval 
zouden de kosten per gewonnen levensjaar ongeveer 24000 gulden bedragen, 
in de huidige praktijk is dit bedrag veel hoger. 
Conclusie 
In Hoofdstuk VII wordt de balans opgemaakt. Er is een algemeen model voor 
bevolkingsonderzoek op kanker opgesteld, wat vele mogeJijkheden tot variatie 
biedt, onder meer voor wat betreft de besehrijving van het ziekteproces, en de 
wijze waarop uitnodiging plaatsvindt. Dit model is geimplementeerd in het 
eomputerprogramma MISCAN. Hiernaast zijn voor specifieke toepassingen 
gesimplifieeerde modellen ontwikkeld en in eompllterprogramma's vertaald. 
Beide typen modellen zijn toegepast voor het analyseren van resultaten van 
gerenommeerde projeeten voor vroege opsporing van baarmoederhalskanker 
en borstkanker, waarbij sehattingen zijn verkregen over de belangrijkste 
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parameters van het ziekteproces en de screenings test. Dit heef! geleid tot een 
beter inzicht in het ziektebeloop en de mogelijkheden tot vroege opsporing. 
De modellen, en dan met name het model voor borstkankerscreening, zijn 
enkele malen met succes overgeheveld tussen screeningsprojecten, waarbij, na 
aanpassing aan de verschillende omstandigheden bij deze projecten, de be-
schrijving van de medisch-biologische processen grotendeels intact konden 
worden gelaten. 
Uiteindelijk zijn de epidemiometrische modellen uitgebreid tot kosten-effec-
ten modellen en gebruikt om voorspellingen te maken over de kosten en 
effecten van bevolkingsonderzoek in Nederland. De conclusies van deze 
kosten-effectiviteits studies hebben aanzienlijke invloed op het beleid gehad. 
Het besluit tot invoering van het landelijke bevolkingsonderzoek op 
borstkanker is mede genomen op de door ons gemaakte berekeningen over de 
te verwachten effecten en kosten. En recentelijk is mede op basis van onze 
aanbevelingen besloten om het oproepschema voor het bevolkingsonderzoek op 
baarmoederhalskanker te wijzigen en in plaats van een 3-jaars een 5-jaars 
interval tussen uitnodigingen te hanteren, en de leeftijdsrange te verruimen van 
35-53 tot 30-60 jaar. 
Ook internationaal bestaat belangstelling voor onze modelmatige evaluatie 
van bevolkingsonderzoek. In samenwerking met groepen uit Australie, Italie, 
Duitsland en Spanje zijn of worden kosten-effecten berekeningen gemaakt, 
waarbij de modellen worden aangepast aan de specifieke omstandigheden in 
deze landen. 
Er vaH nog veel te doen aan de verdere ontwikkeling en toepassing van 
modellen voor bevolkingsonderzoek. Voor een flink deel hangt dit echter af 
van het beschikbaar komen van nieuwe gegevens en uitkomsten van proef-
studies. Dit geldt allereerst voor de vraag naar de effectiviteit van vroege 
opsporing van borstkanker bij vrouwen jonger dan 50 jaar. Hoewel wij als een 
der eersten betoogden dat de resultaten van het HIP project ook voor deze 
groep een gunstig effect lieten zien, kon deze bevinding in latere proefstudies 
nog niet worden bevestigd. Bij baarmoederhalskanker is juist de vraag of 
screening voortgezet moet worden na het 55e jaar. 
Een nieuwe stap in de modeltoepassing is de bewaking van het verloop van de 
Nederlandse bevolkingsonderzoeken op basis van de door ons gemaakte 
voorspellingen. Ais de resultaten van het bevolkingsonderzoek hiervan sterk 
afwijken kan de oorzaak voor het verschil, eventueel met behulp van het 
model, worden opgespoord. Indien nodig zal het model worden aangepast of 
kan het model worden gebruikt om aanbevelingen te doen over aanpassingen 
van het beleid. 
SUMMARY 
Interpretation of the results of screening programmes and answering the 
questions involved in planning of mass screening programmes is difficult 
because of the many factors that determine the direct results of screening, the 
long-term favourable and adverse effects, and the costs and potential savings. 
Different methods can be used and combined to address these issues, including 
experimental studies, careful analysis of existing data, and modelling. 
This thesis focuses on development and application of models for 
interpretation of data from screening programmes for breast cancer and 
cervical cancer. The work reported is part of a larger project "decision 
making in mass screening for cancer", in which the models have been applied 
for predicting the effects and costs of screening policies, using the MISCAN 
microsimulation programme. 
At the heart of models for cancer screening are the IIl1derlying processes 
that are crucial determinants of the effects of screening but cannot be observed 
directly: the preclinical course of the cancer, the sensitivity of the screening 
test, and the improvement in prognosis following early detection and 
treatment. In model-based analysis of screening results, parameters describing 
these processes are estimated and hypotheses about the processes are tested. 
Two different techniques have been applied: MISCAN microsimulation and a 
statistical/numerical approach. Advantages of using MISCAN are that identical 
models can be used for data analysis and for prospective evaluation of 
screening policies, and that models can be quite detailed. The 
statistical/numerical approach can only be used with relatively simple models, 
but has the advantage that it is based on standard maximum-likelihood 
methodology. Given the availability of MISCAN, implementation of 
MISCAN-based model will be faster but the calculations will take much more 
time compared to a statistical/numerical equivalent. 
The methodology of modelling screening for cancer is continues to be one 
of the research issues. Methods for optimization of microsimulation models 
are being investigated and tested in collaboration with the International 
Institute for Applied Systems Analysis. MISCAN is being used for generating 
datasets that are utilized to check methods for analyzing case-control studies of 
the effect of screening. And we are planning a complete revision of the 
MISCAN package, largely motivated by difficulties encountered in further 
refinement of existing models, due to limitations of the current MISCAN 
version. 
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The MISCAN simulation approach has first been used to analyze data from 
the HIP randomized trial of breast cancel' screening, which was carried out 
between 1963 and 1970. Parameter estimates were derived for the sensitivity 
of mammography and physical examination, and for the duration of preclinical 
screen-detectable breast cancer (Chapter II). Values between 50% and 80% 
for the combined sensitivity of the two tests give a good explanation of the 
HIP results. The mean duration of the preclinical stage is between 1.6 years 
for high sensitivity values and 2.7 years for low values. In comparison with 
previous analyses of the HIP data, our estimate for the sensitivity is lower, 
and the mean duration of the preclinical stage is longer. This is a consequence 
of the use of a more detailed model in our analysis, allowing for a more 
complete use of the HIP-data in testing model assumptions. The model is also 
in good agreement with the observed difference in breast cancer mortality 
between study and control group of the HIP trial. 
This breast cancer screening model, which reflects the situation in the USA 
around 1970, has been translated to the current situation in The Netherlands, 
in order to evaluate the costs and effects of breast cancer screening. This 
extended and refined model has been checked against data from the pilot 
projects for breast cancer screening in Nijmegen and Utrecht (Chapter III). 
When the appropriate screening policy is specified, the model reproduces the 
detection rates and the incidence of interval cancers as observed in these pro-
jects. In comparison with the HIP model parameter values, the principal 
differences are the higher sensitivity of mammography, and the age-
dependency of the duration of the preclinical screen-detectable stage. The 
sensitivity is especially high (approximately 95%) for tumours larger than 1 
cm. The average duration is approximately 2 years at age 40 and increases to 
approximately 5 years at age 70. The model-predicted mortality reduction is in 
accordance with the results of the Kopparberg/Ostergiitland randomised trial in 
Sweden. 
The breast cancer screening model has subsequently been utilized in 
prospective evaluation of effects and costs of various screening policies in The 
Netherlands. The outcomes for the proposed Dutch policy of 2-yearly 
screening between ages 50 and 69 were favourable: an acceptable cost per life 
year gained, and relatively modest adverse effects that are more or less 
compensated by the favourable effects which occur in addition to the life-years 
gained. These findings have contributed considerably to the positive decision 
to start nationwide screening. At present, the model is being used in 
monitoring the results of this national programme. Subsequent cost-
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effectiveness analyses have been carried out and are being done for other 
countries and regions, including Australia, Germany, Florence, and Catalonia. 
A statistical/numerical model of cervical cancer screening was constructed, 
and applied for testing hypotheses about the natural history of cervical cancer, 
especially about progression and regression of preclinical lesions (dysplasia 
and carcinoma in situ). Three models are considered and checked against data 
from the screening programme in British Columbia (Chapter IV). The data 
cover two birth cohorts and the period 1950-1969. A model without regression 
does not give an adequate fit of the data (p<O.OOI), and results in an 
implausible estimate of 33 years for the mean duration of pre-invasive lesions. 
A model with an equal regression rate at all ages still does not result in a good 
reproduction of the data. A good fit is achieved for the model that has 
different regression rates in lesions that develop under and over age 34. Under 
age 34, 84% of the new lesions will regress spontaneously, with a 95% 
confidence interval of 76%-92% regression. Over age 34, we estimate that 
40% of the new lesions will regress. Testing more detailed age-dependency 
assumptions would require additional data. The average duration of dysplasia 
+ CIS is 1I.8 years, and the sensitivity of the Pap-smear is 80%. It is 
concluded that a considerable proportion of pre-invasive lesions in young 
women do not progress. The findings about progression and duration of pre-
invasive lesions indicate that cervical cancer screening in young women has 
substantial adverse effects. 
The mean total duration of the preclinical stages is estimated at about 16 
years. Similar estimates had been obtained in another model-based analysis of 
cervical cancer and screening based on Swedish data. In an analysis of data 
from 10 large screening programmes, an International Agency for Research on 
Cancer (JARC) working group observed the build-up of incidence of invasive 
cervical cancer after one or more negative smears, and the results suggest a 
median durations of 5-10 years. An investigation has been made into the 
differences between the estimates for the duration of preclinical cervical 
cancer resulting from these two types of studies (Chapter V). Our British 
Columbia model has been used to predict the build-up of the incidence of 
invasive cancer after one and after two negative smears. The model 
predictions appear to correspond closely to the observed incidence trends 
following negative smears. The seemingly contradiction between model 
estimates and observed data is explained by recognizing that many of the 
women who have had negative smears will have further Pap smears, resulting 
in earlier diagnosis of invasive cervical cancers and thus an apparent faster 
build-up of the incidence. When the impact of further Pap smears is neglected, 
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the data suggest that the risk of invasive cancer following one or more 
negative smears return close to pre-screening levels within 6-10 years. This is 
an overestimation of the risk of clinical invasive cancer. In case of cessation 
of screening it will take longer before the incidence of clinical cancer will' 
increase. And in case of continuous screening the screen-detected cancers have 
a relatively favourable prognosis, thus contributing less to the serious 
morbidity and mortality risks associated with invasive cancer, which should be 
taken into account in making comparisons with the pre-screening situation. 
The latter finding has been investigated in more detail. The reduction in 
risk of death (i.e., lethal invasive cancer) from cervical cancer after two or 
more negative smear test results has been calculated on basis of the long-term 
lethality risk of both screen-detected and clinically diagnosed cancers (Chapter 
VI). In women with two negative smear results estimates of protection against 
cervical cancer were about 50% higher when lethal invasive cancer was used 
as the criterion rather than all invasive cancer. This difference was due to 
these women being more likely to attend for further tests at which interval 
cancer could be detected: screen detected cancer has a better prognosis than 
clinically diagnosed cancer. Screening intervals could be longer than three 
years: screening women aged 35-64 every five years was predicted to result in 
a 90% reduction in mortality from cervical cancer. Because protection from 
mortality is higher than from disease and because of the high costs and 
negative side effects of frequent screening, it is concluded that screening inter-
vals should be longer than three years. 
The British Columbia model has been implemented in MISCAN and adapted 
to the situation in The Netherlands, and extended and refined in order to 
investigate the cervical cancer screening data from the last decades, and to 
compare a large range of different future screening policies. Transfer to 
MISCAN was necessary in view of the complex screening patterns which have 
occurred in the Dutch population and other complications such as birth cohort 
related trends in risk of cervical cancer. The cost-effectiveness comparisons 
indicated that efficient policies are characterized by a broad age-range, starting 
at ages 25-30 and continuing to beyond age 60. This was quite different from 
the prevailing policy in The Netherlands in which women were invited 
between age 35 and 53 with 3-years intervals. Our findings have had a major 
influence on the recent revision of this policy. Screening now starts at age 30 
and ends at age 60, with 5 years intervals. We will be involved in continuous 
evaluation of the Dutch screening. Special attention will be given to evaluation 
of the possibilities of new screening test based on detection of Human 
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Papilloma Virus (HPV), that could serve as an addition or substitute of 
cytologic screening. 
Why did the outcomes of the project "decision making in mass screening for 
cancer" made a real impact on actual decision making? To a large extent this 
may be attributed to the comprehensiveness of the evaluation, in which public 
health effects, experience of screening projects, diagnostic and clinical aspects, 
economic considerations, and epidemiological data and knowledge have each 
been carefully investigated and fully integrated into MISCAN cost-
effectiveness models. This thesis describes some of the fundamental elements 
of these models. 
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